Mitesco (MITI) 10-K 14 Jul 23 2022 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2022	Jun. 15, 2023	Jun. 30, 2022
Document Information Line Items
Entity Registrant Name	MITESCO, INC.
Trading Symbol	N/A
Document Type	10-K
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		5,115,437
Entity Public Float			$ 23,837,001
Amendment Flag	false
Entity Central Index Key	0000802257
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Dec. 31, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
ICFR Auditor Attestation Flag	true
Document Annual Report	true
Document Transition Report	false
Entity File Number	000-53601
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	87-0496850
Entity Address, Address Line One	18202 Minnetonka Blvd., Suite 100
Entity Address, City or Town	Deephaven
Entity Address, State or Province	MN
Entity Address, Postal Zip Code	55391
City Area Code	844
Local Phone Number	383-8689
Title of 12(b) Security	N/A
Security Exchange Name	NONE
Entity Interactive Data Current	Yes
Document Financial Statement Error Correction [Flag]	false
Auditor Firm ID	587
Auditor Name	RBSM LLP
Auditor Location	Las Vegas, NV

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Current assets
Cash and cash equivalents	$ 35,623	$ 1,164,483
Accounts Receivable	30,943	44,313
Inventory	0	25,314
Prepaid expenses	113,722	72,985
Total current assets	180,288	1,307,095
Right to use operating leases, net	544,063	3,886,866
Construction in progress	0	1,984,701
Fixed assets, net of accumulated depreciation of $.06 million and $19,600	1,877,629	3,476,164
Total Assets	2,601,980	10,654,826
Current liabilities
Accounts payable and accrued liabilities	7,353,215	3,976,064
Accrued interest	362,094	7,657
Derivative liabilities	568,912	0
Lease liability - operating leases, current	442,866	161,838
Notes payable, net of discounts	5,112,701	0
SBA Loan Payable	460,406	460,406
Other current liabilities	96,136	169,422
Preferred stock dividends payable	395,407	145,539
Total current liabilities	17,802,471	5,558,988
Lease Liability- operating leases, non-current	3,936,858	3,972,964
Total Liabilities	21,739,329	9,531,952
Commitments and contingencies
Preferred stock, Value	0	0
Common stock subscribed	36,575	132,163
Common stock, $0.01 par value, 500,000,000 shares authorized, 4,630,372 and 4,266,669 shares issued and outstanding as of December 31, 2022 and 2021, respectively	46,305	42,667
Additional paid-in capital	29,452,514	26,385,728
Accumulated deficit	(48,714,461)	(25,478,332)
Total stockholders' equity (deficit)	(19,137,349)	1,122,874
Total liabilities and stockholders' equity (deficit)	2,601,980	10,654,826
Series A Preferred Stock [Member]
Current liabilities
Preferred stock, Value	0	0
Series C Preferred Stock [Member]
Current liabilities
Preferred stock, Value	10,476	9,406
Series D Preferred Stock [Member]
Current liabilities
Preferred stock, Value	31,000	31,000
Series X Preferred Stock [Member]
Current liabilities
Preferred stock, Value	242	242
Related Party [Member]
Current liabilities
Accrued interest	198,753	0
Notes payable, net of discounts	2,776,962	588,432
Preferred stock dividends payable	$ 35,019	$ 49,630

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Fixed assets, accumulated depreciation (in Dollars)	$ 60,000	$ 19,600
Notes payable, discounts (in Dollars)	$ 40,000	$ 0
Common stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	4,630,372	4,266,669
Common stock, shares outstanding	4,630,372	4,266,669
Series A Preferred Stock [Member]
Preferred stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Series C Preferred Stock [Member]
Preferred stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares issued	1,038,708	940,644
Preferred stock, shares outstanding	1,038,708	940,644
Series D Preferred Stock [Member]
Preferred stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares issued	3,100,000	3,100,000
Preferred stock, shares outstanding	3,100,000	3,100,000
Series X Preferred Stock [Member]
Preferred stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares issued	24,227	24,227
Preferred stock, shares outstanding	24,227	24,227
Related Party [Member]
Notes payable, discounts (in Dollars)	$ 30,000	$ 0

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Revenue	$ 690,534	$ 115,994
Cost of goods sold	2,056,218	455,587
Gross (loss) profit	(1,365,684)	(339,593)
Operating expenses:
General and administrative	9,221,670	6,058,996
Impairment of fixed assets	7,597,558	0
Total operating expenses	16,819,228	6,058,996
Net Operating Loss	(18,184,912)	(6,398,589)
Other income (expense):
Interest expense	(3,210,763)	(968,471)
Loss on legal settlement	0	(70,000)
Loss on true-up shares	(9,007)	0
Gain on waiver and commitment fee shares	91,444	0
Gain on settlement of accrued salary	15,032	0
(Loss) Gain on settlement of accounts payable	(88,235)	6,045
Gain on settlement of notes payable	0	1,836
Loss on revaluation of derivative liabilities	(687,178)	(493,455)
Total other expense	(5,051,217)	(1,524,045)
Loss before provision for income taxes	(23,236,129)	(7,922,634)
Provision for income taxes	0	0
Net loss	(23,236,129)	(7,922,634)
Preferred stock dividends	(249,868)	(185,202)
Preferred stock deemed dividends	0	(3,118,530)
Net loss available to common shareholders	$ (23,558,439)	$ (11,226,366)
Net loss per share - basic and diluted (in Dollars per share)	$ (5.29)	$ (2.77)
Weighted average shares outstanding - basic and diluted (in Shares)	4,451,962	4,060,005
Service [Member]
Revenue	$ 673,385	$ 115,994
Cost of goods sold	1,979,688	455,587
Product [Member]
Revenue	17,149	0
Cost of goods sold	76,530	0
Related Party [Member]
Other income (expense):
Interest expense	(1,243,639)	0
Gain on waiver and commitment fee shares	81,129	0
Preferred stock dividends	$ (72,442)	$ 0

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (DEFICIT) - USD ($)	Diamond Note 1 [Member] Additional Paid-in Capital [Member]	Diamond Note 1 [Member]	Discount on Note Payable Due to Warrants [Member] Additional Paid-in Capital [Member]	Discount on Note Payable Due to Warrants [Member]	Convertible Debt [Member] Common Stock [Member]	Convertible Debt [Member] Additional Paid-in Capital [Member]	Convertible Debt [Member]	Accounts Payable [Member] Common Stock [Member]	Accounts Payable [Member] Additional Paid-in Capital [Member]	Accounts Payable [Member]	Series A Preferred Stock [Member] Preferred Stock [Member]	Series A Preferred Stock [Member] Common Stock [Member]	Series A Preferred Stock [Member] Additional Paid-in Capital [Member]	Series A Preferred Stock [Member] Retained Earnings [Member]	Series A Preferred Stock [Member]	Series X Preferred Stock [Member] Preferred Stock [Member] Share Settlement [Member]	Series X Preferred Stock [Member] Preferred Stock [Member]	Series X Preferred Stock [Member] Common Stock [Member] Stock Issued for Dividends Payable [Member]	Series X Preferred Stock [Member] Additional Paid-in Capital [Member] Stock Issued for Dividends Payable [Member]	Series X Preferred Stock [Member] Stock Issued for Dividends Payable [Member]	Series X Preferred Stock [Member]	Series C Preferred Stock [Member] Preferred Stock [Member]	Series C Preferred Stock [Member] Common Stock [Member]	Series C Preferred Stock [Member] Additional Paid-in Capital [Member]	Series C Preferred Stock [Member] Retained Earnings [Member]	Series C Preferred Stock [Member]	Series D Preferred Stock [Member] Preferred Stock [Member]	Series D Preferred Stock [Member] Additional Paid-in Capital [Member]	Series D Preferred Stock [Member] Retained Earnings [Member]	Series D Preferred Stock [Member]	Common Stock [Member] Private Placement [Member]	Common Stock [Member] Share-Based Payment Arrangement, Option [Member]	Common Stock [Member] Share Settlement [Member]	Common Stock [Member] Stock Subscribed [Member]	Common Stock [Member] Commitments [Member]	Common Stock [Member] Waiver Fee [Member]	Common Stock [Member] Shares Previously Subscribed [Member]	Common Stock [Member] Make-Good Agreement [Member]	Common Stock [Member] Rounding in Reverse Split [Member]	Common Stock [Member]	Additional Paid-in Capital [Member] Private Placement [Member]	Additional Paid-in Capital [Member] Share-Based Payment Arrangement, Option [Member]	Additional Paid-in Capital [Member] Share Settlement [Member]	Additional Paid-in Capital [Member] Stock Subscribed [Member]	Additional Paid-in Capital [Member] Commitments [Member]	Additional Paid-in Capital [Member] Waiver Fee [Member]	Additional Paid-in Capital [Member] Shares Previously Subscribed [Member]	Additional Paid-in Capital [Member] Make-Good Agreement [Member]	Additional Paid-in Capital [Member] Rounding in Reverse Split [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Stock Subscribed [Member] Stock Subscribed [Member]	Stock Subscribed [Member] Shares Previously Subscribed [Member]	Stock Subscribed [Member]	Private Placement [Member]	Share-Based Payment Arrangement, Option [Member]	Share Settlement [Member]	Commitments [Member]	Waiver Fee [Member]	Make-Good Agreement [Member]	Total
Balance at Dec. 31, 2020											$ 48						$ 262																							$ 31,076										$ 11,863,557	$ (14,437,168)										$ (2,542,225)
Balance (in Shares) at Dec. 31, 2020											4,800						26,227																							3,107,624
Vesting of shares issued to employees																																																		13,032											13,032
Vesting of stock options issued to employees																																																		676,423											676,423
Shares issued for services																																								$ 221										222,259											222,480
Shares issued for services (in Shares)																																								21,988
Stock issued for conversion					$ 6,789	$ 2,647,006	$ 2,653,795				$ (48)	$ 120	$ (72)			$ (20)						$ (20,594)	$ 1,647	$ 18,947								$ 1,656	$ (272)	$ 96								$ 237,344	$ 128,202	$ 119,770								$ (119,866)		$ 252,029		$ 239,000	$ 127,910				252,029
Stock issued for conversion (in Shares)					678,884						(4,800)	12,000				(2,000)						(2,059,356)	164,750									165,634	(27,241)	9,590
Deemed dividend on Preferred Stock													$ 206,242	$ (206,242)										126,000	$ (126,000)			$ 2,786,288	$ (2,786,288)
Preferred stock dividends																					$ (61,818)					$ (87,059)				$ (35,327)																				$ (185,204)											$ (185,204)
Sale of Stock																						$ 30,000		$ 1,461,283		$ 1,491,283	$ 31,000	$ 1,722,282		$ 1,753,282	$ 1,334										$ 1,666,666														$ 1,668,000
Sale of Stock (in Shares)																						3,000,000					3,100,000				133,440																														4,266,669
Warrants issued (in Shares)																								1,268,717		1,268,717		1,145,418		1,145,418																				261,568											261,568
Gain on settlement of accrued payroll																																																													$ 0
Net loss for the period																																																			(7,922,634)										(7,922,634)
Balance at Dec. 31, 2021																	$ 242					$ 9,406					$ 31,000													$ 42,667										$ 26,385,728	(25,478,332)			132,163							$ 1,122,874
Balance (in Shares) at Dec. 31, 2021																	24,227					940,644					3,100,000													4,266,669																					4,266,669
Vesting of shares issued to employees																																																		4,387											$ 4,387
Vesting of stock options issued to employees																																																		345,578											345,578
Shares issued for services																																								$ 63										101,187											101,250
Shares issued for services (in Shares)																																								6,329
Stock issued for conversion								$ 636	$ 577,599	$ 578,235								$ 82	$ 86,971	$ 87,053		$ 1,070		$ (1,070)													$ 76	$ 913	$ 29	$ 271							$ 95,512	$ 318,735	$ (29)	180,302			$ (95,588)							$ 319,648	180,573
Stock issued for conversion (in Shares)								63,593										8,103				106,975															7,648	91,329	2,875	27,064
Issuance of shares																																			$ 1,196	$ 452									$ 1,218,466	$ 366,706												$ 1,219,662	$ 367,158
Issuance of shares (in Shares)																																			119,527	45,235
Preferred stock dividends															$ (1,000)						$ (60,564)					$ (66,447)				$ (195,299)																				$ (322,310)											$ (322,310)
Sale of Stock (in Shares)																																																													4,630,372
Warrants issued (in Shares)	2,914	2,914	2,213	2,213																																														89,545											89,545
Gain on settlement of accrued payroll																																								$ (80)										$ 80											$ (88,235)
Gain on settlement of accrued payroll (in Shares)																																								(8,000)
Net loss for the period																																																			(23,236,129)										(23,236,129)
Balance at Dec. 31, 2022																	$ 242					$ 10,476					$ 31,000													$ 46,305										$ 29,452,514	$ (48,714,461)			$ 36,575							$ (19,137,349)
Balance (in Shares) at Dec. 31, 2022																	24,227					1,047,619					3,100,000													4,630,372																					4,630,372

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (DEFICIT) (Parentheticals)	12 Months Ended
	Dec. 31, 2021 $ / shares
Statement of Stockholders' Equity [Abstract]
Preferred stock dividends, per share	$ 3.62

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (23,236,129)	$ (7,922,634)
Adjustments to reconcile net loss to net cash used in operating activities:
Impairment of assets	7,597,558	0
Depreciation	868,508	182,426
Amortization of right-to-use asset	357,700	162,276
Net gain on settlement of notes payable	0	0
Financing cost - waiver fee shares	565,431	0
Gain on waiver fee shares	(198,273)	0
Loss on commitment shares	34,707	0
Gain on conversion of accrued salary	(15,032)	0
(Gain) loss on revaluation of derivative liabilities	687,178	493,455
Loss on settlement of accounts payable	88,235	0
Amortization of discount on notes payable	2,116,194	756,795
Share-based compensation	451,215	1,039,843
Changes in assets and liabilities:
Accounts receivables	13,370	(44,313)
Prepaid expenses	139,836	(47,985)
Inventory	25,314	(25,314)
Accounts payable and accrued liabilities	3,933,770	54,527
Operating lease liability, net	(126,566)	75,017
Other current liabilities	(73,286)	74,166
Accrued interest	354,437	205,795
Net cash used in operating activities	(5,173,840)	(4,995,946)
CASH FLOWS FROM INVESTING ACTIVITIES
Cash paid for acquisition of fixed assets and construction in progress	(1,748,826)	(1,928,192)
Net cash used in investing activities	(1,748,826)	(1,928,192)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from private placement of common stock	0	1,668,000
Proceeds from sale of common stock	0	51,500
Proceeds from landlord financing of leasehold improvements	171,000,000,000
Proceeds from convertible notes payable, net of discount	0	850,000
Proceeds from notes payable, net of discounts	4,359,350	0
Principal payments on notes payable	0	(179,368)
Net cash provided by financing activities	5,793,806	8,023,832
Net increase in cash and cash equivalents	(1,128,860)	1,099,694
Cash and cash equivalents at beginning of period	1,164,483	64,789
Cash and cash equivalents at end of period	35,623	1,164,483
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Interest paid	0	2,680
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Stock issued for common stock subscribed	95,512	0
Settlement of derivative liabilities	0	(1,301,137)
Preferred stock dividend	322,310	0
Deemed dividends on Preferred Stock	0	3,118,530
Conversion of payable to common stock	0	50,000
Conversion of accounts payable to common stock subscribed	0	252,029
Discount on notes payable due to warrants	94,672	261,568
(Decrease) Increase in capital expenditures included in accounts payable	(51,587)	3,291,735
Series C Preferred Stock [Member]
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from sales of Preferred Stock, net of fees	0	2,760,000
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Conversion of Preferred stock to common stock	0	61,781
Series D Preferred Stock [Member]
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from sales of Preferred Stock, net of fees	0	2,873,700
Series A Preferred Stock [Member]
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Conversion of Preferred stock to common stock	0	6,000
Accounts Payable [Member]
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Conversion of payable to common stock	578,235	102,333
Related Party [Member]
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of discount on notes payable	1,043,240	0
Changes in assets and liabilities:
Accrued interest	198,753	0
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from notes payable, net of discounts	1,498,750	0
Principal payments on notes payable related parties	$ (235,294)	$ 0

Description of Business

Description of Business	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	Note 1: Description of Business Company Overview Mitesco, Inc. (the “Company,” “we,” “us,” or “our”) was formed in the state of Delaware on January 18, 2012. On December 9, 2015, we restructured our operations and acquired Newco4pharmacy, LLC, a development stage company which sought to acquire compounding pharmacy businesses. As a part of the restructuring, we completed a “spin out” of our former business line. On April 24, 2020, we changed our name to Mitesco, Inc. Since 2020, our operations have focused on establishing medical clinics utilizing Nurse Practitioners under The Good Clinic name and development and acquisition of telemedicine technology. In March of 2020, we formed an owned subsidiary, Mitesco NA LLC, which holds The Good Clinic LLC, a Colorado limited liability company for our clinic business. The Company had previously established a strategy to address opportunities in Europe seeking technology solutions, or financing situations, through a Dublin based subsidiary, Acelerar Healthcare Holdings Ltd. After a review of its near-term opportunities in North America, the Board of Directors has determined that any efforts in the European community should be discontinued so that it can best focus on its North American operations. We opened our first The Good Clinic in Minneapolis, Minnesota in the first quarter of 2021 and had six operating clinics during the year ended December 31, 2022, with two additional sites under contract. In the fourth quarter of fiscal 2022 we made the strategic decision to reduce our capital needs by closing our clinic operations and releasing a significant portion of our staff. As we redevelop our new strategy for lower cost operations, we hope to slowly open clinics, using the same staffing approach, but with a wider range of services for a broader portion of the population with healthcare needs. Reverse Stock Split On December 12, 2022, the Company effected a one-for-fifty (1-for-50) reverse stock split of its common stock (the “Reverse Stock Split”). All references to common stock, warrants to purchase common stock, options to purchase common stock, share data, per share data and related information contained in the consolidated financial statements have been retrospectively adjusted to reflect the effect of the Reverse Stock Split for all periods presented.

Going Concern

Going Concern	12 Months Ended
	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Substantial Doubt about Going Concern [Text Block]	Note 2: Going Concern Effective December 8, 2022, we closed all of our clinic locations due to a lack of funding. Subsequent to that date we have lost possession of all except one clinic location. Due to difficulty in securing financing, we are uncertain of when or even if we will be able to resume operations at any clinic location. As a result of these factors, there is substantial doubt about the ability of the Company to continue as a going concern for one year from the date the financial statements are issued. The Company’s continuance is dependent on raising capital and generating revenues sufficient to sustain operations. However, as of the date of these consolidated financial statements, no formal agreement exists. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts classified as liabilities that might be necessary should the Company be forced to take any such actions. The COVID-19 pandemic, decades-high inflation and concerns about an economic recession in the United States or other major markets has resulted in, among other things, volatility in the capital markets that may have the effect of reducing the Company’s ability to access capital, which could in the future negatively affect the Company’s liquidity. In addition, a recession or market correction due to these factors could materially affect the Company’s business and the value of its common stock.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	Note 3: Summary of Significant Accounting Policies Basis of Accounting Principles of Consolidation Use of Estimates - Cash - Property, Plant, and Equipment - Years Office equipment 3 to 5 Furniture & fixtures 3 to 7 Machinery & equipment 3 to 10 Leasehold improvements Term of lease Construction in Progress - Revenue Recognition The Company applied the modified retrospective approach to all contracts when adopting ASC 606. As a result, at the adoption of ASC 606 what was previously classified as the provision for bad debts in the statement of operations is now reflected as implicit price concessions (as defined in ASC 606) and therefore included as a reduction to net operating revenues in 2018. For changes in credit issues not assessed at the date of service, the Company will prospectively recognize those amounts in other operating expenses on the statement of operations. For periods prior to the adoption of ASC 606, the provision for bad debts has been presented consistent with the previous revenue recognition standards that required it to be presented separately as a component of net operating revenues. Our revenues generally relate to net patient fees received from various payers and patients themselves under contracts in which our performance obligations are to provide services to the patients. Revenues are recorded during the period our obligations to provide services are satisfied. The contractual relationships with patients, in most cases, also involve a third-party payer (Medicare, Medicaid, managed care health plans and commercial insurance companies, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent upon the terms provided by (Medicare and Medicaid) or negotiated with (managed care health plans and commercial insurance companies) the third-party payers. The payment arrangements with third-party payers for the services we provide to the related patients typically specify payments at amounts less than our standard charges and generally provide for payments based upon predetermined rates for services or discounted fee-for-service rates. Management continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals. Stock-Based Compensation - Equity instruments issued to those other than employees are recognized pursuant to FASB issued ASU 2018-07, Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting. This ASU relates to the accounting for non-employee share-based payments. The amendment in this update expands the scope of Topic 718 to include all share-based payment transactions in which a grantor acquired goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards. The ASU excludes share-based payment awards that relate to: (1) financing to the issuer; or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under Topic 606, Revenue from Contracts from Customers. The share-based payments are to be measured at grant-date fair value of the equity instruments that the entity is obligated to issue when the goods or service has been delivered or rendered and all other conditions necessary to earn the right to benefit from the equity instruments have been satisfied. This standard will be effective for public business entities for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. We adopted the provisions of this ASU on January 1, 2019. The adoption had no impact on our results of operations, cash flows, or financial condition. Convertible Instruments Derivative Financial Instruments Common Stock Purchase Warrants- Stockholders Equity- Per Share Data- Income Taxes- Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all the deferred tax assets will not be realized. The Company has determined that a valuation allowance is needed due to recent taxable net operating losses and the limited taxable income in the carry back periods. The effect on deferred tax assets and liabilities of a change in tax rates is recognized as income or expense in the period that includes the enactment date. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes and certain tax loss carryforwards, less any valuation allowance. The Company accounts for uncertain tax positions as required in that a position taken or expected to be taken in a tax return is recognized in the consolidated financial statements when it is more likely than not (i.e., a likelihood of more than 50%) that the position would be sustained upon examination by tax authorities. A recognized tax position is then measured at the largest amount of benefit that is greater than 50% of being realized upon ultimate settlement. The Company does not have any material unrecognized tax benefits. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as components of interest expense and other expense, respectively, in arriving at pretax income or loss. The Company does not have any interest and penalties accrued. The Company is no longer subject to U.S. federal, state, and local income tax examinations for the years before 2012. Business Combinations- ● future expected cash flows from product sales, support agreements, consulting contracts, other customer contracts, and acquired developed technologies and patents; and ● discount rates utilized in valuation estimates. Unanticipated events and circumstances may occur that may affect the accuracy or validity of such assumptions, estimates or actual results. Additionally, any change in the fair value of the acquisition-related contingent consideration subsequent to the acquisition date, including changes from events after the acquisition date, such as changes in our estimates of relevant revenue or other targets, will be recognized in earnings in the period of the estimated fair value change. A change in fair value of the acquisition-related contingent consideration or the occurrence of events that cause results to differ from our estimates or assumptions could have a material effect on the consolidated financial position, statements of operations or cash flows in the period of the change in the estimate. Impairment of Long-Lived Assets- Financial Instruments and Fair Values- Level 1 – inputs include exchange quoted prices for identical instruments and are the most observable. Level 2 – inputs include brokered and/or quoted prices for similar assets and observable inputs such as interest rates. Level 3 – inputs include data not observable in the market and reflect management judgment about the assumptions market participants would use in pricing the asset or liability. The use of observable and unobservable inputs and their significance in measuring fair value are reflected in our hierarchy assessment. The carrying amount of cash, prepaid assets, accounts payable and accrued liabilities approximate fair value due to the short-term maturities of these instruments. Because cash and cash equivalents are readily liquidated, management classifies these values as Level 1. The fair value of the derivative liabilities approximates their book value as the instruments are short-term in nature and contain market rates of interest. Because there is no ready market or observable transactions, management classifies the derivative liabilities as Level 3. Recent Accounting Standards In August 2020, the FASB issued ASU 2020-06, "Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40)”. This ASU reduces the number of accounting models for convertible debt instruments and convertible Preferred Stock, and amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. In addition, this ASU improves and amends the related EPS guidance. This standard is effective for us on January 1, 2022, including interim periods within those fiscal years. Adoption is either a modified retrospective method or a fully retrospective method of transition. The adoption of this new guidance did not have a material effect on our consolidated financial statements. There are various other updates recently issued, most of which represent technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s consolidated financial position, results of operations or cash flows.

Net Loss Per Share Applicable t

Net Loss Per Share Applicable to Common Shareholders	12 Months Ended
	Dec. 31, 2022
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	Note 4: Net Loss Per Share Applicable to Common Shareholders Net Loss per Share Applicable to Common Stockholders Basic loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the reporting period. Diluted loss per common share is computed similarly to basic loss per common share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock. The following table sets forth the computation of loss per share for the years ended December 31, 2022 and 2021, respectively: For the Years Ended December 31, 2022 2021 Numerator: Net loss applicable to common shareholders $ (23,558,439 ) $ (11,226,366 ) Denominator: Weighted average common shares outstanding 4,451,962 4,060,005 Net loss per share: Basic and diluted $ (5.29 ) $ (2.77 ) The Company excluded all common equivalent shares for warrants, options, and convertible instruments from the calculation of diluted net loss per share because all such securities are antidilutive for the periods presented. As of December 31, 2022 and 2021, the following shares were issuable and excluded from the calculation of diluted loss: December 31, 2022 2021 Options 310,692 374,924 Warrants 672,334 596,400 Preferred Stock 347,652 347,652 Accrued Interest 42,002 17,443 Total 1,372,680 1,336,419

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2022
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	Note 5: Related Party Transactions The Company was involved in a significant number of fundraising transactions with related parties during the years ended December 31, 2022 and 2021. See notes 10 and 12.

Accounts Payable and Accrued Li

Accounts Payable and Accrued Liabilities	12 Months Ended
	Dec. 31, 2022
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	Note 6: Accounts Payable and Accrued Liabilities Accounts payable and accrued liabilities consisted of the following at December 31, 2022 and 2021: December 31, December 31, 2022 2021 Trade accounts payable $ 6,761,793 $ 3,933,305 Accrued payroll and payroll taxes 590,915 23,554 Other 507 19,205 Total accounts payable and accrued liabilities $ 7,353,215 $ 3,976,064 Accounts Payable Exchanged for Common Stock On January 5, 2022, we entered into an exchange agreement with Gardner Builders Holdings, LLC (“Gardner”) (the “Gardner Agreement”). Pursuant to the Gardner Agreement, we have authorized the issuance of shares of the Company’s restricted common stock to Gardner in exchange for the certain accounts payable and additional amounts due to Gardner as defined below. The Gardner Agreement settles certain amounts owed by us to Gardner (the “Accounts Payable Amount”) as well as upcoming amounts that will become due between the date of the Gardner Agreement and April 1, 2022. The Gardner Agreement also settled incurred interest and penalties on the amounts owed through January 5, 2022, as well as future interest payments on amounts to be incurred in the first quarter of 2022 (collectively, the “Additional Costs”, and combined with the Accounts Payable Amount, the “Company Debt Obligations”). The Accounts Payable Amount is $500,000, the Additional Costs is $294,913 and the conversion price is $12.50. As a result, 63,593 Restricted Shares were authorized to be issued. Our Board of Directors approved the Gardner Agreement on January 5, 2022.

Right to Use Assets and Lease L

Right to Use Assets and Lease Liabilities - Operating Leases	12 Months Ended
	Dec. 31, 2022
Disclosure Text Block [Abstract]
Lessee, Operating Leases [Text Block]	Note 7: Right to Use Assets and Lease Liabilities Operating Leases The Company has an operating lease for its clinic with a remaining lease term of approximately 7.5 years. The Company’s lease expense was entirely comprised of operating leases. Lease expense for the years ended December 31, 2022 and 2021 amounted to $860,705 and $351,854, respectively. The Company’s RTU asset amortization for the years ended December 31, 2022 and 2021 was $357,700 and $162,276, respectively. During the year ended December 31, 2022, the Company recognized an impairment of RTU assets in the amount of $3,185,591 in connection with the closing of its clinics during the period. The remaining difference between the lease expense and the associated RTU asset amortization consists of interest at a rate of 12% for the years ended December 31, 2022 and 2021. The weighted-average lease term outstanding was 84.0 and 92.1 months at December 31, 2022 and 2021, respectively. Right to use assets – operating leases are summarized below: December 31, 2022 December 31, 2021 Right to use assets, net $ 544,063 $ 3,886,866 Operating lease liabilities are summarized below: December 31, 2022 December 31, 2021 Lease liability $ 4,379,724 $ 4,134,802 Less: current portion (442,866 ) (161,838 ) Lease liability, non-current $ 3,936,858 $ 3,972,964 Maturity analysis under these lease agreements are as follows: For the period ended December 31, 2023 $ 945,102 For the period ended December 31, 2024 884,990 For the period ended December 31, 2025 906,666 For the period ended December 31, 2026 926,988 For the period ended December 31, 2027 946,745 Thereafter 1,939,476 Total $ 6,549,967 Less: Present value discount (2,170,243 ) Lease liability $ 4,379,724

SBA Loan Payable

SBA Loan Payable	12 Months Ended
	Dec. 31, 2022
Small Business Administration Loan Payable Abstract
Small Business Administration Loan Payable [Text Block]	Note 8: SBA Loan Payable PPP Loan During March 2020, in response to the COVID-19 crisis, the federal government announced plans to offer loans to small businesses in various forms, including the Payroll Protection Program, or “PPP”, established as part of the Corona Virus Aid, Relief and Economic Security Act (“CARES Act”) and administered by the U.S. Small Business Administration. On April 25, 2020, the Company entered an unsecured Promissory Note (the “Note”) with Bank of America for a loan in the original principal amount of $460,400, and the Company received the full amount of the loan proceeds on May 4, 2020 (the “PPP Loan”). The PPP Loan bears interest at the rate of 1% per year. During the year ended December 31, 2022, the Company accrued interest in the amount of $4,632. The current balance is $460,406. The PPP Loan is in default at December 31, 2022.

Notes Payable

Notes Payable	12 Months Ended
	Dec. 31, 2022
Notes Payable [Line Items]
Debt Disclosure [Text Block]	Note 9: Notes Payable AJB Note On March 18, 2022, the Company entered into a Securities Purchase Agreement (the “AJB Agreement”) with AJB Capital Investments, LLC (“AJB”) with respect to the sale and issuance to AJB of: (i) an initial commitment fee in the amount of $430,000 in the form of 34,400 shares (the “AJB Commitment Fee Shares”) of the Company’s Common Stock, (ii) a promissory note in the aggregate principal amount of $750,000 (the “AJB Note”), and (iii) Common Stock Purchase Warrants to purchase 15,000 shares of the Company’s Common Stock (the “AJB Warrants”). The AJB Note and AJB Warrants were issued on March 17, 2022 and were held in escrow pending effectiveness of the AJB Agreement. Should AJB receive net proceeds of less than $430,000 from the sale of the AJB Commitment Fee Shares, the Company will issue additional shares to AJB or pay the shortfall amount to AJB in cash (the “AJB True-up Obligation”. The terms of the AJB Agreement resulted in the Company recording a derivative liability in the initial amount of $106,608. On November 18, 2022, the Company issued 91,328 shares of common stock to AJB and recorded a loss in the amount of $9,007 in connection with the settlement of the AJB True-up Obligation. See notes 11 and 12. The AJB Note was issued in the principal amount of $750,000 for a purchase price of $675,000, resulting in an original issue discount of $75,000, and has a due date, as extended, of March 17, 2023. The AJB Note bears interest at the rate of 10% per year for the first six months and 12% thereafter. In the event of default as defined in the AJB Note this rate will increase to 18% and the AJB Note will become convertible at a price per share equal to the lowest trading price during the previous twenty trading days prior to the conversion date. The AJB Note entered default status on October 6, 2022. The AJB Commitment Fee Shares and AJB Warrants resulted in a discount to the AJB Note in the amount of $349,914. The Company charged the amount of $62,000 to interest on the AJB Note during the year ended December 31, 2022. Discounts in the amount of $424,914 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $750,000 and $22,833, respectively, were due on the AJB Note at December 31, 2022. The AJB Note was in default at December 31, 2022. Anson Investments Note On April 6, 2022, the Company entered into a Securities Purchase Agreement (the “Anson Investments Agreement”) with Anson Investments Master Fund LP (“Anson Investments”) with respect to the sale and issuance to Anson Investments of: (i) an initial commitment fee in the amount of $322,500 in the form of 25,800 shares (the “Anson Investments Commitment Fee Shares”) of the Company’s Common Stock, (ii) a promissory note in the aggregate principal amount of $562,500 (the “Anson Investments Note”), and (iii) Common Stock Purchase Warrants to purchase 11,250 shares of the Common Stock (the “Anson Investments Warrants”). Should Anson Investments receive net proceeds of less than $322,500 from the sale of the Anson Investments Commitment Fee Shares, the Company will issue additional shares to Anson Investments or pay the shortfall amount to Anson Investments in cash. The terms of the Anson Investments Agreement resulted in the Company recording a derivative liability in the initial amount of $27,040. The Anson Investments Note was issued in the principal amount of $562,500 for a purchase price of $506,250 resulting in an original issue discount of $56,250. The Anson Investments Note has a due date of October 6, 2022 and bears interest at the rate of 10% per year for the first six months and 12% thereafter. In the event of default as defined in the Anson Investments Note this rate will increase to 18% and the Anson Investment Note will become convertible at a price per share equal to the lowest trading price during the previous twenty trading days prior to the conversion date. The Anson Investments Note entered default status on October 6, 2022. The Anson Investments Commitment Fee Shares and Anson Investments Warrants resulted in a discount to the Anson Investments Note in the amount of $416,375. The Company charged the amount of $68,844 to interest on the Anson Investments note during the year ended December 31, 2022. Discounts in the amount of $472,625 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $562,500 and $41,500, respectively, were due on the AJB Note at December 31, 2022. The Anson Investments Note was in default at December 31, 2022. Anson East Note On April 6, 2022, the Company entered into a Securities Purchase Agreement (the “Anson East Agreement”) with Anson East Master Fund LP (“Anson East”) with respect to the sale and issuance to Anson East of: (i) an initial commitment fee in the amount of $107,500 in the form of 8,600 shares (the “Anson East Commitment Fee Shares”) of the Company’s Common Stock, (ii) a promissory note in the aggregate principal amount of $187,500 (the “Anson East Note”), and (iii) Common Stock Purchase Warrants to purchase 3,750 shares of the Company’s common stock (the “Anson East Warrants”). Should Anson East receive net proceeds of less than $107,500 from the sale of the Anson East Commitment Fee Shares, the Company will issue additional shares to Anson East or pay the shortfall amount to Anson East in cash. The terms of the Anson East Agreement resulted in the Company recording a derivative liability in the initial amount of $9,014. The Anson East Note was issued in the principal amount of $187,500 for a purchase price of $168,750 resulting in an original issue discount of $18,750. The Anson East Note has a due date of October 6, 2022 and bears interest at the rate of 10% per year for the first six months and 12% thereafter. In the event of default as defined in the Anson East Note this rate will increase to 18%, and the Anson East Note will become convertible at a price per share equal to the lowest trading price during the previous twenty trading days prior to the conversion date. The Anson East Note entered default status on October 6, 2022. The Anson East Commitment Fee Shares and Anson East Warrants resulted in a discount to the Anson East Note in the amount of $147,290. The Company charged the amount of $22,948 to interest on the Anson Investments note during the year ended December 31, 2022. Discounts in the amount of $166,040 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $187,500 and $13,833, respectively, were due on the Anson East Note at December 31, 2022. The Anson East Note was in default at December 31, 2022. GS Capital Note On April 18, 2022, the Company entered into a Securities Purchase Agreement (the “GS Capital Agreement”) with GS Capital Investments, LLC (“GS Capital”) with respect to the sale and issuance to GS Capital of: (i) an initial commitment fee in the amount of $159,259 in the form of 12,741 shares (the “GS Capital Commitment Fee Shares”) of the Company’s Common Stock, (ii) a promissory note in the aggregate principal amount of $277,777 (the “GS Capital Note”), and (iii) Common Stock Purchase Warrants to purchase 5,556 shares of the Company’s common stock (the “GS Capital Warrants”). Should GS Capital receive net proceeds of less than $159,259 from the sale of the GS Capital Commitment Fee Shares, the Company will issue additional shares to GS Capital or pay the shortfall amount to GS Capital in cash. The terms of the GS Capital Agreement resulted in the Company recording a derivative liability in the initial amount of $21,920. The GS Capital Note was issued in the principal amount of $277,777 for a purchase price of $250,000 resulting in an original issue discount of $27,777. The GS Capital Note has a due date of November 10, 2022 and bears interest at the rate of 10% per year for the first six months and 12% thereafter. In the event of default as defined in the GS Capital Note this rate will increase to 18%, and the GS Capital Note will become convertible at a price per share equal to the lowest trading price during the previous twenty trading days prior to the conversion date. The GS Capital Note entered default status on October 19, 2022. The GS Capital Commitment Fee Shares and GS Capital Warrants resulted in a discount to the GS Capital Note in the amount of $162,158. The Company charged the amount of $32,155 to interest on the GS Capital Note during the year ended December 31, 2022. Discounts in the amount of $212,435 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $277,777 and $19,578, respectively, were due on the GS Capital Note at December 31, 2022. The GS Capital Note was in default at December 31, 2022. Kishon Note On May 10, 2022, the Company entered into a Securities Purchase Agreement (the “Kishon Agreement”) with Kishon Investments, LLC (“Kishon”) with respect to the sale and issuance to Kishon of: (i) an initial commitment fee in the amount of $159,259 in the form of 12,741 shares (the “Kishon Commitment Fee Shares”) of the Company’s Common Stock, (ii) a promissory note in the aggregate principal amount of $277,777 (the “Kishon Note”), and (iii) Common Stock Purchase Warrants to purchase 5,556 shares of the Company’s common stock (the “Kishon Warrants”). Should Kishon receive net proceeds of less than $159,259 from the sale of the Kishon Commitment Fee Shares, the Company will issue additional shares to Kishon or pay the shortfall amount to Kishon in cash. The terms of the Kishon Agreement resulted in the Company recording a derivative liability in the initial amount of $27,793. The Kishon Note was issued in the principal amount of $277,777 for a purchase price of $250,000 resulting in an original issue discount of $27,777. The Kishon Note has a due date of November 10, 2022 and bears interest at the rate of 10% per year for the first six months and 12% thereafter. In the event of default as defined in the Kishon Note this rate will increase to 18%, and the Kishon Note will become convertible at a price per share equal to the lowest trading price during the previous twenty trading days prior to the conversion date. The Kishon Note entered default status on November 11, 2022. The Kishon Commitment Fee Shares and Kishon Warrants resulted in a discount to the Kishon Note in the amount of $138,492. The Company charged the amount of $28,624 to interest on the Kishon Note during the year ended December 31, 2022. Discounts in the amount of $181,269 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $277,777 and $17,822, respectively, were due on the Kishon Note at December 31, 2022. The Kishon Note was in default at December 31, 2022. Finnegan Note 1 On May 23, 2022, the Company issued a 10% Promissory Note in the principal amount of $47,059 to Jessica Finnegan (the “Finnegan Note 1”). The Finnegan Note 1 bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 20, 2022, as extended, or (ii) five (5) business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Finnegan Note 1 was $40,000; the amount payable at maturity will be $47,059 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Finnegan Note 1, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Finnegan Note 1 entered default status on November 21, 2022, and the interest rate increased to 18%. The Finnegan Note 1 contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Ms. Finnegan reasonably believes contains a term that is more favorable than those in the Finnegan Note 1, the Company shall notify Ms. Finnegan of such term, and such term, at the option of Ms. Finnegan, shall become a part of the Finnegan Note 1. In addition, Ms. Finnegan received five-year warrants to purchase 386 shares of common stock at a price of $25.00 per share with a fair value of $2,000 at the date of issuance, and 1,930 shares of common stock with a value of $3,240; these amounts were recorded as discounts to the Finnegan Note 1. Interest in the amount of $3,285 was accrued on the Finnegan Note 1 during the year ended December 31, 2022. Discounts in the amount of $17,005 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $51,765 and $3,285, respectively, were due on the Finnegan Note 1 at December 31, 2022. The Finnegan Note 1 was in default at December 31, 2022. M Diamond Note On May 26, 2022, the Company issued a 10% Promissory Note in the principal amount of $58,823 to Melissa Diamond (the “M Diamond Note”). The M Diamond Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the M Diamond Note was $50,000; the amount payable at maturity will be $58,823 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the M Diamond Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The M Diamond Note entered default status on December 1, 2022, and the interest rate increased to 18%. The M Diamond Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Ms. Diamond reasonably believes contains a term that is more favorable than those in the M Diamond Note, the Company shall notify Ms. Diamond of such term, and such term, at the option of Ms. Diamond, shall become a part of the M Diamond Note. In addition, Ms. Diamond received five-year warrants to purchase 483 shares of common stock at a price of $25.00 per share with a fair value of $2,500 at the date of issuance, and 483 shares of common stock with a value of $4,050; these amounts were recorded as discounts to the M Diamond Note. Interest in the amount of $3,929 was accrued on the M Diamond Note during the year ended December 31, 2022. Discounts in the amount of $21,256 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $64,705 and $3,929, respectively, were due on the M Diamond Note at December 31, 2022. The M Diamond Note was in default at December 31, 2022. Finnegan Note 2 On May 26, 2022, the Company issued a 10% Promissory Note in the principal amount of $29,412 to Jessica Finnegan (the “Finnegan Note 2”). The Finnegan Note 2 bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Finnegan Note 2 was $25,000; the amount payable at maturity will be $29,412 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Finnegan Note 2, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Finnegan Note 2 entered default status on December 1, 2022, and the interest rate increased to 18%. The Finnegan Note 2 contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Ms. Finnegan reasonably believes contains a term that is more favorable than those in the Finnegan Note 2, the Company shall notify Ms. Finnegan of such term, and such term, at the option of Ms. Finnegan, shall become a part of the Finnegan Note 2. In addition, Ms. Finnegan received five-year warrants to purchase 242 shares of common stock at a price of $25.00 per share with a fair value of $1,250 at the date of issuance, and 242 shares of common stock with a value of $2,025; these amounts were recorded as discounts to the Finnegan Note 2. Interest in the amount of $1,965 was accrued on the Finnegan Note 2 during the year ended December 31, 2022. Discounts in the amount of $10,625 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $32,353 and $1,965, respectively, were due on the Finnegan Note 2 at December 31, 2022. The Finnegan Note 2 was in default at December 31, 2022. Dragon Note On June 9, 2022, the Company issued a 10% Promissory Note in the principal amount of $588,235 (the “Dragon Note”) to Dragon Dynamic Funds Platform Ltd (“Dragon Dynamic”). The Dragon Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) December 9, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Dragon Note was $500,000; the amount payable at maturity will be $588,235 plus 10% of that amount plus any accrued and unpaid interest. Costs in the amount of $47,500 were charged to discount on the Dragon Note. Following an event of default as defined in the Dragon Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Dragon Note entered default status on December 10, 2022, and the interest rate increased to 18%. The Dragon Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Dragon Dynamic reasonably believes contains a term that is more favorable than those in the Dragon Note, the Company shall notify Dragon Dynamic of such term, and such term, at the option of Dragon Dynamic, shall become a part of the Dragon Note. In addition, Dragon Dynamic received five-year warrants to purchase 4,824 shares of common stock at a price of $25.00 per share with a fair value of $21,500 at the date of issuance, and 4,824 shares of common stock with a value of $44,000; these amounts were recorded as discounts to the Dragon Note. Interest in the amount of $35,874 was accrued on the Dragon Note during the year ended December 31, 2022. Discounts in the amount of $260,059 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $647,059 and $35,874, respectively, were due on the Dragon Note at December 31, 2022. The Dragon Note was in default at December 31, 2022. Mackay Note On July 7, 2022, the Company issued a 10% Promissory Note in the principal amount of $294,118 to Mackay Investments, LLC (the “Mackay Note”). The Mackay Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) August 10, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Mackay Note was $250,000; the amount payable at maturity will be $294,118 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Mackay Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Mackay Note entered default status on August 11, 2022, and the interest rate increased to 18%. The Mackay Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mackay Investments, LLC reasonably believes contains a term that is more favorable than those in the Mackay Note, the Company shall notify Mackay Investments, LLC of such term, and such term, at the option of Mackay Investments, LLC , shall become a part of the Mackay Note. In addition, Mackay Investments, LLC received five-year warrants to purchase 2,412 shares of common stock at a price of $25.00 per share with a fair value of $10,250 at the date of issuance, and 2,412 shares of common stock with a value of $44,118; these amounts were recorded as discounts to the Mackay Note. Interest in the amount of $20,193 was accrued on the Mackay Note during the year ended December 31, 2022. Discounts in the amount of $96,280 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $323,530 and $20,193, respectively, were due on the Mackay Note at December 31, 2022. The Mackay Note was in default at December 31, 2022. Schrier Note On July 7, 2022, the Company issued a 10% Promissory Note in the principal amount of $23,259 to Charles Schrier (the “Schrier Note”). The Schrier Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) January 8, 2023, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Schrier Note was $20,000; the amount payable at maturity will be $23,529 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Schrier Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Schrier Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Schrier reasonably believes contains a term that is more favorable than those in the Schrier Note, the Company shall notify Mr. Schrier of such term, and such term, at the option of Mr. Schrier, shall become a part of the Schrier Note. In addition, Mr. Schrier received five-year warrants to purchase 193 shares of common stock at a price of $25.00 per share with a fair value of $820 at the date of issuance, and 193 shares of common stock with a value of $1,000; these amounts were recorded as discounts to the Schrier Note. Interest in the amount of $1,141 was accrued on the Schrier Note during the year ended December 31, 2022. Discounts in the amount of $7,367 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $335 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $25,882 and $1,141, respectively, were due on the Schrier Note at December 31, 2022. Nommsen Note On July 26, 2022, the Company issued a 10% Promissory Note in the principal amount of $58,823 to Eric S. Nommsen (the “Nommsen Note”). The Nommsen Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, as extended, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Nommsen Note was $50,000; the amount payable at maturity will be $58,823 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Nommsen Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Nommsen Note entered default status on December 1, 2022, and the interest rate increased to 18%. The Nommsen Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Nommsen reasonably believes contains a term that is more favorable than those in the Nommsen Note, the Company shall notify Mr. Nommsen of such term, and such term, at the option of Mr. Nommsen, shall become a part of the Nommsen Note. In addition, Mr. Nommsen received five-year warrants to purchase 483 shares of common stock at a price of $25.00 per share with a fair value of $1,850 at the date of issuance, and 483 shares of common stock with a value of $2,350; these amounts were recorded as discounts to the Nommsen Note. Interest in the amount of $2,946 was accrued on the Nommsen Note during the year ended December 31, 2022. Discounts in the amount of $18,905 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $64,705 and $2,946, respectively, were due on the Nommsen Note at December 31, 2022. The Nommsen Note was in default at December 31, 2022. Caplan Note On July 27, 2022, the Company issued a 10% Promissory Note in the principal amount of $58,823 to James H. Caplan (the “Caplan Note”). The Caplan Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) January 21, 2023, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Caplan Note was $50,000; the amount payable at maturity will be $58,823 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Caplan Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Caplan Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Caplan reasonably believes contains a term that is more favorable than those in the Caplan Note, the Company shall notify Mr. Caplan of such term, and such term, at the option of Mr. Caplan, shall become a part of the Caplan Note. In addition, Mr. Caplan received five-year warrants to purchase 483 shares of common stock at a price of $25.00 per share with a fair value of $1,850 at the date of issuance, and 483 shares of common stock with a value of $2,350; these amounts were recorded as discounts to the Caplan Note. Interest in the amount of $2,531 was accrued on the Caplan Note during the year ended December 31, 2022. Discounts in the amount of $16,675 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $2,230 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $64,705 and $2,531, respectively, were due on the Caplan Note at December 31, 2022. Finnegan Note 3 On August 4, 2022, the Company issued a 10% Promissory Note in the principal amount of $29,412 (the “Finnegan Note 3”) to Jessica, Kevin C., Brody, Isabella and Jack Finnegan (collectively, the “Finnegans”). The Finnegan Note 3 bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) February 3, 2023, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Finnegan Note 3 was $25,000; the amount payable at maturity will be $29,412 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Finnegan Note 3, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Finnegan Note 3 contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which The Finnegans reasonably believes contains a term that is more favorable than those in the Finnegan Note 3, the Company shall notify The Finnegans of such term, and such term, at the option of The Finnegans, shall become a part of the Finnegan Note 3. In addition, The Finnegans received five-year warrants to purchase 242 shares of common stock at a price of $25.00 per share with a fair value of $850 at the date of issuance, and 242 shares of common stock with a value of $1,100; these amounts were recorded as discounts to the Finnegan Note 3. Interest in the amount of $1,200 was accrued on the Finnegan Note 3 during the year ended December 31, 2022. Discounts in the amount of $7,575 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $1,728 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $32,353 and $1,200, respectively, were due on the Finnegan Note 3 at December 31, 2022. Enright Note On August 4, 2022, the Company issued a 10% Promissory Note in the principal amount of $120,000 to Jack Enright (the “Enright Note”). The Enright Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) February 3, 2023, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Enright Note was $102,000; the amount payable at maturity will be $120,000 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Enright Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Enright Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Enright reasonably believes contains a term that is more favorable than those in the Enright Note, the Company shall notify Mr. Enright of such term, and such term, at the option of Mr. Enright, shall become a part of the Enright Note. In addition, Mr. Enright received 984 shares of common stock with a value of $6,317; this amount was recorded as a discount to the Enright Note. Interest in the amount of $4,899 was accrued on the Enright Note during the year ended December 31, 2022. Discounts in the amount of $29,571 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $6,746 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $132,000 and $4,899, respectively, were due on the Enright Note at December 31, 2022. Mitchell Note On September 2, 2022, the Company issued a 10% Promissory Note in the principal amount of $71,000 to John Mitchell (the “Mitchell Note”). The Mitchell Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Mitchell Note was $60,350; the amount payable at maturity will be $71,000 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Mitchell Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Mitchell Note ent
Related Party [Member]
Notes Payable [Line Items]
Debt Disclosure [Text Block]	Note 10: Notes Payable Related Parties Howe Note 1 On December 30, 2021, we issued a 10% Promissory Note in the principal amount of $1,000,000 in a related party transaction to the Michael C. Howe Living Trust (the “Howe Note 1”). Michael C. Howe is the Chief Executive Officer of the Good Clinic LLC, one of our subsidiaries. The Howe Note 1 bears interest at the rate of 10% interest rate per annum and has a maturity date that is the earlier of (i) November 30, 2022, as extended, or (ii) five (5) business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Howe Note 1 was $850,000; the amount payable at maturity will be $1,000,000 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default, as defined in the Howe Note 1, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Howe Note 1 entered delinquent status on December 1, 2022, and the interest rate increased to 18%. The Howe Note 1 contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security, which Mr. Howe reasonably believes contains a term that is more favorable than those in the Howe Note 1, we shall notify Mr. Howe of such term, and such term, at the option of Mr. Howe, shall become a part of th e Howe Note 1. In addition, Mr. Howe five-year warrants to purchase 42,000 shares of common stock at a price of $25.00 per share, and five-year warrants to purchase 42,000 shares of common stock at $37.50 per share with an aggregate fair value of $261,568 at the date of issuance, which was recorded as a discount to this note. Interest in the amount of $106,795 was accrued on the Howe Note 1 during the year ended December 31, 2022. Discounts in the amount of $511,568 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $1,100,000 and $106,795, respectively, were due on the Howe Note 1 at December 31, 2022. The Howe Note 1 was in default at December 31, 2022. Diamond Note 1 On February 24, 2022, the Company issued a 10% Promissory Note in the principal amount of $175,000 in a related party transaction to Lawrence Diamond, our Chief Executive Officer and a member of our Board of Directors (the “Diamond Note 1”). The Diamond Note 1 bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, as extended, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Diamond Note 1 was $148,750; the amount payable at maturity will be $175,000 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Diamond Note 1, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Diamond Note 1 entered default status on December 1, 2022, and the interest rate increased to 18%. The Diamond Note 1 contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Diamond reasonably believes contains a term that is more favorable than those in the Diamond Note 1, the Company shall notify Mr. Diamond of such term, and such term, at the option of Mr. Diamond, shall become a part of the Diamond Note 2. In addition, Mr. Diamond received five-year warrants to purchase 7,350 shares of common stock at a price of $25.00 per share, and five-year warrants to purchase 7,350 shares of common stock at $37.50 per share with an aggregate fair value of $2,914 at the date of issuance, which was recorded as a discount to this note. Interest in the amount of $16,052 was accrued on the Diamond Note 1 during the year ended December 31, 2022. Discounts in the amount of $46,664 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $192,500 and $16,052, respectively, were due on the Diamond Note 1 at December 31, 2022. The Diamond Note 1 was in default at December 31, 2022. Diamond Note 2 On March 18, 2022, the Company issued a 10% Promissory Note in the principal amount of $235,294 in a related party transaction to Lawrence Diamond, our Chief Executive Officer and a member of our Board of Directors (the “Diamond Note 2). The Diamond Note 2 bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, as extended, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Diamond Note 2 was $200,000; the amount payable at maturity will be $235,294 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Diamond Note 2, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Diamond Note 2 entered default status on December 1, 2022, and the interest rate increased to 18%. The Diamond Note 2 contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Diamond reasonably believes contains a term that is more favorable than those in the Diamond Note 2, the Company shall notify Mr. Diamond of such term, and such term, at the option of Mr. Diamond, shall become a part of the Diamond Note 2. In addition, Mr. Diamond received five-year warrants to purchase 1,930 shares of common stock at a price of $25.00 per share a fair value of $2,213 at the date of issuance, which was recorded as a discount to this note. Interest in the amount of $1,676 was accrued on the Diamond Note 2 during the year ended December 31, 2022. Principal in the amount of $235,294 was paid on the Diamond Note 2 during the year ended December 31, 2022. Discounts in the amount of $61,036 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $23,529 and $1,676, respectively, were due on the Diamond Note 2 at December 31, 2022. The Diamond Note 2 was in default at December 31, 2022. Diamond Note 3 On April 27, 2022, Diamond Note 4 On May 18, 2022, the Company issued a 10% Promissory Note in the principal amount of $47,059 in a related party transaction to Lawrence Diamond, our Chief Executive Officer and a member of our Board of Directors (the “Diamond Note 4”). The Diamond Note 4 bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, as extended, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Diamond Note 4 was $40,000; the amount payable at maturity will be $47,059 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Diamond Note 4, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Diamond Note 4 entered default status on December 1, 2022, and the interest rate increased to 18%. The Diamond Note 4 contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Diamond reasonably believes contains a term that is more favorable than those in the Diamond Note 4, the Company shall notify Mr. Diamond of such term, and such term, at the option of Mr. Diamond, shall become a part of the Diamond Note 4. In addition, Mr. Diamond received five-year warrants to purchase 386 shares of common stock at a price of $25.00 per share with a fair value of $2,960 at the date of issuance, and 1,930 shares of common stock with a value of $3,160; these amounts were recorded as discounts on the Diamond Note 4. Interest in the amount of $3,245 was accrued on the Diamond Note 4 during the year ended December 31, 2022. Discounts in the amount of $17,885 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $51,765 and $3,245, respectively, were due on the Diamond Note 4 at December 31, 2022. The Diamond Note 4 was in default at December 31, 2022. Diamond Note 5 On May 26, 2022, the Company issued a 10% Promissory Note in the principal amount of $58,823 in a related party transaction to Lawrence Diamond, our Chief Executive Officer and a member of our Board of Directors (the “Diamond Note 5”). The Diamond Note 5 bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Diamond Note 5 was $50,000; the amount payable at maturity will be $58,823 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Diamond Note 5, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Diamond Note 5 entered default status on December 1, 2022, and the interest rate increased to 18%. The Diamond Note 5 contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Diamond reasonably believes contains a term that is more favorable than those in the Diamond Note 5, the Company shall notify Mr. Diamond of such term, and such term, at the option of Mr. Diamond, shall become a part of the Diamond Note 5. In addition, Mr. Diamond received five-year warrants to purchase 483 shares of common stock at a price of $25.00 per share with a fair value of $2,500 at the date of issuance, and 483 shares of common stock with a value of $4,050; these amounts were recorded as discounts to the Diamond Note 5. Interest in the amount of $3,929 was accrued on the Diamond Note 5 during the year ended December 31, 2022. Discounts in the amount of $21,256 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $64,705 and $3,929, respectively, were due on the Diamond Note 5 at December 31, 2022. The Diamond Note 5 was in default at December 31, 2022. Lindstrom Note 1 On May 26, 2022, the Company issued a 10% Promissory Note in the principal amount of $41,176 in a related party transaction to Jenny Lindstrom, the Company’s Chief Legal Officer (the “Lindstrom Note 1”). The Lindstrom Note 1 bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Lindstrom Note 1 was $35,000; the amount payable at maturity will be $41,176 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Lindstrom Note 1, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Lindstrom Note 1 entered default status on December 1, 2022, and the interest rate increased to 18%. The Lindstrom Note 1 contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Ms. Lindstrom reasonably believes contains a term that is more favorable than those in the Lindstrom Note 1, the Company shall notify Ms. Lindstrom of such term, and such term, at the option of Ms. Lindstrom, shall become a part of the Lindstrom Note 1. In addition, Ms. Lindstrom received five-year warrants to purchase 338 shares of common stock at a price of $25.00 per share with a fair value of $1,750 at the date of issuance, and 338 shares of common stock with a value of $2,835; these amounts were recorded as discounts to the Lindstrom Note 1. Interest in the amount of $2,750 was accrued on the Lindstrom Note 1 during the year ended December 31, 2022. Discounts in the amount of $14,879 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $45,294 and $2,750, respectively, were due on the Lindstrom Note 1 at December 31, 2022. The Lindstrom Note 1 was in default at December 31, 2022. Dobbertin Note 1 On May 26, 2022, the Company issued a 10% Promissory Note in the principal amount of $17,647 in a related party transaction to Alexander Dobbertin (the “Dobbertin Note”). Mr. Dobbertin is the spouse of Jenny Lindstrom, the Company’s Chief Legal Officer. The Dobbertin Note bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Dobbertin Note was $15,000; the amount payable at maturity will be $17,647 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Dobbertin Note, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Dobbertin Note entered default status on December 1, 2022, and the interest rate increased to 18%. The Dobbertin Note contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Dobbertin reasonably believes contains a term that is more favorable than those in the Dobbertin Note, the Company shall notify Mr. Dobbertin of such term, and such term, at the option of Mr. Dobbertin, shall become a part of the Dobbertin Note. In addition, Mr. Dobbertin received five-year warrants to purchase 145 shares of common stock at a price of $25.00 per share with a fair value of $750 at the date of issuance, and 145 shares of common stock with a value of $1,215; these amounts were recorded as discounts to the Dobbertin Note. Interest in the amount of $1,179 was accrued on the Dobbertin Note during the year ended December 31, 2022. Discounts in the amount of $6,377 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $19,412 and $1,179, respectively, were due on the Dobbertin Note at December 31, 2022. The Dobbertin Note was in default at December 31, 2022. Howe Note 2 On June 9, 2022, the Company issued a 10% Promissory Note in the principal amount of $300,000 in a related party transaction to the Michael C. Howe Living Trust (the “Howe Note 2”). Michael C. Howe is the Chief Executive Officer of the Good Clinic LLC, one of our subsidiaries. The Howe Note 2 bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Howe Note 2 was $255,000; the amount payable at maturity will be $300,000 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Howe Note 2, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Howe Note 2 entered default status on December 1, 2022, and the interest rate increased to 18%. The Howe Note 2 contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Howe reasonably believes contains a term that is more favorable than those in the Howe Note 2, the Company shall notify Mr. Howe of such term, and such term, at the option of Mr. Howe, shall become a part of the Howe Note 2. In addition, Mr. Howe received five-year warrants to purchase 2,460 shares of common stock at a price of $25.00 per share with a fair value of $10,965 at the date of issuance, and 2,460 shares of common stock with a value of $22,440; these amounts were recorded as discounts to the Howe Note 2. Interest in the amount of $18,888 was accrued on the Howe Note 2 during the year ended December 31, 2022. Discounts in the amount of $108,405 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $330,000 and $18,888, respectively, were due on the Howe Note 2 at December 31, 2022. The Howe Note 2 was in default at December 31, 2022. Howe Note 3 On July 21, 2022, the Company issued a 10% Promissory Note in the principal amount of $300,000 in a related party transaction to the Michael C. Howe Living Trust (the “Howe Note 3”). Michael C. Howe is the Chief Executive Officer of the Good Clinic LLC, one of our subsidiaries. The Howe Note 3 bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, as extended, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Howe Note 3 was $255,000; the amount payable at maturity will be $300,000 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Howe Note 3, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Howe Note 3 entered default status on December 1, 2022, and the interest rate increased to 18%. The Howe Note 3 contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Howe reasonably believes contains a term that is more favorable than those in the Howe Note 3, the Company shall notify Mr. Howe of such term, and such term, at the option of Mr. Howe, shall become a part of the Howe Note 3. In addition, Mr. Howe received five-year warrants to purchase 2,460 shares of common stock at a price of $25.00 per share with a fair value of $9,945 at the date of issuance, and 2,460 shares of common stock with a value of $12,495; these amounts were recorded as discounts to the Howe Note 3. Interest in the amount of $15,436 was accrued on the Howe Note 3 during the year ended December 31, 2022. Discounts in the amount of $97,440 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $330,000 and $15,436, respectively, were due on the Howe Note 3 at December 31, 2022. The Howe Note 3 was in default at December 31, 2022. Iturregui Note 1 On July 21, 2022, the Company issued a 10% Promissory Note in the principal amount of $29,412 in a related party transaction to Juan Carlos Iturregui, a member of the Company’s Board of Directors (the “Iturregui Note 1”). The Iturregui Note 1 bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) January 21, 2023, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Iturregui Note 1 was $25,000; the amount payable at maturity will be $29,412 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Iturregui Note 1, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Iturregui Note 1 contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Iturregui reasonably believes contains a term that is more favorable than those in the Iturregui Note 1, the Company shall notify Mr. Iturregui of such term, and such term, at the option of Mr. Iturregui, shall become a part of the Iturregui Note 1. In addition, Mr. Iturregui received five-year warrants to purchase 242 shares of common stock at a price of $25.00 per share with a fair value of $975 at the date of issuance, and 242 shares of common stock with a value of $1,225; these amounts were recorded as discounts to the Iturregui Note 1. Interest in the amount of $1,313 was accrued on the Iturregui Note 1 during the year ended December 31, 2022. Discounts in the amount of $8,464 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $1,089 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $32,353 and $1,313, respectively, were due on the Iturregui Note 1 at December 31, 2022. Howe Note 4 On August 18, 2022, the Company issued a 10% Promissory Note in the principal amount of $200,000 in a related party transaction to the Michael C. Howe Living Trust (the “Howe Note 4”). Michael C. Howe is the Chief Executive Officer of the Good Clinic LLC, one of our subsidiaries. The Howe Note 4 bears interest at the rate of 10% per annum accrued monthly and has a maturity date that is the earlier of (i) November 30, 2022, or (ii) five business days after the date on which the Company successfully lists its shares of common stock on Nasdaq or NYSE. The purchase price of the Howe Note 4 was $170,000; the amount payable at maturity will be $200,000 plus 10% of that amount plus any accrued and unpaid interest. Following an event of default as defined in the Howe Note 4, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The Howe Note 4 entered default status on December 1, 2022, and the interest rate increased to 18%. The Howe Note 4 contains a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which Mr. Howe reasonably believes contains a term that is more favorable than those in the Howe Note 4, the Company shall notify Mr. Howe of such term, and such term, at the option of Mr. Howe, shall become a part of the Howe Note 4. In addition, Mr. Howe received 1,640 shares of common stock with a value of $10,775; this amount was recorded as a discount to the Howe Note 4. Interest in the amount of $8,756 was accrued on the Howe Note 4 during the year ended December 31, 2022. Discounts in the amount of $60,775 were amortized to interest expense during the year ended December 31, 2022, and total discounts in the amount of $0 remained outstanding at December 31, 2022. Principal and accrued interest in the amounts $220,000 and $8,756, respectively, were due on the Howe Note 4 at December 31, 2022. The Howe Note 4 was in default at December 31, 2022. November 29, 2022 Notes On November 29, 2022, the Company issued seven identical promissory notes (the “November 29 Notes”) in related party transactions to the following individuals: (1) Thomas Brodmerkel, the Company’s CFO and Board Member; (2) Lawrence Diamond, the Company’s Chief Executive Officer and Board Member; (3) Sheila Schweitzer, Board Member; (4) Faraz Naqvi, a former Board Member; (5) Juan Carlos Iturregui, Board Member; (6) Jenny Lindstrom, the Company’s former Vice President and Chief Legal Officer; and (7) Michael C. Howe, Chief Executive Officer of The Good Clinic, one of our subsidiaries (collectively, the “November 29 Lenders”). The November 29 notes have due dates of May 28, 2023. The November 29 Notes are subject to the Series E Exchange Agreement whereby each of the November 29 Lenders will exchange (a) amounts due under the November 29 Notes for a number of shares of the Company’s Series E Convertible Preferred Stock equal to 150% of the principal amount of each November 29 Note. See note 12. The November 29 Notes bear interest at the rate of 10% per annum which will accrue from the date of the note only if the November 29 Notes are not converted pursuant to the Series E Exchange Agreement by May 10, 2023. Following an event of default as defined in the November 29 Notes, the principal amount shall bear interest for each day until paid at a rate per annum equal to the lesser of the maximum interest permitted by applicable law and 18%. The November 29 Notes contain a “most favored nations” clause that provides that, so long as the note is outstanding, if the Company issues any new security which November 29 Lender reasonably believes contains a term that is more favorable than those in the November 29 Note, the Company shall notify the November 29 Lenders of such term, and such term, at the option of the November 29 Lenders, shall become a part of the November 29 Note. In addition, each of the November 29 Lenders will receive five-year warrants to purchase 750 shares of the Company’s common stock at a price equal to the price of any warrant included in an offering in connection with listing at the Nasdaq Global Market. These warrants are not deemed issued at December 31, 2022 because the exercise price was not yet determined. Discounts in the amount of $667 were amortized to interest expense for each of the November 29 Notes during the year ended December 31, 2022, and discounts in the amount of $3,083 remained outstanding for each of the November 29 Notes at December 31, 2022. Principal and accrued interest in the amounts $18,750 and $164, respectively, were due on each of the seven November 29 Note at December 31, 2022. Concurrent with the November 29 Notes, the Company entered into separate exchange agreements (the “November 29 Notes Exchange Agreements”). Pursuant to the November 29 Notes Exchange Agreements, amounts due under the November 29 Notes will be exchanged for a number Series E Convertible Preferred Stock equal to 150% of the principal amount of the Notes. No transactions occurred pursuant to the November 29 Notes Exchange Agreements during the year ended December 31, 2022. See notes 12 and 16. These amounts are reflected in the table below: December 31, 2022 December 31, 2021 Notes Payable $ 2,799,632 $ 1,100,000 Less: Discount $ (22,670 ) $ (511,568 ) Notes payable – net of discounts $ 2,776,962 $ 588,432 Current Portion, net of discount $ 2,776,962 $ 588,432 Long-term portion, net of discount $ - $ - Interest expense on notes payable – related parties was $1,243,639 and $0 for the years ended December 31, 2022 and 2021, respectively Accrued interest on notes payable – related parties was $198,753 and $0 at December 31, 2022 and 2021, respectively.

Derivative Liabilities

Derivative Liabilities	12 Months Ended
	Dec. 31, 2022
Disclosure Text Block [Abstract]
Derivatives and Fair Value [Text Block]	Note 11: Derivative Liabilities Certain of the Company’s convertible notes and warrants contain features that create derivative liabilities. The pricing model the Company uses for determining fair value of its derivatives is the Lattice Model. Valuations derived from this model are subject to ongoing internal and external verification and review. The model uses market-sourced inputs such as interest rates and stock price volatilities. Selection of these inputs involves management’s judgment and may impact net income. The derivative components of these notes are valued at issuance, at conversion, at restructure, and at each period end. Derivative liability activity for the years ended December 31, 2022 and 2021 is summarized in the table below: December 31, 2020 $ 807,683 Settled upon conversion or exercise (1,302,138 ) Loss on revaluation 494,455 December 31, 2021 $ - True-up features issued 192,375 Settled upon conversion or exercise (310,641 ) Loss on revaluation 687,178 December 31, 2022 $ 568,912 The Company uses a Monte Carlo model to value certain features of its notes payable that create derivative liabilities. The following table summarizes the assumptions for the valuations: December 31, 2022 Volatility 95.1% to 123.2 % Stock Price $ 1.06 to 3.50 Risk-free interest rates 4.35% to 4.37 % Term (years) 0.73 to 0.86 Certain of our notes payable contain a commitment fee obligation with a true-up feature. The following assumptions were used for the valuation of the derivative liability associated with this obligation: ● The stock price would fluctuate with the Company projected volatility. ● The projected volatility curve from an annualized analysis for each valuation date was based on the historical volatility of the Company and the term remaining for the True-Up obligation. ● The Company expected the note would be repaid 90% of the time by the maturity date, at which point the Company would redeem the 1,000,000 redeemable commitment fee shares for $1. ● In the event the Company did not repay the note in time, the shareholders would sell their shares subject to volume restrictions. ● Discount rates were based on risk free rates in effect based on the remaining term. 50,000 simulations were run for each Monte Carlo simulation.

Stockholders_ Equity (Deficit)

Stockholders’ Equity (Deficit)	12 Months Ended
	Dec. 31, 2022
Stockholders' Equity Note [Abstract]
Equity [Text Block]	Note 12: Stockholders Equity (Deficit) Common Stock The Company has authorized 500,000,000 shares of common stock, par value $0.01; 4,630,372 and 4,266,669 shares were issued and outstanding at December 31, 2022 and December 31, 2021, respectively. On December 12, 2022, the Company effected one-for-fifty reverse-split of its common stock. The number of shares of common stock outstanding immediately before the reverse-split was 231,374,330; the number of shares of common stock immediately following the reverse-split was 4,630,372, a decrease of 226,743,958 shares. Common Stock Transactions During the Year Ended December 31, 2022 On January 12, 2022, the Company entered into a settlement agreement with an ex-employee. Pursuant to the terms of this agreement, the Company agreed to pay the amount of $19,032 for accrued salary, and the employee returned to the Company for cancellation 8,000 shares of common stock previously issued as compensation. These shares were valued at par value of $0.01 or a total value of $80; the Company recorded a gain on cancellation of these shares in the amount of $15,032. The Company entered into a debt-for-equity exchange agreement with Gardner Builders Holdings, LLC (“Gardner”) on January 7, 2022 (the “Gardner Equity Agreement”). Pursuant to Gardner Equity Agreement, the Company issued shares of restricted common stock to Gardner in exchange for the Company Debt Obligations, as defined below. The Gardner Equity Agreement settled for certain accounts payable amounts owed by the Company to Gardner. The Gardner Equity Agreement also settled accrued interest and penalties on the amounts due through January 5, 2022, as well as interest payments on amounts incurred in the first quarter of 2022 (collectively, the “Additional Costs”, and combined with the Accounts Payable Amount, the “Company Debt Obligations”). The Accounts Payable Amount was $500,000, the Additional Costs were $294,912 and the conversion price was $12.50. As a result, 63,593 Restricted Shares were authorized to be issued. On March 22, 2022 and March 31, 2022, the Company issued an aggregate 30,835 shares of common stock as waiver fees to holders of the Series C and Series D Preferred Stock for their waivers of certain covenants as set forth and defined in the Series C and Series D Certificates of Designations. The Company valued these shares at their contractual price of $12.50 per share and recorded the amount of $385,431 as waiver fees. The Company recorded an aggregate gain upon issuance of these shares in the amount of $198,273 based on the market price of the Company’s common stock on the date of issuance. On March 31, 2022, the Company issued 34,400 Commitment Fee Shares to AJB Capital Investors, LLC. A Monte Carlo model was used to value the warrants and call features, and a probability weighted expected return model was used to value the True-Up Provision. The contractual price of the common stock $12.50 per share; valuation purposes, the common stock was valued at the market price on the date of the transaction of $6.35 per share. The discount on the notes due to the Commitment Fee Shares and warrants was valued at $349,914. The Company recorded the amount of $226,106 to additional paid-in capital pursuant to this transaction. On March 31, 2022, the Company issued 7,648 shares of common stock at a price of $12.50 per share which were previously subscribed for the conversion of accounts payable in the amount of $95,558. On April 27, 2022, the Company issued 14,400 shares of stock to Cavalry Fund 1 LP at a price of $6.35 per share for a total value of $91,440 as compensation for the waiver of certain covenants as set forth in the Series C Certificate of Designation. The Company recorded a gain in the amount of $88,560 on this transaction. On April 27, 2022, the Company issued 1,929 shares of common stock with a contract price of $12.50 per share or $24,118 and a grant date market value of $8.00 or $15,434 to Larry Diamond, it’s Chief Executive as commitment shares as set forth and defined in Diamond Note 3. The Company recorded these shares at their relative fair value of the components of Diamond Note 3, or $16,200, and recorded a loss in the amount of $765 on this transaction. The Company also issued five-year warrants to purchase 1,929 shares of common stock at a price of $12.50 to Mr. Diamond pursuant to Diamond Note 3. On May 1, 2022, the Company issued 15,000 shares of common stock to a service provider at a price of $6.88 per share. On May 10, 2022, the Company entered into a securities purchase agreement with Kishon Investments, LLC with respect to the sale and issuance of: (i) an initial commitment fee in the amount of $159,259 in the form of 12,741 shares of the Company’s common stock , (ii) promissory note in the principal amount of $277,777 due on November 10, 2022, and (iii) warrants to purchase up to 5,556 shares of the common stock . The note and warrants were issued on May 10, 2022 and were held in escrow pending effectiveness of the Purchase Agreement. Pursuant to the terms of the purchase agreement, the initial shares were issued at a value of $159,259, the note was issued in the principal amount of $277,777 for a purchase price of $250,000, resulting in the original issue discount of $27,777; and the warrants were issued, with an initial exercise price of $12.50 per share, subject to adjustment. On May 18, 2022, the Company issued 386 shares of common stock to Larry Diamond, it’s Chief Executive Officer at a contractual price of $12.50 per share and a market price at issuance date of $7.585 per share as commitment shares as set forth and defined in Diamond Note 4. The Company recorded these shares at their relative fair value of the components of Diamond Note 4, or $3,160 and recorded a loss in the amount of $249 on this transaction. The Company also issued five-year warrants to purchase 386 shares of common stock at a price of $12.50 to Mr. Diamond pursuant to Diamond Note 4. On May 23, 2022, the Company issued 386 shares of common stock to Jessica Finnegan at a contractual price of $12.50 per share and a market price at issuance date of $8.97 per share as commitment shares as set forth and defined in Finnegan Note 1. The Company recorded these shares at their relative fair value of the components of Finnegan Note 1, or $3,240, and recorded a gain in the amount of $222 on this transaction. The Company also issued five-year warrants to purchase 386 shares of common stock at a price of $12.50 to Ms. Finnegan pursuant to Finnegan Note 1. On May 26, 2022, the Company issued 1,688 shares of common stock to the May 26 Lenders at a contractual price of $12.50 per share and a market price at issuance date of $7.585 per share as commitment shares as set forth and defined in the May 26, 2022 Notes. The Company recorded these shares at their relative fair value of the components of the May 26 Note, or $14,175, and recorded a loss in the amount of $1,369 on these transactions. The Company also issued five-year warrants to purchase 1,688 shares of common stock at a price of $25.00 to the May 26 Lenders pursuant to the May 26, 2022. On June 7, 2022, the Company issued 8,103 shares of common stock at a price of $12.50 per share to investors for accumulated dividends on Series X Preferred Stock. See Note 12. On June 9, 2022, the Company issued 7,284 shares of common stock to the June 9 Lenders at a contractual price of $12.50 per share and a market price at issuance date of $7,425 per share as commitment shares as set forth and defined in the June 9 Notes. The Company recorded these shares at the relative fair value of the components of June 9 Notes, or $66,400, and recorded an aggregate loss in the amount of $9,356 on these transactions. The Company also issued five-year warrants to purchase 7,284 shares of common stock at a price of $25.00 to the May 26 Lenders pursuant to the June 9 notes. On June 22, 2022, the Company issued 4,824 shares of common stock at fair value of $10.45 per share to Dragon Dynamic at a fair value of $10.45 per share as a commitment fee. On June 22, 2022, the Company issued 12,741 shares of common stock at fair value of $10.45 per share to GS Capital at a fair value of $10.45 per share as a commitment fee. On June 22, 2022, the Company issued 8,600 shares of common stock at fair value of $10.45 per share to Anson East and an additional 25,800 shares of common stock at a fair value of $10.45 per share to Anson Investments as a commitment fee. On July 7, 2022, the Company issued 2,412 shares of common stock to William Mackay at a contractual price of $12.50 per share and a market price at issuance date of $7.445 per share as commitment shares as set forth and defined in the Mackay Note. The Company recorded these shares at their relative fair value of the components of Mackay Note, or $12,500, and recorded a gain in the amount of $5,456 on this transaction. The Company also issued five-year warrants to purchase 2,412 shares of common stock at a price of $12.50 to Mr. Mackay pursuant to the Mackay Note. On July 7, 2022, the Company issued 193 shares of common stock to Charlies Schrier at a contractual price of $12.50 per share and a market price at issuance date of $7.445 per share as commitment shares as set forth and defined in the Schrier Note. The Company recorded these shares at their relative fair value of the components of Schrier Note, or $1,000, and recorded a gain in the amount of $436 on this transaction. The Company also issued five-year warrants to purchase 193 shares of common stock at a price of $25.00 to Mr. Schrier pursuant to the Schrier Note. On July 21, 2022, the Company issued 241 shares of common stock to Juan Carlos Iturregui, a related party, at a contractual price of $12.50 per share and a market price at issuance date of $7.225 per share as commitment shares as set forth and defined in the Iturregui Note. The Company recorded these shares at their relative fair value of the components of Schrier Note, or $1,225, and recorded a gain in the amount of $518 on this transaction. The Company also issued five-year warrants to purchase 241 shares of common stock at a price of $25.00 to Mr. Iturregui pursuant to the Iturregui Note. On July 21, 2022, the Company issued 2,460 shares of common stock to the Michael C. Howe Living Trust, a related party, at a contractual price of $12.50 per share and a market price at issuance date of $7.225 per share as commitment shares as set forth and defined in the Howe Note 3. The Company recorded these shares at their relative fair value of the components of Howe Note 3, or $12,495, and recorded a gain in the amount of $5,729 on this transaction. The Company also issued five-year warrants to purchase 2,460 shares of common stock at a price of $25.00 to the Michael C. Howe Living Trust pursuant to the Howe Note 3. On July 26, 2022, the Company issued 482 shares of common stock to Eric S. Nommsen at a contractual price of $12.50 per share and a market price at issuance date of $6.84 per share as commitment shares as set forth and defined in the Nommsen Note. The Company recorded these shares at their relative fair value of the components of Nommsen Note, or $2,350, and recorded a gain in the amount of $949 on this transaction. The Company also issued five-year warrants to purchase 482 shares of common stock at a price of $25.00 to Mr. Nommsen pursuant to the Nommsen Note. On July 27, 2022, the Company issued 482 shares of common stock to James H. Caplan at a contractual price of $12.50 per share and a market price at issuance date of $6.935 per share as commitment shares as set forth and defined in the Caplan Note. The Company recorded these shares at their relative fair value of the components of the Caplan Note, or $2,350, and recorded a gain in the amount of $995 on this transaction. The Company also issued five-year warrants to purchase 482 shares of common stock at a price of $25.00 to Mr. Caplan pursuant to the Caplan Note. On August 4, 2022, the Company issued a total of 241 shares of common stock to Jessica, Kevin C., Brody, Isabella, and Jack Finnegan at a contractual price of $25.00 per share and a market price at issuance date of $6.42 per share as commitment shares as set forth and defined in the Finnegan Note 3. The Company recorded these shares at their relative fair value of the components of the Finnegan Note 3, or $1,000, and recorded a gain in the amount of $448 on this transaction. The Company also issued five-year warrants to purchase a total of 241 shares of common stock at a price of $25.00 to the holders of the Finnegan Note 3. On August 4, 2022, the Company issued 984 shares of common stock to Jack Enright at a contractual price of $12.50 per share and a market price at issuance date of $6.42 per share as commitment shares as set forth and defined in the Caplan Note. The Company recorded these shares at their fair value of $6,317. On August 4, 2022, the Company issued 12,064 shares of common stock to a service provider as payment for investor relations services. The transaction was effective August 1, 2022 and has a six month term. The shares were valued at the closing price of the Company’s common stock on August 4, 2022, of $6.42 per share or $77,448. On August 18, 2022, the Company issued 1,640 shares of common stock to the Michael C. Howe Living Trust, a related party, at a contractual price of $12.50 per share and a market price at issuance date of $6.57 per share as commitment shares as set forth and defined in the Howe Note 4. The Company recorded these shares at their fair value of $10,775. On September 2, 2022, the Company issued 582 shares of common stock to John Mitchell at a contractual price of $12.50 per share and a market price at issuance date of $5.365 per share as commitment shares as set forth and defined in the Mitchell Note. The Company recorded these shares at their fair value of $3,124. On September 2, 2022, the Company issued 492 shares of common stock to Frank Lightmas at a contractual price of $12.50 per share and a market price at issuance date of $5.365 per share as commitment shares as set forth and defined in the Lightmas Note. The Company recorded these shares at their fair value of $2,640. On September 2, 2022, the Company issued 246 shares of common stock to Lisa Lewis at a contractual price of $12.50 per share and a market price at issuance date of $5.365 per share as commitment shares as set forth and defined in the Lewis Note. The Company recorded these shares at their fair value of $1,320. On September 2, 2022, the Company issued 246 shares of common stock to Sharon Goff at a contractual price of $12.50 per share and a market price at issuance date of $5.65 per share as commitment shares as set forth and defined in the Goff Note. The Company recorded these shares at their fair value of $1,320. On September 9, 2022, the Company issued 820 shares of common stock to Cliff Hagan at a contractual price of $12.50 per share and a market price at issuance date of $5.75 per share as commitment shares as set forth and defined in the Hagan Note. The Company recorded these shares at their fair value of $4,715. On September 14, 2022, the Company issued 1,640 shares of common stock to Darling Capital at a contractual price of $12.50 per share and a market price at issuance date of $6.60 per share as commitment shares as set forth and defined in the Darling Capital Note. The Company recorded these shares at their fair value of $10,824. On September 15, 2022, the Company issued 410 shares of common stock to Mack Leath at a contractual price of $12.50 per share and a market price at issuance date of $6.995 per share as commitment shares as set forth and defined in the Leath Note. The Company recorded these shares at their fair value of $2,868. On October 1, 2022, the Company issued 6,329 shares of common stock at a price of $16.00 per share to a service provider. On November 18, 2022, the Company issued 91,328 shares of common stock to AJB in settlement of the AJB True-up Obligation. See note 9. Common Stock Transactions During the Year Ended December 31, 2021 On January 4, 2021, the Company issued 82,475 shares of common stock at a price of $0.60 per share pursuant to the conversion of $45,000 of principal and $4,485 of accrued interest in Eagle Equities Note 4. On January 6, 2021, the Company issued 70,119 shares of common stock at a price of $0.612 per share pursuant to the conversion of $39,000 of principal and $3,913 of accrued interest in Eagle Equities Note 4. On January 11, 2021, the Company issued 89,270 shares of common stock at a price of $0.612 per share pursuant to the conversion of $50,000 of principal and $4,633 of accrued interest in Eagle Equities Note 5. On January 14, 2021, the Company issued 86,388 shares of common stock at a price of $0.633 per share pursuant to the conversion of $50,000 of principal and $4,683 of accrued interest in Eagle Equities Note 5. On January 21, 2021, the Company issued 128,992 shares of common stock at a price of $0.77 per share pursuant to the conversion of $93,000 of principal and $6,324 of accrued interest in Eagle Equities Note 6. On January 28, 2021, the Company issued 145,702 shares of common stock at a price of $0.7875 per share pursuant to the conversion of $107,200 of principal and $7,540 of accrued interest in Eagle Equities Note 6. On February 1, 2021, the Company issued 133,440 shares of common stock in a private placement (the "2021 Private Placement”) at a price of $12.50 per share for cash proceeds of $1,668,000. On February 5, 2021, the Company entered into a settlement agreement with the holders of the Eagle Equities Note 7 whereby the Company issued 23,683 shares of common stock at a price of $12.492 per share in satisfaction of $200,200 of principal and all accrued interest and prepayment penalties due under this note. On February 5, 2021, the Company entered into a settlement agreement with the holders of the Eagle Equities Note 8 whereby the Company issued 12,792 shares of common stock at a price of $11.926 per share in satisfaction of $114,400 of principal and all accrued interest and prepayment penalties due under this note. On February 5, 2021, the Company entered into a settlement agreement with the holders of the Eagle Equities Note 9 whereby the Company issued 12,104 shares of common stock at a price of $12,492 per share in satisfaction of $114,400 of principal and all accrued interest and prepayment penalties due under this note. On February 5, 2021, the Company entered into a settlement agreement with the holders of the Eagle Equities Note 10 whereby the Company issued 21,903 shares of common stock at a price of $11,874 per share in satisfaction of $200,200 of principal and all accrued interest and prepayment penalties due under this note. On February 22, 2021, the Company issued 6,720 shares of common stock for the exercise of options at a price of $15.00 per share. On March 11, 2021, the Company issued 12,000 shares of common stock to four officers of The Good Clinic in exchange for 4,800 shares of Series A Preferred Stock. The 4,800 shares of Series A Preferred Stock were cancelled. On March 17, 2021, the Company issued 6,000 shares of common stock at a price of $15.50 per share to a service provider. On March 23, 2021, the Company issued 9,227 shares of common stock at a price of $13.00 per share to the underwriters of the 2021 Private Placement. On April 19, 2021, the Company issued 39 shares of common stock for professional fees which had been performed in a prior period. The Company recorded these shares at the par value of $0.01 per share. On May 4 through May 26, 2021, the Company issued 84,748 shares of common stock for the conversion of 1,059,356 shares of Series C Preferred Stock at a price of $12.50 per share. On May 12, 2021, the Company issued 50,000 shares of common stock at a price of $15.00 per share for the exercise of stock options by an investor. On June 10 through June 29, 2021, the Company issued 102,333 shares of common stock at a price of $15.00 per share for the exercise of stock options by officers and directors. On June 23, 2021, the Company cancelled 40,000 shares of common stock held by an ex-officer in connection with a settlement agreement. The cancellation of these shares was recorded at the par value of $0.01 per share. Also, in connection with the settlement agreement, the Company issued 12,759 shares to the ex-officer at the market price of $10.00 per share. On August 17, 2021, accrued liabilities in the amount of $156,441 were converted to 12,515 shares of common stock. 9,589 shares were issued during December 2021 and the remaining 2,926 shares was not issued and recorded in common stock subscribed as of December 31, 2021. Among the 12,515 shares, 6,256 restricted shares of the Company’s common stock was issued to settled $78,200 cash compensation owed to the Company’s Chief Executive Officer for services rendered to the Company prior to 2021. Between August 11, 2021 and September 2, 2021, the Company issued 80,000 shares of the Company common stock in connection with the conversion of Series C preferred stock issued in the first quarter. Also, during the year ended December 31, 2021, the Company charged the amount of $13,032 to operations in connection with the vesting of stock granted to its officers, employees, and board members; the Company also charged the amount of $676,423 to operations in connection with the vesting of options granted to its officers, employees, and board members. Preferred Stock We have authorized to issue 100,000,000 shares of Preferred Stock with such rights designations and preferences as determined by our Board of Directors. We have designated 500,000 shares of series A stock, 3,000,000 shares of Series C Preferred, 10,000,000 shares of Series D Preferred, 10,000 shares of Series E Preferred, and 27,324 shares as Series X Preferred Stock. Series A Preferred Stock The Series A Preferred Stock has a par value of $0.01 per share, no stated maturity, a liquidation preference of $25.00 per share and accrued dividends at the rate of 12% on $25.00 per share. The Company had no shares of Series A Preferred Stock outstanding at December 31, 2022 and 2021. Series A Preferred Stock Transactions During the Year Ended December 31, 2022 None. Series A Preferred Stock Transactions During the Year Ended December 31, 2021 During the year ended December 31, 2021, the Company accrued dividends in the amount of $1,000 on the Series A Preferred Stock. On March 11, 2021, the Company issued 600,000 shares of common stock to the four officers of The Good Clinic in exchange for the previously issued Series A Preferred Stock and accrued dividends. The Series A preferred stock was canceled and there are no Series A Preferred shares outstanding at December 31, 2021. Series C Preferred Stock The Series C Preferred Stock has the following terms: Ranking Pari passu Voting Rights. Conversion. Dividends. Liquidation Rights. Pari passu Rights and Preferences. Redemption Rights. Price Adjustments Protection Preemptive or Similar Rights Fully Paid and Nonassessable Series C Preferred Stock Transactions During the Year Ended December 31, 2022 During the year ended December 31, 2022, the Company accrued dividends on the Series C Preferred Stock in the amount of $66,447. The Company also adjusted the number of shares of Series C Preferred Stock outstanding by an increase in the amount of 98,064 shares in connection with previous conversions of Series C Preferred Stock to common stock; the amount of $981 was charged to additional paid-in capital pursuant to this adjustment. Series C Preferred Stock Transactions During the Year Ended December 31, 2021 On March 25, 2021, the Company sold 3,000,000 shares of its Series C Preferred Stock along with (i) five-year warrants to purchase 6,300,000 shares of the Company’s common stock at a price of $0.50 per share, and (ii) five On May 4 through May 26, 2021, 1,059,356 shares of Series C Preferred Stock were converted at a price of $0.25 per share to 4,237,424 shares of common stock. Between August 11,2021 through September 2, 2021, 1,000,000 shares of Series C Preferred Stock were converted at a price of $0.25 per share to 4,000,001 shares of common stock. During the year ended December 31, 2021, the Company accrued dividends on the Series C Preferred Stock in the amount of $87,059. Series D Preferred Stock The Series D Preferred Stock has the following terms: Ranking Pari passu Voting Rights. Conversion. Dividends. Liquidation Rights. Pari passu Rights and Preferences. Redemption Rights. Price Adjustments Protection Preemptive or Similar Rights Series D Preferred Stock Transactions During the Year Ended December 31, 2022 During the year ended December 31, 2022, the Company accrued dividends on the Series D Preferred Stock in the amount of $195,299. Series D Preferred Stock Transactions During the Year Ended December 31, 2021 On October 18, 2021, the Company sold 2,050,000 shares of Series D Preferred Stock and (i) five-year warrants to acquire 85,050 shares of the Company’s common stock at a price of $25.00 per shares, and (ii) five On November 10, 2021, the Company sold 1,075,000 shares of Series D Preferred Stock and (i) five-year warrants to acquire 45,150 shares of the Company’s common stock at a price of $25.00 per shares, and (ii) five During the year ended December 31, 2021, the Company accrued dividends on the Series D Preferred Stock in the amount of $35,327. Series E Preferred Stock On November 7, 2022, the Company filed a Certificate of Designations, Preferences and Rights of Series E Convertible Perpetual Preferred Stock (the “Series E”) with the Delaware Secretary of State. The number of shares of Series E designated is 10,000 and each share of Series E has a stated value equal to $1,000. Each share of Series E Preferred Stock shall have a par value of $0.01. There are 0 shares of Series E Preferred Stock outstanding at December 31, 2022 and 2021. As long as any shares of Series E are outstanding, the Company shall not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series E, (a) alter or change the preferences, rights, privileges or powers given to the Series E or alter or amend the Certificate of Incorporation or bylaws, (b) increase or decrease (other than by conversion) the number of authorized shares of Series E, or (c) create or authorize any new class of shares that has a preference over Series E. Unless previously converted into shares of Common Stock, any shares of Series E issued and outstanding, shall be redeemable at the option of the Company for cash at a redemption price per share equal to 110% of the initial issuance price, or $1,100, plus all dividends declared thereon. Each share of Series E shall become convertible, at the option of the holder, commencing on the date of issuance, into such number of fully paid and non-assessable shares of Common Stock. The conversion price shall be, as of the conversion date, (a) prior to the date of the qualified offering the average VWAP per share of the Common Stock for the five (5) trading days prior to the date of conversion and (b) on or following the date of the qualified offering, the qualified offering price (the “Conversion Price”). Immediately following the 120 th th Series E Exchange Agreements During the year ended December 31, 2022, the Company entered into the following agreements to exchange certain debt and equity amounts for shares of Series E Preferred Stock (see notes 9, 10, and 16): On October 5, 2022, the Company entered into the Cavalry Exchange Agreement, pursuant to which Cavalry shall exchange (a) 1,000,000 shares of the Company’s Series C Convertible Preferred Stock (b) 750,000 shares of the Company’s Series D Convertible Preferred Stock and (c) amounts owing under the Cavalry Note, for a number of Series E Convertible Preferred Stock (the “Series E Shares”) equal to 150% of the principal amount of the Cavalry Note, plus 150% of the stated value of the Series C Shares and Series D Shares (the “Series E Exchange Value”). No transactions occurred pursuant to the Cavalry Exchange Agreement during the year ended December 31, 2022. See note 9 and 16. On October 7, 2022, the Company entered into the Mercer Exchange Agreement whereby Mercer shall exchange (a) 47,619 shares of the Company’s Series C Convertible Preferred Stock, (b) 750,000 shares of the Company’s Series D Convertible Preferred Stock, and (c) amounts owing under the Mercer Note, for a number of Series E Convertible Preferred Stock (the “Series E Shares”) equal to 150% of the principal amount of the Mercer Note, plus 150% of the stated value of the Series C Shares and Series D Shares (the “Series E Exchange Value”). No transactions occurred pursuant to the Mercer Exchange Agreement during the year ended December 31, 2022. See note 9. Amounts due under the Mercer Note 2 will also convert pursuant to the terms of the Mercer Exchange Agreement into shares of the Company’s series E Preferred Stock. See note 9 and 16. On October 10, 2022, the Company entered into the Pinz Exchange Agreement whereby Pinz shall exchange (a) 100,000 shares of the Company’s Series D Convertible Preferred Stock, and (b) amounts owing under the Pinz Note, for a number of Series E Convertible Preferred Stock equal to 150% of the principal amount of the Pinz Note, plus 150% of the stated value of the Series D Shares. No transactions occurred pursuant to the Pinz Exchange Agreement during the year ended December 31, 2022. See note 9 and 16. On October 18, 2022, the Company entered into separate exchange agreements with each of Anson East Master Fund LP and Anson Investments Master Fund LP (collectively, “Ansons”), (the “Ansons Exchange Agreements”). Pursuant to the Ansons Exchange Agreements, Ansons shall exchange an aggregate of 750,000 shares of the Company’s Series D Stock for a number of Series E Convertible Preferred Stock (the “Series E Shares”) equal to 150% of the stated value of the Series D Shares (the "Series E Exchange Value"), and the Funds have agreed to invest no less than an aggregate amount of $375,000 into the uplisting offering. No transactions occurred pursuant to the terms of the Ansons Exchange Agreements during the year ended December 31, 2022. See notes 9 and 16. On November 29, 2022, the Company entered into the November 29 Notes Exchange Agreements whereby amounts due under the November 29 Notes will be exchanged for a number Series E Convertible Preferred Stock equal to 150% of the principal amount of the Notes. No transactions occurred pursuant to the November 29 Notes Exchange Agreements during the year ended December 31, 2022. See notes 10 and 16. Series X Preferred Stock The Company has 24,227 shares of its 10% Series X Cumulative Redeemable Perpetual Preferred Stock (the “Series X Preferred Stock”) outstanding as of December 31, 2022 and December 31, 2021. The Series X Preferred Stock has a par value of $0.01 per share, no stated maturity, a liquidation preference of $25.00 per share, and will not be subject to any sinking fund or mandatory redemption and will remain outstanding indefinitely unless the Company decides to redeem or otherwise repurchase the Series X Preferred Stock; the Series X Preferred Stock is not redeemable prior to November 4, 2020. The Series X Preferred Stock will rank senior to all classes of the Company’s common and preferred stock and accrues dividends at the rate of 10% on $25.00 per share. The Company reserves the right to pay the dividends in shares of the Company’s common stock at a price equal to the average closing price over the five days prior to the date of the dividend declaration. Each one share of the Series X Preferred Stock is entitled to 400 votes on all matters submitted to a vote of our shareholders. Series X Preferred Stock Transactions During the Year Ended December 31, 2022 During the year ended December 31, 2022, the Company accrued dividends on the Series X Preferred Stock in the amount of $60,564. Series X Preferred Stock Transactions During the Year Ended December 31, 2021 On June 23, 2021, 2,000 shares of Series X Preferred Stock were cancelled pursuant to a settlement agreement with an ex-officer. Stock Options The following table summarizes the options outstanding at December 31, 2022 and the related prices for the options to purchase shares of the Company’s common stock: Weighted Weighted Weighted average average average exercise exercise Range of Number of remaining price of Number of price of exercise options contract

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	Note 13: Income Taxes Deferred income taxes result from the temporary differences primarily attributable to amortization of intangible assets and debt discount and an accumulation of net operating loss carryforwards for income tax purposes with a valuation allowance against the carryforwards for book purposes. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. Included in deferred tax assets are Federal and State net operating loss carryforwards of approximately $9.7 million, which will expire through 2040. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. Due to significant changes in the Company’s ownership, the Company’s future use of its existing net operating losses may be limited. The provision (benefit) for income taxes for the years ended December 31, 2022 and 2021 consist of the following: 2022 2021 Current $ - $ - Deferred - - Total $ - $ - For the years ended December 31, 2022 and 2021, the expected tax expense (benefit) based on the U. S. federal statutory rate is reconciled with the actual tax provision (benefit) as follows: For the Years Ended December 31, 2022 2021 Expected tax at statutory rates $ (4,879,000 ) 21 % $ (2,351,000 ) 21 % Permanent Differences 1,610,000 7 % 692,000 6 % State Income Tax, Net of Federal benefit 380,000 2 % (612,000 ) 5 % Current Year Change in Valuation Allowance 2,137,000 9 % 2,291,000 20 % Prior Year True-Ups 752,000 3 % (20,000 ) 0 % Income tax expense $ - 0 % $ - 0 % Deferred income taxes reflect the tax impact of temporary differences between the amounts of assets and liabilities for financial reporting purposes and such amounts as measured by tax laws and regulations. Deferred income taxes include the net tax effects of net operating loss (NOL) carryforwards and the temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. As of December 31, 2022, and 2021 significant components of the Company’s deferred tax assets are as follows: For the Years Ended December 31, 2022 2021 Deferred Tax Assets (Liabilities): Accrued payroll $ 112,000 $ 22,000 ASC842-ROU Asset (68,000 ) (1,117,000 ) ASC842-ROU (Liability) 830,000 1,189,000 Loss from derivatives (130,000 ) (4,000 ) Waiver and commitment fee shares (32,000 ) - Stock based compensation (85,000 ) 398,000 Depreciation 33,000 (764,000 ) Net operating loss 9,679,000 8,478,000 Net deferred tax assets (liabilities) 10,339,000 8,202,000 Valuation allowance (10,339,000 ) (8,202,000 ) Net deferred tax assets (liabilities) $ - $ -

Fair Value of Financial Instrum

Fair Value of Financial Instruments	12 Months Ended
	Dec. 31, 2022
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	Note 14: Fair Value of Financial Instruments The following summarizes the Company’s derivative financial liabilities that are recorded at fair value on a recurring basis at December 31, 2022 and 2021. December 31, 2022 Level 1 Level 2 Level 3 Total Liabilities Derivative liabilities $ - $ - $ 568,912 $ 568,912 December 31, 2021 Level 1 Level 2 Level 3 Total Liabilities Derivative liabilities $ - $ - $ - $ -

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	Note 15: Commitments and Contingencies Legal From time to time, we may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business. During March 2020, in response to the COVID-19 crisis, the federal government announced plans to offer loans to small businesses in various forms, including the Payroll Protection Program, or “PPP”, established as part of the Corona Virus Aid, Relief and Economic Security Act (“CARES Act”) and administered by the U.S. Small Business Administration. On April 18, 2020, the Company’s former President and COO completed and applied on behalf of the Company to Bank of America, NA (“Bank of America”) for a PPP loan, which was subsequently approved. On April 25, 2020, the Company entered into an unsecured Promissory Note (the “Note”) with Bank of America for a loan in the original principal amount of $460,406, and the Company received the full amount of the loan proceeds on May 4, 2020. On July 21, 2020, Bank of America notified the Company in writing that it should not have received $440,000 of the loan proceeds disbursed under the Note. The Company investigated the terms of the application and discovered its former President had erroneously represented it was refinancing an Economic Injury Disaster Loan when no such loan had been received. Bank of America requested that the Company remit the funds received back to Bank of America. The Company negotiated the conversion of this to a 60 month note at 1% interest. We are currently in default on this note. If we are not successful in bringing this liability current, it could have a material adverse effect on our financial condition. On October 25, 2022, the company was notified that a vendor filed suit related to a contract dispute naming both The Good Clinic and The CEO of the Good Clinic. This suit was settled on May 5, 2023, and dismissed with prejudice on May 12, 2023. The settlement included the issuance of the Company’s restricted common stock. As a part of the settlement the Company issued 2,552 shares of its restricted common stock to the plaintiff and it issued to the CEO of The Good Clinic 19,622 shares of its restricted common stock, plus $3,000 in cash for reimbursement of expenses related to settling the suit with the vendor. The Company has a number of legal situations involved with the winding down of its clinic business activities including claims regarding certain construction contracts and as a part of the process of cancellation of leases. The following is a summary as of the date of this filing: ● The Wayzata, MN clinic leases was terminated for a commitment to pay $25,000. ● The two Denver, Colorado clinic lease, known as Quincy and Radiant, possession has been relinquished to the landlords. The lease obligations remain in negotiations as does the handling of the mechanics liens placed on the properties. ● The Eagan clinic, aka Vikings clinic, gave up possession in January of 2023. The mechanics lien has been placed on the property was settled by the landlord in a confidential settlement with the lien holder. Mitesco is now in settlement negotiations with the landlord for the handling of lease obligations. ● The St. Paul clinic possession was relinquished in March 2023. The handling of lease obligations remain in negotiations as does the handling of the mechanics liens placed on the properties. ● The St. Louis Park clinic possession was relinquished in April 2023. The handling of lease obligations remain in negotiations as does the handling of the mechanics liens placed on the properties. ● The Maple Grove clinic eviction occurred in April 2023. The handling of lease obligations remain in negotiations as does the handling of the mechanics liens placed on the properties. ● The Northeast Minneapolis clinic, aka Nordhaus clinic, possession was relinquished in May 2023. There is no lien on the property. The handling of lease obligations remains in negotiations with the landlord.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2022
Subsequent Events [Abstract]
Subsequent Events [Text Block]	Note 16: Subsequent Events Common Stock Issued On January 23, 2023, the Company issued 150,000 shares of common stock at a price of $3.45 per share to a service provider. On January 23, 2023, the Company issued a total of 8,063 shares of common stock at a price of $4.33 per share to holders of the Series X Preferred Stock for accrued dividends. Larry Diamond, the Company’s Chief Executive Officer, received 666 of these shares. On February 15, 2023, the Company issued 9,846 shares of common stock to an investor at a price of $1.32 per share pursuant to a true-up agreement. On February 21, 2023, the Company issued 150,000 shares of common stock at a price of $2.63 per share to a service provider. On March 1, 2023, the Company issued 13,555 shares of common stock to an investor at a price of $1.32 per share pursuant to a true-up agreement. On March 9, 2023, the Company issued 15,265 shares of common stock to an investor at a price of $1.32 per share pursuant to a true-up agreement. On March 28, 2023, the Company issued 18,472 shares of common stock to an investor at a price of $1.32 per share pursuant to a true-up agreement. On April 4, 2023, the Company issued 94,738 shares of common stock to an investor at a price of $1.32 per share pursuant to a true-up agreement. On May 5, 2023, the Company issued 2,952 shares of common stock at a price of $1.05 per share to a service provider. On May 5, 2023, the Company issued 2,552 shares of common stock to an investor at a price of $1.05 per share for satisfaction of accounts payable. On May 9, 2023, the Company issued 19,622 shares of common stock to Michael C. Howe, a related party, at a price of $0.94 per share to reimburse Mr. Howe for costs incurred in connection with a settlement agreement with a vendor. Spartan Capital Advisory Agreement On January 12, 2023 the Company entered into an advisory agreement with Spartan Capital (“Spartan”) pursuant to which Spartan will act as exclusive financial advisor in providing general financial advisory services to the Company. In consideration for the financial advisory services to be rendered thereunder, the Company will issue to Spartan 150,000 restricted common shares of the Company (“Common Stock”). In addition, the Company will issue to Spartan an additional 50,000 Common Stock within three business days of completion of a gross raise of at least $2,000,000. Sale of Series F Preferred Stock On March 23, 2023, the Company filed a Certificate of Designations, Preferences and Rights of Series F 12% PIK Convertible Perpetual Preferred Stock (the “Series F”) with the Delaware Secretary of State. The number of shares of Series F designated is 140,000 and each share of Series F has a stated value equal to $1,000. Each share of Series F Preferred Stock shall have a par value of $0.01.Holders of the Series F are entitled to receive payment in kind dividends (“PIK Dividends”) at the quarterly rate of three-hundredths of one share outstanding per Series F Share. The Series F can be converted at the option of the Series F shareholder into shares of the Company’s common stock at a price equal to 65% of the Volume Weighted Average Price (“VWAP”) on the conversion date. Purchase Agreement On April 11, 2023, the Company entered into securities purchase agreements (each a “Purchase Agreement”) with investors providing for the sale and issuance of (i) Series F 12% PIK Convertible Perpetual Preferred Stock, par value $0.01 per share (the “Series F Shares”) and (ii) warrants to purchase shares of Common Stock (the “Warrants,” and together with the Series F Shares, the “Securities”). The closing on the first tranche of the offering resulted in gross proceeds to the Company of $650,000. The net proceeds to the Company from the first tranche of the offering were $511,000, after deducting placement agent fees and expenses and estimated offering expenses payable by the Company. The Company intends to use the net proceeds from the offering for general operating expenses. In connection with the Purchase Agreement, the Company also entered into a registration rights agreement. Exchange Agreements Also in connection with the Purchase Agreement, the Company entered into separate exchange agreements pursuant to which the investors in the Series E Preferred Stock exchanged certain securities, as defined in each individual Exchange Agreement, for a number Series F Shares (based on their liquidation preference of $1,000) equal to 120%, 165% or 230%, depending on whether the investor is investing additional funds into the bridge financing, of the “Principal Amount,” “Stated Value” and/or liquidation preference of the Exchange Securities (including any payoff bonus, accrued dividends or interest). Appointment of Ms. Sheila Schweitzer as Chairperson of the Board of Directors and President, Chief Operating Officer Effective June 1, 2023, the Board of Directors appointed Ms. Sheila Schweitzer to the position of President and Chief Operating Officer. Ms. Schweitzer will receive a salary in the amount of $200,000 per year. Her employment agreement is for a period of one year. Effective June 06, 2023, the Board of Directors of the Company appointed Ms. Schweitzer who has been a member of the Board of Directors since 2021, to the position of Chairperson, replacing Mr. Tom Brodmerkel, who has completed his term as Chair. Mr. Brodmerkel will remain as Chief Financial Officer and continue to serve as a member of the Company’s Board of Directors.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Accounting
Consolidation, Policy [Policy Text Block]	Principles of Consolidation
Use of Estimates, Policy [Policy Text Block]	Use of Estimates -
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash -
Property, Plant and Equipment, Policy [Policy Text Block]	Property, Plant, and Equipment - Years Office equipment 3 to 5 Furniture & fixtures 3 to 7 Machinery & equipment 3 to 10 Leasehold improvements Term of lease
Construction in Progress, Policy [Policy Text Block]	Construction in Progress -
Revenue [Policy Text Block]	Revenue Recognition The Company applied the modified retrospective approach to all contracts when adopting ASC 606. As a result, at the adoption of ASC 606 what was previously classified as the provision for bad debts in the statement of operations is now reflected as implicit price concessions (as defined in ASC 606) and therefore included as a reduction to net operating revenues in 2018. For changes in credit issues not assessed at the date of service, the Company will prospectively recognize those amounts in other operating expenses on the statement of operations. For periods prior to the adoption of ASC 606, the provision for bad debts has been presented consistent with the previous revenue recognition standards that required it to be presented separately as a component of net operating revenues. Our revenues generally relate to net patient fees received from various payers and patients themselves under contracts in which our performance obligations are to provide services to the patients. Revenues are recorded during the period our obligations to provide services are satisfied. The contractual relationships with patients, in most cases, also involve a third-party payer (Medicare, Medicaid, managed care health plans and commercial insurance companies, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent upon the terms provided by (Medicare and Medicaid) or negotiated with (managed care health plans and commercial insurance companies) the third-party payers. The payment arrangements with third-party payers for the services we provide to the related patients typically specify payments at amounts less than our standard charges and generally provide for payments based upon predetermined rates for services or discounted fee-for-service rates. Management continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals.
Share-Based Payment Arrangement [Policy Text Block]	Stock-Based Compensation - Equity instruments issued to those other than employees are recognized pursuant to FASB issued ASU 2018-07, Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting. This ASU relates to the accounting for non-employee share-based payments. The amendment in this update expands the scope of Topic 718 to include all share-based payment transactions in which a grantor acquired goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards. The ASU excludes share-based payment awards that relate to: (1) financing to the issuer; or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under Topic 606, Revenue from Contracts from Customers. The share-based payments are to be measured at grant-date fair value of the equity instruments that the entity is obligated to issue when the goods or service has been delivered or rendered and all other conditions necessary to earn the right to benefit from the equity instruments have been satisfied. This standard will be effective for public business entities for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. We adopted the provisions of this ASU on January 1, 2019. The adoption had no impact on our results of operations, cash flows, or financial condition.
Convertible Instruments, Policy [Policy Text Block]	Convertible Instruments
Derivatives, Policy [Policy Text Block]	Derivative Financial Instruments
Warrants, Policy [Policy Text Block]	Common Stock Purchase Warrants-
Stockholders' Equity, Policy [Policy Text Block]	Stockholders Equity-
Earnings Per Share, Policy [Policy Text Block]	Per Share Data-
Income Tax, Policy [Policy Text Block]	Income Taxes- Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all the deferred tax assets will not be realized. The Company has determined that a valuation allowance is needed due to recent taxable net operating losses and the limited taxable income in the carry back periods. The effect on deferred tax assets and liabilities of a change in tax rates is recognized as income or expense in the period that includes the enactment date. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes and certain tax loss carryforwards, less any valuation allowance. The Company accounts for uncertain tax positions as required in that a position taken or expected to be taken in a tax return is recognized in the consolidated financial statements when it is more likely than not (i.e., a likelihood of more than 50%) that the position would be sustained upon examination by tax authorities. A recognized tax position is then measured at the largest amount of benefit that is greater than 50% of being realized upon ultimate settlement. The Company does not have any material unrecognized tax benefits. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as components of interest expense and other expense, respectively, in arriving at pretax income or loss. The Company does not have any interest and penalties accrued. The Company is no longer subject to U.S. federal, state, and local income tax examinations for the years before 2012.
Business Combinations Policy [Policy Text Block]	Business Combinations- ● future expected cash flows from product sales, support agreements, consulting contracts, other customer contracts, and acquired developed technologies and patents; and ● discount rates utilized in valuation estimates. Unanticipated events and circumstances may occur that may affect the accuracy or validity of such assumptions, estimates or actual results. Additionally, any change in the fair value of the acquisition-related contingent consideration subsequent to the acquisition date, including changes from events after the acquisition date, such as changes in our estimates of relevant revenue or other targets, will be recognized in earnings in the period of the estimated fair value change. A change in fair value of the acquisition-related contingent consideration or the occurrence of events that cause results to differ from our estimates or assumptions could have a material effect on the consolidated financial position, statements of operations or cash flows in the period of the change in the estimate.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Impairment of Long-Lived Assets-
Fair Value of Financial Instruments, Policy [Policy Text Block]	Financial Instruments and Fair Values- Level 1 – inputs include exchange quoted prices for identical instruments and are the most observable. Level 2 – inputs include brokered and/or quoted prices for similar assets and observable inputs such as interest rates. Level 3 – inputs include data not observable in the market and reflect management judgment about the assumptions market participants would use in pricing the asset or liability. The use of observable and unobservable inputs and their significance in measuring fair value are reflected in our hierarchy assessment. The carrying amount of cash, prepaid assets, accounts payable and accrued liabilities approximate fair value due to the short-term maturities of these instruments. Because cash and cash equivalents are readily liquidated, management classifies these values as Level 1. The fair value of the derivative liabilities approximates their book value as the instruments are short-term in nature and contain market rates of interest. Because there is no ready market or observable transactions, management classifies the derivative liabilities as Level 3.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Standards In August 2020, the FASB issued ASU 2020-06, "Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40)”. This ASU reduces the number of accounting models for convertible debt instruments and convertible Preferred Stock, and amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. In addition, this ASU improves and amends the related EPS guidance. This standard is effective for us on January 1, 2022, including interim periods within those fiscal years. Adoption is either a modified retrospective method or a fully retrospective method of transition. The adoption of this new guidance did not have a material effect on our consolidated financial statements. There are various other updates recently issued, most of which represent technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s consolidated financial position, results of operations or cash flows.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Property, Plant and Equipment [Table Text Block]	Property, plant, and equipment are depreciated using the straight-line method based on the lesser of the estimated useful lives of the assets or the lease term based upon the following life expectancy: Years Office equipment 3 to 5 Furniture & fixtures 3 to 7 Machinery & equipment 3 to 10 Leasehold improvements Term of lease

Net Loss Per Share Applicable_2

Net Loss Per Share Applicable to Common Shareholders (Tables)	12 Months Ended
	Dec. 31, 2022
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	The following table sets forth the computation of loss per share for the years ended December 31, 2022 and 2021, respectively: For the Years Ended December 31, 2022 2021 Numerator: Net loss applicable to common shareholders $ (23,558,439 ) $ (11,226,366 ) Denominator: Weighted average common shares outstanding 4,451,962 4,060,005 Net loss per share: Basic and diluted $ (5.29 ) $ (2.77 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	The Company excluded all common equivalent shares for warrants, options, and convertible instruments from the calculation of diluted net loss per share because all such securities are antidilutive for the periods presented. As of December 31, 2022 and 2021, the following shares were issuable and excluded from the calculation of diluted loss: December 31, 2022 2021 Options 310,692 374,924 Warrants 672,334 596,400 Preferred Stock 347,652 347,652 Accrued Interest 42,002 17,443 Total 1,372,680 1,336,419

Accounts Payable and Accrued _2

Accounts Payable and Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2022
Payables and Accruals [Abstract]
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	Accounts payable and accrued liabilities consisted of the following at December 31, 2022 and 2021: December 31, December 31, 2022 2021 Trade accounts payable $ 6,761,793 $ 3,933,305 Accrued payroll and payroll taxes 590,915 23,554 Other 507 19,205 Total accounts payable and accrued liabilities $ 7,353,215 $ 3,976,064

Right to Use Assets and Lease_2

Right to Use Assets and Lease Liabilities - Operating Leases (Tables)	12 Months Ended
	Dec. 31, 2022
Disclosure Text Block [Abstract]
Lease, Cost [Table Text Block]	Right to use assets – operating leases are summarized below: December 31, 2022 December 31, 2021 Right to use assets, net $ 544,063 $ 3,886,866 December 31, 2022 December 31, 2021 Lease liability $ 4,379,724 $ 4,134,802 Less: current portion (442,866 ) (161,838 ) Lease liability, non-current $ 3,936,858 $ 3,972,964
Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]	Maturity analysis under these lease agreements are as follows: For the period ended December 31, 2023 $ 945,102 For the period ended December 31, 2024 884,990 For the period ended December 31, 2025 906,666 For the period ended December 31, 2026 926,988 For the period ended December 31, 2027 946,745 Thereafter 1,939,476 Total $ 6,549,967 Less: Present value discount (2,170,243 ) Lease liability $ 4,379,724

Notes Payable (Tables)

Notes Payable (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Payable (Tables) [Line Items]
Schedule of Debt [Table Text Block]	These amounts are reflected in the table below: December 31, 2022 December 31, 2021 Notes Payable $ 5,144,742 $ - Less: Discount (32,040 ) Notes payable - net of discount $ 5,112,702 $ - Current Portion, net of discount $ 5,112,702 $ - Long-term portion, net of discount $ - $ -
Related Party [Member]
Notes Payable (Tables) [Line Items]
Schedule of Debt [Table Text Block]	These amounts are reflected in the table below: December 31, 2022 December 31, 2021 Notes Payable $ 2,799,632 $ 1,100,000 Less: Discount $ (22,670 ) $ (511,568 ) Notes payable – net of discounts $ 2,776,962 $ 588,432 Current Portion, net of discount $ 2,776,962 $ 588,432 Long-term portion, net of discount $ - $ -

Derivative Liabilities (Tables)

Derivative Liabilities (Tables)	12 Months Ended
	Dec. 31, 2022
Disclosure Text Block [Abstract]
Schedule of Derivative Instruments [Table Text Block]	Derivative liability activity for the years ended December 31, 2022 and 2021 is summarized in the table below: December 31, 2020 $ 807,683 Settled upon conversion or exercise (1,302,138 ) Loss on revaluation 494,455 December 31, 2021 $ - True-up features issued 192,375 Settled upon conversion or exercise (310,641 ) Loss on revaluation 687,178 December 31, 2022 $ 568,912
Fair Value, Assets and Liabilities Measured on Nonrecurring Basis, Valuation Techniques [Table Text Block]	The Company uses a Monte Carlo model to value certain features of its notes payable that create derivative liabilities. The following table summarizes the assumptions for the valuations: December 31, 2022 Volatility 95.1% to 123.2 % Stock Price $ 1.06 to 3.50 Risk-free interest rates 4.35% to 4.37 % Term (years) 0.73 to 0.86

Stockholders_ Equity (Deficit)

Stockholders’ Equity (Deficit) (Tables)	12 Months Ended
	Dec. 31, 2022
Stockholders' Equity Note [Abstract]
Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]	The following table summarizes the options outstanding at December 31, 2022 and the related prices for the options to purchase shares of the Company’s common stock: Weighted Weighted Weighted average average average exercise exercise Range of Number of remaining price of Number of price of exercise options contractual outstanding options exercisable prices outstanding life (years) options exercisable options $ 1.50-16.00 310,692 7.97 $ 10.01 136,303 $ 7.89 310,692 7.97 $ 10.01 136,303 $ 7.89
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	Transactions involving stock options are summarized as follows: Shares Weighted- Average Exercise Price ($) (A) Outstanding at December 31, 2020 269,078 $ 1.50 Granted 285,900 13.00 Cancelled/Expired (7,000 ) 1.50 Outstanding at December 31, 2021 366,591 $ 10.29 Granted 4,000 $ 12.50 Cancelled/Expired (59,899 ) $ 12.18 Exercised - - Outstanding at December 31, 2022 310,692 $ 10.01 Options vested and exercisable 136,303 $ 7.89
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	The Company valued stock options during the years ended December 31, 2022 and 2021 using the Black-Scholes valuation model utilizing the following variables: December 31, December 31, 2022 2021 Volatility 134.9% to 149.9 % 153.5% to 183.5 % Dividends $ - $ - Risk-free interest rates 2.82% to 4.25 % 0.820% to 1.69 % Term (years) 5.00 5.00-6.5
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	The following table summarizes the warrants outstanding at December 30, 2022 and the related prices for the warrants to purchase shares of the Company’s common stock: Shares Weighted- Average Exercise Price ($) Outstanding at December 31, 2020 - $ - Granted 596,400 $ 31.25 Exercised - $ - Outstanding at December 31, 2021 596,400 $ 31.25 Granted 75,934 $ 26.21 Exercised - $ - Outstanding at December 31, 2022 672,334 $ 30.68

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	The provision (benefit) for income taxes for the years ended December 31, 2022 and 2021 consist of the following: 2022 2021 Current $ - $ - Deferred - - Total $ - $ -
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	For the years ended December 31, 2022 and 2021, the expected tax expense (benefit) based on the U. S. federal statutory rate is reconciled with the actual tax provision (benefit) as follows: For the Years Ended December 31, 2022 2021 Expected tax at statutory rates $ (4,879,000 ) 21 % $ (2,351,000 ) 21 % Permanent Differences 1,610,000 7 % 692,000 6 % State Income Tax, Net of Federal benefit 380,000 2 % (612,000 ) 5 % Current Year Change in Valuation Allowance 2,137,000 9 % 2,291,000 20 % Prior Year True-Ups 752,000 3 % (20,000 ) 0 % Income tax expense $ - 0 % $ - 0 %
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	As of December 31, 2022, and 2021 significant components of the Company’s deferred tax assets are as follows: For the Years Ended December 31, 2022 2021 Deferred Tax Assets (Liabilities): Accrued payroll $ 112,000 $ 22,000 ASC842-ROU Asset (68,000 ) (1,117,000 ) ASC842-ROU (Liability) 830,000 1,189,000 Loss from derivatives (130,000 ) (4,000 ) Waiver and commitment fee shares (32,000 ) - Stock based compensation (85,000 ) 398,000 Depreciation 33,000 (764,000 ) Net operating loss 9,679,000 8,478,000 Net deferred tax assets (liabilities) 10,339,000 8,202,000 Valuation allowance (10,339,000 ) (8,202,000 ) Net deferred tax assets (liabilities) $ - $ -

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2022
Fair Value Disclosures [Abstract]
Schedule of Derivative Liabilities at Fair Value [Table Text Block]	The following summarizes the Company’s derivative financial liabilities that are recorded at fair value on a recurring basis at December 31, 2022 and 2021. December 31, 2022 Level 1 Level 2 Level 3 Total Liabilities Derivative liabilities $ - $ - $ 568,912 $ 568,912 December 31, 2021 Level 1 Level 2 Level 3 Total Liabilities Derivative liabilities $ - $ - $ - $ -

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Accounting Policies [Abstract]
Cash and Cash Equivalents, at Carrying Value	$ 35,623	$ 1,164,483

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details) - Property, Plant and Equipment	Dec. 31, 2022
Office Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Office Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Furniture and Fixtures [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Furniture and Fixtures [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	7 years
Machinery and Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Machinery and Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	10 years
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	Term of lease

Net Loss Per Share Applicable_3

Net Loss Per Share Applicable to Common Shareholders (Details) - Schedule of Earnings Per Share, Basic and Diluted - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Numerator:
Net loss applicable to common shareholders	$ (23,558,439)	$ (11,226,366)
Denominator:
Weighted average common shares outstanding	4,451,962	4,060,005
Net loss per share:
Basic and diluted	$ (5.29)	$ (2.77)

Net Loss Per Share Applicable_4

Net Loss Per Share Applicable to Common Shareholders (Details) - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share - shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,372,680	1,336,419
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	310,692	374,924
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	672,334	596,400
Preferred Stock [Member] | Convertible Debt Securities [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	347,652	347,652
Accrued Interest [Member] | Convertible Debt Securities [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	42,002	17,443

Accounts Payable and Accrued _3

Accounts Payable and Accrued Liabilities (Details) - Gardner Agreement [Member]	Jan. 05, 2022 USD ($) $ / shares shares
Accounts Payable and Accrued Liabilities (Details) [Line Items]
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares	$ 12.5
Restricted Stock [Member]
Accounts Payable and Accrued Liabilities (Details) [Line Items]
Common Stock, Shares Authorized (in Shares) | shares	63,593
Accounts Payable [Member]
Accounts Payable and Accrued Liabilities (Details) [Line Items]
Debt Conversion, Original Debt, Amount	$ 500,000
Additional Costs [Member]
Accounts Payable and Accrued Liabilities (Details) [Line Items]
Debt Conversion, Original Debt, Amount	$ 294,913

Accounts Payable and Accrued _4

Accounts Payable and Accrued Liabilities (Details) - Schedule of Accounts Payable and Accrued Liabilities - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Schedule Of Accounts Payable And Accrued Liabilities Abstract
Trade accounts payable	$ 6,761,793	$ 3,933,305
Accrued payroll and payroll taxes	590,915	23,554
Other	507	19,205
Total	$ 7,353,215	$ 3,976,064

Right to Use Assets and Lease_3

Right to Use Assets and Lease Liabilities - Operating Leases (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Disclosure Text Block [Abstract]
Lessee, Operating Lease, Remaining Lease Term	7 years 6 months
Operating Lease, Expense	$ 860,705	$ 351,854
Operating Lease, Right-of-Use Asset, Periodic Reduction	357,700	$ 162,276
Impairment, Lessor Asset under Operating Lease	$ 3,185,591
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amortization, Percent	12%	12%
Operating Lease, Weighted Average Remaining Lease Term	84 months	92 months 3 days

Right to Use Assets and Lease_4

Right to Use Assets and Lease Liabilities - Operating Leases (Details) - Lease, Cost - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Lease, Cost [Abstract]
Right to use assets, net	$ 544,063	$ 3,886,866
Lease liability	4,379,724	4,134,802
Less: current portion	(442,866)	(161,838)
Lease liability, non-current	$ 3,936,858	$ 3,972,964

Right to Use Assets and Lease_5

Right to Use Assets and Lease Liabilities - Operating Leases (Details) - Lessee, Operating Lease, Liability, Maturity - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Lessee Operating Lease Liability Maturity Abstract
For the period ended December 31, 2023	$ 945,102
For the period ended December 31, 2024	884,990
For the period ended December 31, 2025	906,666
For the period ended December 31, 2026	926,988
For the period ended December 31, 2027	946,745
Thereafter	1,939,476
Total	6,549,967
Less: Present value discount	(2,170,243)
Lease liability	$ 4,379,724	$ 4,134,802

SBA Loan Payable (Details)

SBA Loan Payable (Details) - PPP Loan [Member] - USD ($)	12 Months Ended
	Dec. 31, 2022	May 04, 2020
SBA Loan Payable (Details) [Line Items]
Debt Instrument, Face Amount		$ 460,400
Debt Instrument, Interest Rate, Effective Percentage		1%
Debt Instrument, Increase, Accrued Interest	$ 4,632
Notes Payable	$ 460,406

Notes Payable (Details)

Notes Payable (Details) - USD ($)

12 Months Ended

Dec. 02, 2022

Nov. 29, 2022

Oct. 24, 2022

Oct. 10, 2022

Oct. 07, 2022

Sep. 15, 2022

Sep. 14, 2022

Sep. 02, 2022

Aug. 18, 2022

Aug. 04, 2022

Jul. 27, 2022

Jul. 26, 2022

Jul. 21, 2022

Jul. 07, 2022

Jun. 09, 2022

May 26, 2022

May 23, 2022

May 18, 2022

May 10, 2022

Apr. 27, 2022

Apr. 26, 2022

Apr. 18, 2022

Apr. 06, 2022

Mar. 18, 2022

Feb. 24, 2022

Dec. 30, 2021

Jun. 23, 2021

Dec. 31, 2022

Dec. 31, 2021

Nov. 18, 2022

Oct. 05, 2022

Jun. 22, 2022

Jan. 12, 2022

Nov. 10, 2021

Oct. 18, 2021

Mar. 25, 2021

Dec. 31, 2020

Notes Payable (Details) [Line Items]

Stock Issued During Period, Shares, Other (in Shares)

12,759

Class of Warrant or Right, Outstanding (in Shares)

672,334

596,400

Common Stock, Shares, Issued (in Shares)

4,630,372

4,266,669

Common Stock, Value, Issued

$ 46,305

$ 42,667

Debt Instrument, Unamortized Discount

32,040

Amortization of Debt Discount (Premium)

2,116,194

756,795

Debt Instrument, Unamortized Discount, Current

40,000

0

Debt, Current

5,112,702

0

Interest and Debt Expense

3,210,763

968,471

Interest Expense, Debt

$ 362,094

$ 7,657

Common Stock, Par or Stated Value Per Share (in Dollars per share)

$ 0.01

$ 0.01

$ 0.01

$ 0.01

Related Party [Member]

Notes Payable (Details) [Line Items]

Interest and Debt Expense

$ 1,243,639

$ 0

Interest Expense, Debt

198,753

$ 0

Series C Preferred Stock [Member]

Notes Payable (Details) [Line Items]

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

$ 0.5

Series D Preferred Stock [Member]

Notes Payable (Details) [Line Items]

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

$ 25

$ 25

AJB Capital Note [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Face Amount

$ 750,000

Class of Warrant or Right, Outstanding (in Shares)

15,000

Derivative Liability

$ 106,608

Common Stock, Shares, Issued (in Shares)

91,328

Common Stock, Value, Issued

$ 9,007

Payments to Acquire Debt Securities, Available-for-Sale

675,000

Debt Instrument, Unamortized Discount

$ 349,914

Debt Conversion, Converted Instrument, Expiration or Due Date

Mar. 17, 2023

Line of Credit Facility, Interest Rate During Period

10%

Line of Credit Facility, Interest Rate at Period End

12%

Interest Expense, Long-Term Debt

62,000

Amortization of Debt Discount (Premium)

424,914

Debt Instrument, Discount Outstanding

0

Debt Instrument, Debt Default, Amount

750,000

Debt Instrument, Increase, Accrued Interest

22,833

AJB Capital Note [Member] | Measurement Input, Default Rate [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

18%

AJB Capital Note [Member] | Commitments [Member]

Notes Payable (Details) [Line Items]

Stock Issued During Period, Value, Other

$ 430,000

Stock Issued During Period, Shares, Other (in Shares)

34,400

AJB Capital Note [Member] | Original Issue Discount [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Unamortized Discount

$ 75,000

Anson Investments Note [Member]

Notes Payable (Details) [Line Items]

Stock Issued During Period, Value, Other

$ 322,500

Stock Issued During Period, Shares, Other (in Shares)

25,800

Debt Instrument, Face Amount

$ 562,500

Class of Warrant or Right, Outstanding (in Shares)

11,250

Derivative Liability

$ 27,040

Payments to Acquire Debt Securities, Available-for-Sale

506,250

Debt Instrument, Unamortized Discount

$ 416,375

Debt Conversion, Converted Instrument, Expiration or Due Date

Oct. 06, 2022

Line of Credit Facility, Interest Rate During Period

10%

Line of Credit Facility, Interest Rate at Period End

12%

Interest Expense, Long-Term Debt

68,844

Amortization of Debt Discount (Premium)

472,625

Debt Instrument, Discount Outstanding

0

Debt Instrument, Debt Default, Amount

562,500

Debt Instrument, Increase, Accrued Interest

41,500

Anson Investments Note [Member] | Measurement Input, Default Rate [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

18%

Anson Investments Note [Member] | Original Issue Discount [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Unamortized Discount

$ 56,250

Anson East Note [Member]

Notes Payable (Details) [Line Items]

Stock Issued During Period, Value, Other

$ 107,500

Stock Issued During Period, Shares, Other (in Shares)

8,600

Debt Instrument, Face Amount

$ 187,500

Class of Warrant or Right, Outstanding (in Shares)

3,750

Derivative Liability

$ 9,014

Payments to Acquire Debt Securities, Available-for-Sale

168,750

Debt Instrument, Unamortized Discount

$ 147,290

Debt Conversion, Converted Instrument, Expiration or Due Date

Oct. 06, 2022

Line of Credit Facility, Interest Rate During Period

10%

Line of Credit Facility, Interest Rate at Period End

12%

Interest Expense, Long-Term Debt

22,948

Amortization of Debt Discount (Premium)

166,040

Debt Instrument, Discount Outstanding

0

Debt Instrument, Debt Default, Amount

187,500

Debt Instrument, Increase, Accrued Interest

13,833

Common Stock, Par or Stated Value Per Share (in Dollars per share)

$ 10.45

Anson East Note [Member] | Measurement Input, Default Rate [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

18%

Anson East Note [Member] | Original Issue Discount [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Unamortized Discount

$ 18,750

GS Capital Note [Member]

Notes Payable (Details) [Line Items]

Stock Issued During Period, Value, Other

$ 159,259

Stock Issued During Period, Shares, Other (in Shares)

12,741

Debt Instrument, Face Amount

$ 277,777

Class of Warrant or Right, Outstanding (in Shares)

5,556

Derivative Liability

$ 21,920

Payments to Acquire Debt Securities, Available-for-Sale

250,000

Debt Instrument, Unamortized Discount

$ 162,158

Debt Conversion, Converted Instrument, Expiration or Due Date

Nov. 10, 2022

Line of Credit Facility, Interest Rate During Period

10%

Line of Credit Facility, Interest Rate at Period End

12%

Interest Expense, Long-Term Debt

32,155

Amortization of Debt Discount (Premium)

212,435

Debt Instrument, Discount Outstanding

0

Debt Instrument, Debt Default, Amount

277,777

Debt Instrument, Increase, Accrued Interest

19,578

Debt Instrument, Unamortized Discount, Current

$ 27,777

Common Stock, Par or Stated Value Per Share (in Dollars per share)

10.45

GS Capital Note [Member] | Measurement Input, Default Rate [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

18%

Kishon Note [Member]

Notes Payable (Details) [Line Items]

Stock Issued During Period, Value, Other

$ 159,259

Stock Issued During Period, Shares, Other (in Shares)

12,741

Debt Instrument, Face Amount

$ 277,777

Class of Warrant or Right, Outstanding (in Shares)

5,556

Derivative Liability

$ 27,793

Payments to Acquire Debt Securities, Available-for-Sale

250,000

Debt Instrument, Unamortized Discount

$ 138,492

Debt Conversion, Converted Instrument, Expiration or Due Date

Nov. 10, 2022

Line of Credit Facility, Interest Rate During Period

10%

Line of Credit Facility, Interest Rate at Period End

12%

Interest Expense, Long-Term Debt

28,624

Amortization of Debt Discount (Premium)

181,269

Debt Instrument, Discount Outstanding

0

Debt Instrument, Debt Default, Amount

277,777

Debt Instrument, Increase, Accrued Interest

17,822

Debt, Current

$ 277,777

Kishon Note [Member] | Measurement Input, Default Rate [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

18%

Kishon Note [Member] | Original Issue Discount [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Unamortized Discount

$ 27,777

Finnegan Note 1 [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Face Amount

$ 47,059

Class of Warrant or Right, Outstanding (in Shares)

386

Common Stock, Shares, Issued (in Shares)

1,930

Common Stock, Value, Issued

$ 3,240

Payments to Acquire Debt Securities, Available-for-Sale

$ 40,000

Interest Expense, Long-Term Debt

3,285

Amortization of Debt Discount (Premium)

17,005

Debt Instrument, Discount Outstanding

0

Debt Instrument, Debt Default, Amount

51,765

Debt Instrument, Increase, Accrued Interest

3,285

Debt Instrument, Maturity Date

Nov. 20, 2022

Share Price (in Dollars per share)

$ 25

Warrants and Rights Outstanding

$ 2,000

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

$ 12.5

Finnegan Note 1 [Member] | Measurement Input, Default Rate [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

18%

M Diamond Note [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Face Amount

$ 58,823

Class of Warrant or Right, Outstanding (in Shares)

483

Common Stock, Shares, Issued (in Shares)

483

Common Stock, Value, Issued

$ 4,050

Payments to Acquire Debt Securities, Available-for-Sale

$ 50,000

Interest Expense, Long-Term Debt

3,929

Amortization of Debt Discount (Premium)

21,256

Debt Instrument, Discount Outstanding

0

Debt Instrument, Debt Default, Amount

64,705

Debt Instrument, Increase, Accrued Interest

3,929

Debt Instrument, Maturity Date

Nov. 30, 2022

Warrants and Rights Outstanding

$ 2,500

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

$ 25

M Diamond Note [Member] | Measurement Input, Default Rate [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

18%

Finnegan Note 2 [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Face Amount

$ 29,412

Class of Warrant or Right, Outstanding (in Shares)

242

Common Stock, Shares, Issued (in Shares)

242

Common Stock, Value, Issued

$ 2,025

Payments to Acquire Debt Securities, Available-for-Sale

$ 25,000

Interest Expense, Long-Term Debt

1,965

Amortization of Debt Discount (Premium)

10,625

Debt Instrument, Discount Outstanding

0

Debt Instrument, Debt Default, Amount

32,353

Debt Instrument, Increase, Accrued Interest

1,965

Debt Instrument, Maturity Date

Nov. 30, 2022

Share Price (in Dollars per share)

$ 25

Warrants and Rights Outstanding

$ 1,250

Finnegan Note 2 [Member] | Measurement Input, Default Rate [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

18%

Dragon Note [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Face Amount

$ 588,235

Class of Warrant or Right, Outstanding (in Shares)

4,824

Common Stock, Shares, Issued (in Shares)

4,824

Common Stock, Value, Issued

$ 44,000

Payments to Acquire Debt Securities, Available-for-Sale

$ 500,000

Interest Expense, Long-Term Debt

35,874

Amortization of Debt Discount (Premium)

260,059

Debt Instrument, Discount Outstanding

0

Debt Instrument, Debt Default, Amount

647,059

Debt Instrument, Increase, Accrued Interest

35,874

Debt Instrument, Maturity Date

Dec. 09, 2022

Warrants and Rights Outstanding

$ 21,500

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

$ 25

Debt Issuance Costs, Gross

$ 47,500

Common Stock, Par or Stated Value Per Share (in Dollars per share)

$ 10.45

Dragon Note [Member] | Measurement Input, Default Rate [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

18%

Mackay Note [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Face Amount

$ 294,118

Class of Warrant or Right, Outstanding (in Shares)

2,412

Common Stock, Shares, Issued (in Shares)

2,412

Common Stock, Value, Issued

$ 44,118

Payments to Acquire Debt Securities, Available-for-Sale

$ 250,000

Interest Expense, Long-Term Debt

20,193

Amortization of Debt Discount (Premium)

96,280

Debt Instrument, Discount Outstanding

0

Debt Instrument, Debt Default, Amount

323,530

Debt Instrument, Increase, Accrued Interest

20,193

Debt Instrument, Maturity Date

Aug. 10, 2022

Share Price (in Dollars per share)

$ 25

Warrants and Rights Outstanding

$ 10,250

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

$ 12.5

Mackay Note [Member] | Measurement Input, Default Rate [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

18%

Schrier Note [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Face Amount

$ 23,259

Class of Warrant or Right, Outstanding (in Shares)

193

Common Stock, Shares, Issued (in Shares)

193

Common Stock, Value, Issued

$ 1,000

Payments to Acquire Debt Securities, Available-for-Sale

$ 20,000

Interest Expense, Long-Term Debt

1,141

Amortization of Debt Discount (Premium)

7,367

Debt Instrument, Discount Outstanding

335

Debt Instrument, Debt Default, Amount

25,882

Debt Instrument, Increase, Accrued Interest

1,141

Debt Instrument, Maturity Date

Jan. 08, 2023

Warrants and Rights Outstanding

$ 820

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

$ 25

Schrier Note [Member] | Measurement Input, Default Rate [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

18%

Nommsen Note [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Face Amount

$ 58,823

Class of Warrant or Right, Outstanding (in Shares)

483

Common Stock, Shares, Issued (in Shares)

483

Common Stock, Value, Issued

$ 2,350

Payments to Acquire Debt Securities, Available-for-Sale

$ 50,000

Interest Expense, Long-Term Debt

2,946

Amortization of Debt Discount (Premium)

18,905

Debt Instrument, Discount Outstanding

0

Debt Instrument, Debt Default, Amount

64,705

Debt Instrument, Increase, Accrued Interest

2,946

Debt Instrument, Maturity Date

Nov. 30, 2022

Warrants and Rights Outstanding

$ 1,850

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

$ 25

Nommsen Note [Member] | Measurement Input, Default Rate [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

18%

Caplan Note [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Face Amount

$ 58,823

Class of Warrant or Right, Outstanding (in Shares)

483

Common Stock, Shares, Issued (in Shares)

483

Common Stock, Value, Issued

$ 2,350

Payments to Acquire Debt Securities, Available-for-Sale

$ 50,000

Interest Expense, Long-Term Debt

2,531

Amortization of Debt Discount (Premium)

16,675

Debt Instrument, Discount Outstanding

2,230

Debt Instrument, Debt Default, Amount

64,705

Debt Instrument, Increase, Accrued Interest

2,531

Debt Instrument, Maturity Date

Jan. 21, 2023

Warrants and Rights Outstanding

$ 1,850

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

$ 25

Caplan Note [Member] | Measurement Input, Default Rate [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

18%

Finnegan Note 3 [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Face Amount

$ 29,412

Class of Warrant or Right, Outstanding (in Shares)

242

Common Stock, Shares, Issued (in Shares)

242

Common Stock, Value, Issued

$ 1,100

Payments to Acquire Debt Securities, Available-for-Sale

$ 25,000

Interest Expense, Long-Term Debt

1,200

Amortization of Debt Discount (Premium)

7,575

Debt Instrument, Discount Outstanding

1,728

Debt Instrument, Debt Default, Amount

32,353

Debt Instrument, Increase, Accrued Interest

1,200

Debt Instrument, Maturity Date

Feb. 03, 2023

Warrants and Rights Outstanding

$ 850

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

$ 25

Finnegan Note 3 [Member] | Measurement Input, Default Rate [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

18%

Enright Note [Member]

Notes Payable (Details) [Line Items]

Stock Issued During Period, Shares, Other (in Shares)

984

Debt Instrument, Face Amount

$ 120,000

Common Stock, Shares, Issued (in Shares)

984

Common Stock, Value, Issued

$ 6,317

Payments to Acquire Debt Securities, Available-for-Sale

$ 102,000

Interest Expense, Long-Term Debt

4,899

Amortization of Debt Discount (Premium)

29,571

Debt Instrument, Discount Outstanding

6,746

Debt Instrument, Debt Default, Amount

132,000

Debt Instrument, Increase, Accrued Interest

4,899

Debt Instrument, Maturity Date

Feb. 03, 2023

Enright Note [Member] | Measurement Input, Default Rate [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

18%

Mitchell Note [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Face Amount

$ 71,000

Common Stock, Shares, Issued (in Shares)

582

Common Stock, Value, Issued

$ 3,124

Payments to Acquire Debt Securities, Available-for-Sale

$ 60,350

Interest Expense, Long-Term Debt

2,817

Amortization of Debt Discount (Premium)

20,874

Debt Instrument, Discount Outstanding

0

Debt Instrument, Debt Default, Amount

78,100

Debt Instrument, Increase, Accrued Interest

2,817

Debt Instrument, Maturity Date

Nov. 30, 2022

Mitchell Note [Member] | Measurement Input, Default Rate [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

18%

Lightmas Note [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Face Amount

$ 60,000

Common Stock, Shares, Issued (in Shares)

492

Common Stock, Value, Issued

$ 2,640

Payments to Acquire Debt Securities, Available-for-Sale

$ 51,000

Interest Expense, Long-Term Debt

2,380

Amortization of Debt Discount (Premium)

17,640

Debt Instrument, Discount Outstanding

0

Debt Instrument, Debt Default, Amount

66,000

Debt Instrument, Increase, Accrued Interest

2,380

Debt Instrument, Maturity Date

Nov. 30, 2022

Lightmas Note [Member] | Measurement Input, Default Rate [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

18%

Lewis Note [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Face Amount

$ 30,000

Common Stock, Shares, Issued (in Shares)

246

Common Stock, Value, Issued

$ 1,320

Payments to Acquire Debt Securities, Available-for-Sale

$ 25,500

Interest Expense, Long-Term Debt

1,190

Amortization of Debt Discount (Premium)

8,820

Debt Instrument, Discount Outstanding

0

Debt Instrument, Debt Default, Amount

33,000

Debt Instrument, Increase, Accrued Interest

1,190

Debt Instrument, Maturity Date

Nov. 30, 2022

Lewis Note [Member] | Measurement Input, Default Rate [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

18%

Goff Note [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Face Amount

$ 30,000

Common Stock, Shares, Issued (in Shares)

246

Common Stock, Value, Issued

$ 1,320

Payments to Acquire Debt Securities, Available-for-Sale

$ 25,500

Interest Expense, Long-Term Debt

1,190

Amortization of Debt Discount (Premium)

8,820

Debt Instrument, Discount Outstanding

0

Debt Instrument, Debt Default, Amount

33,000

Debt Instrument, Increase, Accrued Interest

1,190

Debt Instrument, Maturity Date

Nov. 30, 2022

Goff Note [Member] | Measurement Input, Default Rate [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

18%

Hagan Note [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Face Amount

$ 100,000

Common Stock, Shares, Issued (in Shares)

820

Common Stock, Value, Issued

$ 4,715

Payments to Acquire Debt Securities, Available-for-Sale

$ 85,000

Interest Expense, Long-Term Debt

3,556

Amortization of Debt Discount (Premium)

29,715

Debt Instrument, Discount Outstanding

0

Debt Instrument, Debt Default, Amount

110,000

Debt Instrument, Increase, Accrued Interest

3,556

Debt Instrument, Maturity Date

Dec. 10, 2022

Hagan Note [Member] | Measurement Input, Default Rate [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

18%

Darling Note [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Face Amount

$ 200,000

Common Stock, Shares, Issued (in Shares)

1,640

Common Stock, Value, Issued

$ 10,824

Payments to Acquire Debt Securities, Available-for-Sale

$ 170,000

Interest Expense, Long-Term Debt

6,619

Amortization of Debt Discount (Premium)

60,824

Debt Instrument, Discount Outstanding

0

Debt Instrument, Debt Default, Amount

220,000

Debt Instrument, Increase, Accrued Interest

6,619

Debt Instrument, Maturity Date

Dec. 15, 2022

Darling Note [Member] | Measurement Input, Default Rate [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

18%

Leath Note [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Face Amount

$ 50,000

Common Stock, Shares, Issued (in Shares)

410

Common Stock, Value, Issued

$ 2,868

Payments to Acquire Debt Securities, Available-for-Sale

$ 42,500

Interest Expense, Long-Term Debt

1,641

Amortization of Debt Discount (Premium)

15,368

Debt Instrument, Discount Outstanding

0

Debt Instrument, Debt Default, Amount

55,000

Debt Instrument, Increase, Accrued Interest

1,641

Debt Instrument, Maturity Date

Dec. 15, 2022

Debt Securities, Held-to-Maturity, Fair Value

$ 55,000

Leath Note [Member] | Measurement Input, Default Rate [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

18%

Cavalry Note [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Face Amount

$ 500,000

Class of Warrant or Right, Outstanding (in Shares)

750

Debt Instrument, Unamortized Discount

$ 7,500

Amortization of Debt Discount (Premium)

10,500

Debt Instrument, Discount Outstanding

0

Debt Instrument, Debt Default, Amount

500,000

Debt Instrument, Increase, Accrued Interest

$ 11,918

Cavalry Note [Member] | Measurement Input, Default Rate [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

18%

Cavalry Note [Member] | Series C Preferred Stock [Member]

Notes Payable (Details) [Line Items]

Preferred Stock, Convertible, Shares Issuable (in Shares)

1,000,000

Cavalry Note [Member] | Series D Preferred Stock [Member]

Notes Payable (Details) [Line Items]

Preferred Stock, Convertible, Shares Issuable (in Shares)

750,000

Cavalry Exchange Agreement [Member] | Series C Preferred Stock [Member]

Notes Payable (Details) [Line Items]

Preferred Stock, Convertible, Shares Issuable (in Shares)

1,000,000

Cavalry Exchange Agreement [Member] | Series D Preferred Stock [Member]

Notes Payable (Details) [Line Items]

Preferred Stock, Convertible, Shares Issuable (in Shares)

750,000

Mercer Note 1 [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Face Amount

$ 300,000

Class of Warrant or Right, Outstanding (in Shares)

750

Interest Expense, Long-Term Debt

$ 6,986

Amortization of Debt Discount (Premium)

10,500

Debt Instrument, Discount Outstanding

0

Debt Instrument, Debt Default, Amount

300,000

Debt Instrument, Increase, Accrued Interest

$ 6,986

Debt Instrument, Maturity Date

Dec. 31, 2022

Mercer Note 1 [Member] | Measurement Input, Default Rate [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

18%

Mercer Note 1 [Member] | Series C Preferred Stock [Member]

Notes Payable (Details) [Line Items]

Preferred Stock, Convertible, Shares Issuable (in Shares)

47,619

Mercer Note 1 [Member] | Series D Preferred Stock [Member]

Notes Payable (Details) [Line Items]

Preferred Stock, Convertible, Shares Issuable (in Shares)

750,000

Mercer Exchange Agreement [Member] | Series C Preferred Stock [Member]

Notes Payable (Details) [Line Items]

Preferred Stock, Convertible, Shares Issuable (in Shares)

47,619

Mercer Exchange Agreement [Member] | Series D Preferred Stock [Member]

Notes Payable (Details) [Line Items]

Preferred Stock, Convertible, Shares Issuable (in Shares)

750,000

Pinz Note [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Face Amount

$ 30,000

Interest Expense, Long-Term Debt

$ 6,986

Amortization of Debt Discount (Premium)

2,100

Debt Instrument, Discount Outstanding

0

Debt Instrument, Debt Default, Amount

30,000

Debt Instrument, Increase, Accrued Interest

$ 674

Debt Instrument, Maturity Date

Dec. 31, 2022

Pinz Note [Member] | Measurement Input, Default Rate [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

18%

Pinz Note [Member] | Series D Preferred Stock [Member]

Notes Payable (Details) [Line Items]

Preferred Stock, Convertible, Shares Issuable (in Shares)

100,000

Pinz Exchange Agreement [Member]

Notes Payable (Details) [Line Items]

Preferred Stock, Convertible, Shares Issuable (in Shares)

100,000

Mercer Note 2 [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Face Amount

$ 100,000

Interest Expense, Long-Term Debt

$ 1,863

Amortization of Debt Discount (Premium)

1,900

Debt Instrument, Discount Outstanding

0

Debt Instrument, Debt Default, Amount

100,000

Debt Instrument, Increase, Accrued Interest

1,863

Debt Instrument, Maturity Date

Dec. 31, 2022

Mercer Note 2 [Member] | Measurement Input, Default Rate [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

18%

Mercer Note 3 [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Face Amount

$ 125,000

Class of Warrant or Right, Outstanding (in Shares)

750

750

Amortization of Debt Discount (Premium)

4,028

Debt Instrument, Discount Outstanding

20,972

Debt Instrument, Debt Default, Amount

125,000

Debt Instrument, Increase, Accrued Interest

993

Debt Instrument, Maturity Date

May 21, 2023

Mercer Note 3 [Member] | Measurement Input, Default Rate [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

18%

Howe Note [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Face Amount

$ 1,000,000

Class of Warrant or Right, Outstanding (in Shares)

42,000

Common Stock, Shares, Issued (in Shares)

42,000

Common Stock, Value, Issued

$ 261,568

Payments to Acquire Debt Securities, Available-for-Sale

$ 850,000

Interest Expense, Long-Term Debt

106,795

Amortization of Debt Discount (Premium)

511,568

Debt Instrument, Discount Outstanding

0

Debt Instrument, Debt Default, Amount

1,100,000

Debt Instrument, Increase, Accrued Interest

106,795

Debt Instrument, Maturity Date

Nov. 30, 2022

Share Price (in Dollars per share)

$ 25

Common Stock, Par or Stated Value Per Share (in Dollars per share)

$ 37.5

Howe Note [Member] | Measurement Input, Default Rate [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

18%

Diamond Note 1 [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Face Amount

$ 175,000

Class of Warrant or Right, Outstanding (in Shares)

7,350

Common Stock, Shares, Issued (in Shares)

7,350

Common Stock, Value, Issued

$ 2,914

Payments to Acquire Debt Securities, Available-for-Sale

$ 148,750

Interest Expense, Long-Term Debt

16,052

Amortization of Debt Discount (Premium)

46,664

Debt Instrument, Discount Outstanding

0

Debt Instrument, Debt Default, Amount

192,500

Debt Instrument, Increase, Accrued Interest

16,052

Debt Instrument, Maturity Date

Nov. 30, 2022

Share Price (in Dollars per share)

$ 25

Common Stock, Par or Stated Value Per Share (in Dollars per share)

$ 37.5

Diamond Note 1 [Member] | Measurement Input, Default Rate [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

18%

Diamond Note 2 [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Face Amount

$ 235,294

Class of Warrant or Right, Outstanding (in Shares)

1,930

Payments to Acquire Debt Securities, Available-for-Sale

$ 200,000

Interest Expense, Long-Term Debt

1,676

Amortization of Debt Discount (Premium)

61,036

Debt Instrument, Discount Outstanding

0

Debt Instrument, Debt Default, Amount

23,529

Debt Instrument, Increase, Accrued Interest

1,676

Debt Instrument, Maturity Date

Nov. 30, 2022

Share Price (in Dollars per share)

$ 25

Warrants and Rights Outstanding

$ 2,213

Debt Instrument, Repaid, Principal

235,294

Diamond Note 2 [Member] | Measurement Input, Default Rate [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

18%

Diamond Note 3 [Member]

Notes Payable (Details) [Line Items]

Stock Issued During Period, Value, Other

$ 16,200

Stock Issued During Period, Shares, Other (in Shares)

1,929

Debt Instrument, Face Amount

$ 235,294

Class of Warrant or Right, Outstanding (in Shares)

1,930

Common Stock, Shares, Issued (in Shares)

1,930

Common Stock, Value, Issued

$ 16,200

Payments to Acquire Debt Securities, Available-for-Sale

$ 200,000

Interest Expense, Long-Term Debt

17,586

Amortization of Debt Discount (Premium)

83,823

Debt Instrument, Discount Outstanding

0

Debt Instrument, Debt Default, Amount

258,823

Debt Instrument, Increase, Accrued Interest

17,586

Debt Instrument, Maturity Date

Nov. 30, 2022

Share Price (in Dollars per share)

$ 25

Warrants and Rights Outstanding

$ 8,800

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

$ 12.5

Diamond Note 3 [Member] | Measurement Input, Default Rate [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

18%

Diamond Note 4 [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Face Amount

$ 47,059

Class of Warrant or Right, Outstanding (in Shares)

386

Common Stock, Shares, Issued (in Shares)

1,930

Common Stock, Value, Issued

$ 3,160

Payments to Acquire Debt Securities, Available-for-Sale

$ 40,000

Interest Expense, Long-Term Debt

3,245

Amortization of Debt Discount (Premium)

17,885

Debt Instrument, Discount Outstanding

0

Debt Instrument, Debt Default, Amount

51,765

Debt Instrument, Increase, Accrued Interest

3,245

Debt Instrument, Maturity Date

Nov. 30, 2022

Share Price (in Dollars per share)

$ 25

Warrants and Rights Outstanding

$ 2,960

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

$ 12.5

Diamond Note 4 [Member] | Measurement Input, Default Rate [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

18%

Diamond Note 5 [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Face Amount

$ 58,823

Class of Warrant or Right, Outstanding (in Shares)

483

Common Stock, Shares, Issued (in Shares)

483

Common Stock, Value, Issued

$ 4,050

Payments to Acquire Debt Securities, Available-for-Sale

$ 50,000

Interest Expense, Long-Term Debt

3,929

Amortization of Debt Discount (Premium)

21,256

Debt Instrument, Discount Outstanding

0

Debt Instrument, Debt Default, Amount

64,705

Debt Instrument, Increase, Accrued Interest

3,929

Debt Instrument, Maturity Date

Nov. 30, 2022

Share Price (in Dollars per share)

$ 25

Warrants and Rights Outstanding

$ 2,500

Diamond Note 5 [Member] | Measurement Input, Default Rate [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

18%

Lindstrom Note 1 [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Face Amount

$ 41,176

Class of Warrant or Right, Outstanding (in Shares)

338

Common Stock, Shares, Issued (in Shares)

338

Common Stock, Value, Issued

$ 2,835

Payments to Acquire Debt Securities, Available-for-Sale

$ 35,000

Interest Expense, Long-Term Debt

2,750

Amortization of Debt Discount (Premium)

14,879

Debt Instrument, Discount Outstanding

0

Debt Instrument, Debt Default, Amount

45,294

Debt Instrument, Increase, Accrued Interest

2,750

Debt Instrument, Maturity Date

Nov. 30, 2022

Share Price (in Dollars per share)

$ 25

Warrants and Rights Outstanding

$ 1,750

Lindstrom Note 1 [Member] | Measurement Input, Default Rate [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

18%

Dobbertin Note 1 [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Face Amount

$ 17,647

Class of Warrant or Right, Outstanding (in Shares)

145

Common Stock, Shares, Issued (in Shares)

145

Common Stock, Value, Issued

$ 1,215

Payments to Acquire Debt Securities, Available-for-Sale

$ 15,000

Interest Expense, Long-Term Debt

1,179

Amortization of Debt Discount (Premium)

6,377

Debt Instrument, Discount Outstanding

0

Debt Instrument, Debt Default, Amount

19,412

Debt Instrument, Increase, Accrued Interest

1,179

Debt Instrument, Maturity Date

Nov. 30, 2022

Share Price (in Dollars per share)

$ 25

Warrants and Rights Outstanding

$ 750

Dobbertin Note 1 [Member] | Measurement Input, Default Rate [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

18%

Howe Note 2 [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Face Amount

$ 300,000

Class of Warrant or Right, Outstanding (in Shares)

2,460

Common Stock, Shares, Issued (in Shares)

2,460

Common Stock, Value, Issued

$ 22,440

Payments to Acquire Debt Securities, Available-for-Sale

$ 255,000

Interest Expense, Long-Term Debt

18,888

Amortization of Debt Discount (Premium)

108,405

Debt Instrument, Discount Outstanding

0

Debt Instrument, Debt Default, Amount

330,000

Debt Instrument, Increase, Accrued Interest

18,888

Debt Instrument, Maturity Date

Nov. 30, 2022

Share Price (in Dollars per share)

$ 25

Warrants and Rights Outstanding

$ 10,965

Howe Note 2 [Member] | Measurement Input, Default Rate [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

18%

Howe Note 3 [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Face Amount

$ 300,000

Class of Warrant or Right, Outstanding (in Shares)

2,460

Common Stock, Shares, Issued (in Shares)

2,460

Common Stock, Value, Issued

$ 12,495

Payments to Acquire Debt Securities, Available-for-Sale

$ 255,000

Interest Expense, Long-Term Debt

15,436

Amortization of Debt Discount (Premium)

97,440

Debt Instrument, Discount Outstanding

0

Debt Instrument, Debt Default, Amount

330,000

Debt Instrument, Increase, Accrued Interest

15,436

Debt Instrument, Maturity Date

Nov. 30, 2022

Share Price (in Dollars per share)

$ 25

Warrants and Rights Outstanding

$ 9,945

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

$ 25

Howe Note 3 [Member] | Measurement Input, Default Rate [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

18%

Iturregui Note [Member]

Notes Payable (Details) [Line Items]

Stock Issued During Period, Shares, Other (in Shares)

241

Debt Instrument, Face Amount

$ 29,412

Class of Warrant or Right, Outstanding (in Shares)

242

Common Stock, Shares, Issued (in Shares)

242

Common Stock, Value, Issued

$ 1,225

Payments to Acquire Debt Securities, Available-for-Sale

$ 25,000

Interest Expense, Long-Term Debt

1,313

Amortization of Debt Discount (Premium)

8,464

Debt Instrument, Discount Outstanding

1,089

Debt Instrument, Debt Default, Amount

32,353

Debt Instrument, Increase, Accrued Interest

1,313

Debt Instrument, Maturity Date

Jan. 21, 2023

Share Price (in Dollars per share)

$ 25

Warrants and Rights Outstanding

$ 975

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

$ 25

Iturregui Note [Member] | Measurement Input, Default Rate [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

18%

Howe Note 4 [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Face Amount

$ 200,000

Common Stock, Shares, Issued (in Shares)

1,640

Common Stock, Value, Issued

$ 10,775

Payments to Acquire Debt Securities, Available-for-Sale

$ 170,000

Interest Expense, Long-Term Debt

8,756

Amortization of Debt Discount (Premium)

60,775

Debt Instrument, Discount Outstanding

0

Debt Instrument, Debt Default, Amount

220,000

Debt Instrument, Increase, Accrued Interest

8,756

Debt Instrument, Maturity Date

Nov. 30, 2022

Howe Note 4 [Member] | Measurement Input, Default Rate [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

18%

November 29, 2022 Notes [Member]

Notes Payable (Details) [Line Items]

Class of Warrant or Right, Outstanding (in Shares)

750

Amortization of Debt Discount (Premium)

667

Debt Instrument, Discount Outstanding

3,083

Debt Instrument, Debt Default, Amount

18,750

Debt Instrument, Increase, Accrued Interest

$ 164

Debt Instrument, Maturity Date

May 28, 2023

November 29, 2022 Notes [Member] | Measurement Input, Default Rate [Member]

Notes Payable (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

18%

Notes Payable (Details) - Sche

Notes Payable (Details) - Schedule of Debt - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Schedule Of Debt Abstract
Notes Payable	$ 5,144,742	$ 0
Less: Discount	(32,040)
Notes payable - net of discount	5,112,702	0
Current Portion, net of discount	5,112,702	0
Long-term portion, net of discount	$ 0	$ 0

Notes Payable - Related Parties

Notes Payable - Related Parties (Details) - Schedule of Debt, Related Parties - Related Party [Member] - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Notes Payable - Related Parties (Details) - Schedule of Debt, Related Parties [Line Items]
Notes Payable	$ 2,799,632	$ 1,100,000
Less: Discount	(22,670)	(511,568)
Notes payable – net of discounts	2,776,962	588,432
Current Portion, net of discount	2,776,962	588,432
Long-term portion, net of discount	$ 0	$ 0

Derivative Liabilities (Details

Derivative Liabilities (Details) - Schedule of Derivative Liability Acitivity - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Schedule Of Derivative Liability Acitivity Abstract
Balance	$ 0	$ 807,683
True-up features issued	192,375
Settled upon conversion or exercise	(310,641)	(1,302,138)
Loss on revaluation	687,178	494,455
Balance	$ 568,912	$ 0

Derivative Liabilities (Detai_2

Derivative Liabilities (Details) - Schedule of Valuation Assumptions	12 Months Ended
	Dec. 31, 2022 $ / shares
Minimum [Member]
Derivative Liabilities (Details) - Schedule of Valuation Assumptions [Line Items]
Volatility	95.10%
Stock Price (in Dollars per share)	$ 1.06
Risk-free interest rates	4.35%
Term (years)	8 months 23 days
Maximum [Member]
Derivative Liabilities (Details) - Schedule of Valuation Assumptions [Line Items]
Volatility	123.20%
Stock Price (in Dollars per share)	$ 3.5
Risk-free interest rates	4.37%
Term (years)	10 months 9 days

Stockholders_ Equity (Deficit_2

Stockholders’ Equity (Deficit) (Details) - USD ($)																																																	1 Months Ended			9 Months Ended	12 Months Ended
	Nov. 18, 2022	Nov. 07, 2022	Oct. 01, 2022	Sep. 15, 2022	Sep. 14, 2022	Sep. 09, 2022	Sep. 02, 2022	Aug. 18, 2022	Aug. 04, 2022	Jul. 27, 2022	Jul. 26, 2022	Jul. 21, 2022	Jul. 07, 2022	Jun. 22, 2022	Jun. 09, 2022	Jun. 07, 2022	May 26, 2022	May 23, 2022	May 18, 2022	May 10, 2022	May 01, 2022	Apr. 27, 2022	Apr. 18, 2022	Apr. 06, 2022	Mar. 31, 2022	Mar. 31, 2022	Mar. 18, 2022	Jan. 12, 2022	Jan. 05, 2022	Nov. 10, 2021	Oct. 18, 2021	Aug. 17, 2021	Jun. 23, 2021	May 12, 2021	Apr. 19, 2021	Mar. 25, 2021	Mar. 23, 2021	Mar. 17, 2021	Mar. 11, 2021	Feb. 22, 2021	Feb. 05, 2021	Feb. 01, 2021	Jan. 28, 2021	Jan. 21, 2021	Jan. 14, 2021	Jan. 11, 2021	Jan. 06, 2021	Jan. 04, 2021	Sep. 02, 2021	Jun. 29, 2021	May 26, 2021	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021	Oct. 18, 2022	Oct. 10, 2022	Oct. 07, 2022	Oct. 05, 2022	Dec. 31, 2020
Stockholders’ Equity (Deficit) (Details) [Line Items]
Common Stock, Shares Authorized																																																					500,000,000	500,000,000
Common Stock, Par or Stated Value Per Share (in Dollars per share)																												$ 0.01					$ 0.01																				$ 0.01	$ 0.01
Stock Issued During Period, Shares, New Issues																																																					4,630,372	4,266,669
Common Stock, Shares, Outstanding																																																					4,630,372	4,266,669
Accrued Salaries, Current (in Dollars)																												$ 19,032
Shares Issued, Shares, Share-Based Payment Arrangement, Forfeited																												8,000
Shares Issued, Value, Share-Based Payment Arrangement, Forfeited (in Dollars)																												$ 80
Gains (Losses) on Restructuring of Debt (in Dollars)																												$ 15,032																									$ 15,032	$ 0
Other Accrued Liabilities, Current (in Dollars)																																																					507	19,205
Stock Issued During Period, Shares, Other																																	12,759
Shares Issued, Price Per Share (in Dollars per share)																																	$ 10	$ 15						$ 15										$ 15
(in Dollars)																																																					198,273	$ 0
Debt Instrument, Unamortized Discount (in Dollars)																																																					$ 32,040
Class of Warrant or Rights, Granted																																																					75,934	596,400
Class of Warrant or Right, Outstanding																																																					672,334	596,400
Stock Issued During Period, Shares, Issued for Services									12,064
Stock Issued During Period, Value, Issued for Services (in Dollars)									$ 77,448																																												$ 101,250	$ 222,480
Stock Issued During Period, Value, Conversion of Convertible Securities (in Dollars)																																																					$ 180,573	$ 252,029
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period																																		50,000						6,720										102,333				0
Conversion of Stock, Shares Issued																																9,589																			84,748
Conversion of Stock, Shares Converted																																12,515
Stock Repurchased and Retired During Period, Shares																																	40,000
Accrued Liabilities, Current (in Dollars)																																$ 156,441
Common Stock, Shares Subscribed but Unissued																																2,926
Stock Issued During Period, Shares, Restricted Stock Award, Gross																																6,256
Restricted Stock, Value, Shares Issued Net of Tax Withholdings (in Dollars)																																$ 78,200
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period																																																						13,032
Preferred Stock, Shares Authorized																																																					100,000,000
Dividends, Preferred Stock (in Dollars)																																																					$ 322,310	$ 185,204
Proceeds from Issuance or Sale of Equity (in Dollars)																																																					0	51,500
Preferred Stock, Value, Issued (in Dollars)																																																					$ 0	0
Before Reverse-Split [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Common Stock, Shares, Outstanding																																																					231,374,330
After Reverse-Split [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Common Stock, Shares, Outstanding																																																					4,630,372
Stock Issued During Period, Shares, Reverse Stock Splits																																																					226,743,958
Stock Subscribed [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Stock Issued During Period, Shares, Other																										7,648
Shares Issued, Price Per Share (in Dollars per share)																									$ 12.5	$ 12.5
Stock Issued During Period, Value, Conversion of Convertible Securities (in Dollars)																																																						$ 252,029
AJB Capital Note [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Debt Instrument, Unamortized Discount (in Dollars)																											$ 349,914
Debt Instrument, Face Amount (in Dollars)																											$ 750,000
Class of Warrant or Right, Outstanding																											15,000
Payments to Acquire Debt Securities, Available-for-Sale (in Dollars)																											$ 675,000
Accounts Payable [Member] | Stock Subscribed [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Debt Conversion, Original Debt, Amount (in Dollars)																										$ 95,558
Cavalry Fund 1 [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Stock Issued During Period, Shares, Other																						14,400
Shares Issued, Price Per Share (in Dollars per share)																						$ 6.35
Deferred Compensation Arrangement with Individual, Fair Value of Shares Issued (in Dollars)																						$ 91,440
Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised (in Dollars)																						$ 88,560
Diamond Note 3 [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Stock Issued During Period, Shares, Other																						1,929
Shares Issued, Price Per Share (in Dollars per share)																						$ 8
(in Dollars)																						$ 765
Contract, Price per share (in Dollars per share)																						$ 12.5
Contract Shares, Value (in Dollars)																						$ 24,118
Commitment Shares, Value (in Dollars)																						15,434
Stock Issued During Period, Value, Other (in Dollars)																						$ 16,200
Class of Warrant or Rights, Granted																						1,929
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)																						$ 12.5
Debt Instrument, Face Amount (in Dollars)																						$ 235,294
Debt Instrument, Maturity Date																						Nov. 30, 2022
Class of Warrant or Right, Outstanding																						1,930
Warrants and Rights Outstanding (in Dollars)																						$ 8,800
Payments to Acquire Debt Securities, Available-for-Sale (in Dollars)																						$ 200,000
Diamond Note 4 [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Stock Issued During Period, Shares, New Issues																			386
Shares Issued, Price Per Share (in Dollars per share)																			$ 7.585
(in Dollars)																			$ 249
Contract, Price per share (in Dollars per share)																			$ 12.5
Commitment Shares, Value (in Dollars)																			$ 3,160
Class of Warrant or Rights, Granted																			386
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)																			$ 12.5
Debt Instrument, Face Amount (in Dollars)																			$ 47,059
Debt Instrument, Maturity Date																			Nov. 30, 2022
Class of Warrant or Right, Outstanding																			386
Warrants and Rights Outstanding (in Dollars)																			$ 2,960
Payments to Acquire Debt Securities, Available-for-Sale (in Dollars)																			$ 40,000
Finnegan Note 1 [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Stock Issued During Period, Shares, New Issues																		386
Shares Issued, Price Per Share (in Dollars per share)																		$ 8.97
(in Dollars)																		$ 222
Contract, Price per share (in Dollars per share)																		$ 12.5
Commitment Shares, Value (in Dollars)																		$ 3,240
Class of Warrant or Rights, Granted																		386
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)																		$ 12.5
Debt Instrument, Face Amount (in Dollars)																		$ 47,059
Debt Instrument, Maturity Date																		Nov. 20, 2022
Class of Warrant or Right, Outstanding																		386
Warrants and Rights Outstanding (in Dollars)																		$ 2,000
Payments to Acquire Debt Securities, Available-for-Sale (in Dollars)																		$ 40,000
May 26 Notes [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Stock Issued During Period, Shares, Other																	1,688
Shares Issued, Price Per Share (in Dollars per share)																	$ 7.585
(in Dollars)																	$ 1,369
Contract, Price per share (in Dollars per share)																	$ 12.5
Commitment Shares, Value (in Dollars)																	$ 14,175
Class of Warrant or Rights, Granted																	1,688
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)																	$ 25
Series X Preferred Stock [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Common Stock, Par or Stated Value Per Share (in Dollars per share)																$ 12.5
Stock Issued During Period, Shares, New Issues																8,103
June 9 Notes [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Stock Issued During Period, Shares, Other															7,284
Shares Issued, Price Per Share (in Dollars per share)															$ 7,425
(in Dollars)															$ 9,356
Contract, Price per share (in Dollars per share)															$ 12.5
Commitment Shares, Value (in Dollars)															$ 66,400
Class of Warrant or Rights, Granted															7,284
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)															$ 25
Dragon Note [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Common Stock, Par or Stated Value Per Share (in Dollars per share)														$ 10.45
Stock Issued During Period, Shares, New Issues														4,824
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)															$ 25
Debt Instrument, Face Amount (in Dollars)															$ 588,235
Debt Instrument, Maturity Date															Dec. 09, 2022
Class of Warrant or Right, Outstanding															4,824
Warrants and Rights Outstanding (in Dollars)															$ 21,500
Payments to Acquire Debt Securities, Available-for-Sale (in Dollars)															$ 500,000
Commitment Fee, Per Share (in Dollars per share)														$ 10.45
GS Capital Note [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Common Stock, Par or Stated Value Per Share (in Dollars per share)														$ 10.45
Stock Issued During Period, Shares, New Issues														12,741
Stock Issued During Period, Shares, Other																							12,741
Debt Instrument, Unamortized Discount (in Dollars)																							$ 162,158
Stock Issued During Period, Value, Other (in Dollars)																							159,259
Debt Instrument, Face Amount (in Dollars)																							$ 277,777
Class of Warrant or Right, Outstanding																							5,556
Payments to Acquire Debt Securities, Available-for-Sale (in Dollars)																							$ 250,000
Commitment Fee, Per Share (in Dollars per share)														$ 10.45
Anson East Note [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Common Stock, Par or Stated Value Per Share (in Dollars per share)														$ 10.45
Stock Issued During Period, Shares, New Issues														8,600
Stock Issued During Period, Shares, Other																								8,600
Debt Instrument, Unamortized Discount (in Dollars)																								$ 147,290
Stock Issued During Period, Value, Other (in Dollars)																								107,500
Debt Instrument, Face Amount (in Dollars)																								$ 187,500
Class of Warrant or Right, Outstanding																								3,750
Payments to Acquire Debt Securities, Available-for-Sale (in Dollars)																								$ 168,750
Anson Investments Note [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Stock Issued During Period, Shares, New Issues														25,800
Stock Issued During Period, Shares, Other																								25,800
Debt Instrument, Unamortized Discount (in Dollars)																								$ 416,375
Stock Issued During Period, Value, Other (in Dollars)																								322,500
Debt Instrument, Face Amount (in Dollars)																								$ 562,500
Class of Warrant or Right, Outstanding																								11,250
Payments to Acquire Debt Securities, Available-for-Sale (in Dollars)																								$ 506,250
Commitment Fee, Per Share (in Dollars per share)														$ 10.45
Mackay Note [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Stock Issued During Period, Shares, New Issues													2,412
(in Dollars)													$ 5,456
Contract, Price per share (in Dollars per share)													$ 12.5
Commitment Shares, Value (in Dollars)													$ 12,500
Class of Warrant or Rights, Granted													2,412
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)													$ 12.5
Debt Instrument, Face Amount (in Dollars)													$ 294,118
Debt Instrument, Maturity Date													Aug. 10, 2022
Class of Warrant or Right, Outstanding													2,412
Warrants and Rights Outstanding (in Dollars)													$ 10,250
Payments to Acquire Debt Securities, Available-for-Sale (in Dollars)													$ 250,000
Commitment Fee, Per Share (in Dollars per share)													$ 7.445
Schrier Note [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Stock Issued During Period, Shares, New Issues													193
Shares Issued, Price Per Share (in Dollars per share)													$ 7.445
(in Dollars)													$ 436
Contract, Price per share (in Dollars per share)													$ 12.5
Commitment Shares, Value (in Dollars)													$ 1,000
Class of Warrant or Rights, Granted													193
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)													$ 25
Debt Instrument, Face Amount (in Dollars)													$ 23,259
Debt Instrument, Maturity Date													Jan. 08, 2023
Class of Warrant or Right, Outstanding													193
Warrants and Rights Outstanding (in Dollars)													$ 820
Payments to Acquire Debt Securities, Available-for-Sale (in Dollars)													$ 20,000
Iturregui Note [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Stock Issued During Period, Shares, Other												241
Shares Issued, Price Per Share (in Dollars per share)												$ 7.225
(in Dollars)												$ 518
Contract, Price per share (in Dollars per share)												$ 12.5
Commitment Shares, Value (in Dollars)												$ 1,225
Class of Warrant or Rights, Granted												241
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)												$ 25
Debt Instrument, Face Amount (in Dollars)												$ 29,412
Debt Instrument, Maturity Date												Jan. 21, 2023
Class of Warrant or Right, Outstanding												242
Warrants and Rights Outstanding (in Dollars)												$ 975
Payments to Acquire Debt Securities, Available-for-Sale (in Dollars)												$ 25,000
Howe Note 3 [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Stock Issued During Period, Shares, New Issues												2,460
Shares Issued, Price Per Share (in Dollars per share)												$ 7.225
(in Dollars)												$ 5,729
Contract, Price per share (in Dollars per share)												$ 12.5
Commitment Shares, Value (in Dollars)												$ 12,495
Class of Warrant or Rights, Granted												2,460
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)												$ 25
Debt Instrument, Face Amount (in Dollars)												$ 300,000
Debt Instrument, Maturity Date												Nov. 30, 2022
Class of Warrant or Right, Outstanding												2,460
Warrants and Rights Outstanding (in Dollars)												$ 9,945
Payments to Acquire Debt Securities, Available-for-Sale (in Dollars)												$ 255,000
Nommsen Note [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Stock Issued During Period, Shares, New Issues											482
Shares Issued, Price Per Share (in Dollars per share)											$ 6.84
(in Dollars)											$ 949
Contract, Price per share (in Dollars per share)											$ 12.5
Commitment Shares, Value (in Dollars)											$ 2,350
Class of Warrant or Rights, Granted											482
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)											$ 25
Debt Instrument, Face Amount (in Dollars)											$ 58,823
Debt Instrument, Maturity Date											Nov. 30, 2022
Class of Warrant or Right, Outstanding											483
Warrants and Rights Outstanding (in Dollars)											$ 1,850
Payments to Acquire Debt Securities, Available-for-Sale (in Dollars)											$ 50,000
Caplan Note [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Stock Issued During Period, Shares, New Issues										482
Shares Issued, Price Per Share (in Dollars per share)										$ 6.935
(in Dollars)										$ 995
Contract, Price per share (in Dollars per share)										$ 12.5
Commitment Shares, Value (in Dollars)										$ 2,350
Class of Warrant or Rights, Granted										482
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)										$ 25
Debt Instrument, Face Amount (in Dollars)										$ 58,823
Debt Instrument, Maturity Date										Jan. 21, 2023
Class of Warrant or Right, Outstanding										483
Warrants and Rights Outstanding (in Dollars)										$ 1,850
Payments to Acquire Debt Securities, Available-for-Sale (in Dollars)										$ 50,000
Finnegan Note 3 [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Stock Issued During Period, Shares, New Issues									241
Shares Issued, Price Per Share (in Dollars per share)									$ 6.42
(in Dollars)									$ 448
Contract, Price per share (in Dollars per share)									$ 25
Commitment Shares, Value (in Dollars)									$ 1,000
Class of Warrant or Rights, Granted									241
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)									$ 25
Debt Instrument, Face Amount (in Dollars)									$ 29,412
Debt Instrument, Maturity Date									Feb. 03, 2023
Class of Warrant or Right, Outstanding									242
Warrants and Rights Outstanding (in Dollars)									$ 850
Payments to Acquire Debt Securities, Available-for-Sale (in Dollars)									$ 25,000
Enright Note [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Stock Issued During Period, Shares, Other									984
Contract, Price per share (in Dollars per share)									$ 12.5
Commitment Shares, Value (in Dollars)									$ 6,317
Debt Instrument, Face Amount (in Dollars)									$ 120,000
Debt Instrument, Maturity Date									Feb. 03, 2023
Payments to Acquire Debt Securities, Available-for-Sale (in Dollars)									$ 102,000
Howe Note 4 [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Stock Issued During Period, Shares, New Issues								1,640
Shares Issued, Price Per Share (in Dollars per share)								$ 6.57
Contract, Price per share (in Dollars per share)								$ 12.5
Commitment Shares, Value (in Dollars)								$ 10,775
Debt Instrument, Face Amount (in Dollars)								$ 200,000
Debt Instrument, Maturity Date								Nov. 30, 2022
Payments to Acquire Debt Securities, Available-for-Sale (in Dollars)								$ 170,000
Mitchell Note [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Stock Issued During Period, Shares, New Issues							582
Shares Issued, Price Per Share (in Dollars per share)							$ 5.365
Contract, Price per share (in Dollars per share)							$ 12.5
Commitment Shares, Value (in Dollars)							$ 3,124
Debt Instrument, Face Amount (in Dollars)							$ 71,000
Debt Instrument, Maturity Date							Nov. 30, 2022
Payments to Acquire Debt Securities, Available-for-Sale (in Dollars)							$ 60,350
Lightmas Note [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Stock Issued During Period, Shares, New Issues							492
Shares Issued, Price Per Share (in Dollars per share)							$ 5.365
Contract, Price per share (in Dollars per share)							$ 12.5
Commitment Shares, Value (in Dollars)							$ 2,640
Debt Instrument, Face Amount (in Dollars)							$ 60,000
Debt Instrument, Maturity Date							Nov. 30, 2022
Payments to Acquire Debt Securities, Available-for-Sale (in Dollars)							$ 51,000
Lewis Note [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Stock Issued During Period, Shares, New Issues							246
Shares Issued, Price Per Share (in Dollars per share)							$ 5.365
Contract, Price per share (in Dollars per share)							$ 12.5
Commitment Shares, Value (in Dollars)							$ 1,320
Debt Instrument, Face Amount (in Dollars)							$ 30,000
Debt Instrument, Maturity Date							Nov. 30, 2022
Payments to Acquire Debt Securities, Available-for-Sale (in Dollars)							$ 25,500
Goff Note [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Stock Issued During Period, Shares, New Issues							246
Shares Issued, Price Per Share (in Dollars per share)							$ 5.65
Contract, Price per share (in Dollars per share)							$ 12.5
Commitment Shares, Value (in Dollars)							$ 1,320
Debt Instrument, Face Amount (in Dollars)							$ 30,000
Debt Instrument, Maturity Date							Nov. 30, 2022
Payments to Acquire Debt Securities, Available-for-Sale (in Dollars)							$ 25,500
Hagan Note [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Stock Issued During Period, Shares, New Issues							820
Shares Issued, Price Per Share (in Dollars per share)						$ 5.75
Contract, Price per share (in Dollars per share)						$ 12.5
Commitment Shares, Value (in Dollars)						$ 4,715
Debt Instrument, Face Amount (in Dollars)							$ 100,000
Debt Instrument, Maturity Date							Dec. 10, 2022
Payments to Acquire Debt Securities, Available-for-Sale (in Dollars)							$ 85,000
Darling Note [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Stock Issued During Period, Shares, New Issues					1,640
Shares Issued, Price Per Share (in Dollars per share)					$ 6.6
Contract, Price per share (in Dollars per share)					$ 12.5
Commitment Shares, Value (in Dollars)					$ 10,824
Debt Instrument, Face Amount (in Dollars)					$ 200,000
Debt Instrument, Maturity Date					Dec. 15, 2022
Payments to Acquire Debt Securities, Available-for-Sale (in Dollars)					$ 170,000
Leath Note [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Stock Issued During Period, Shares, New Issues				410
Shares Issued, Price Per Share (in Dollars per share)				$ 6.995
Contract, Price per share (in Dollars per share)				$ 12.5
Commitment Shares, Value (in Dollars)				$ 2,868
Debt Instrument, Face Amount (in Dollars)				$ 50,000
Debt Instrument, Maturity Date				Dec. 15, 2022
Payments to Acquire Debt Securities, Available-for-Sale (in Dollars)				$ 42,500
Eagle Equities Note 4 [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Debt Instrument, Convertible, Conversion Price (in Dollars per share)																																															$ 0.612	$ 0.6
Debt Conversion, Converted Instrument, Shares Issued																																															70,119	82,475
Eagle Equities Note 4 [Member] | Principal [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Debt Conversion, Original Debt, Amount (in Dollars)																																															$ 39,000	$ 45,000
Eagle Equities Note 4 [Member] | Accrued Interest [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Debt Conversion, Original Debt, Amount (in Dollars)																																															$ 3,913	$ 4,485
Eagle Equities Note 5 [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Debt Instrument, Convertible, Conversion Price (in Dollars per share)																																													$ 0.633	$ 0.612
Debt Conversion, Converted Instrument, Shares Issued																																													86,388	89,270
Eagle Equities Note 5 [Member] | Principal [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Debt Conversion, Original Debt, Amount (in Dollars)																																													$ 50,000	$ 50,000
Eagle Equities Note 5 [Member] | Accrued Interest [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Debt Conversion, Original Debt, Amount (in Dollars)																																													$ 4,683	$ 4,633
Eagle Equities Note 6 [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Debt Instrument, Convertible, Conversion Price (in Dollars per share)																																											$ 0.7875	$ 0.77
Debt Conversion, Converted Instrument, Shares Issued																																											145,702	128,992
Eagle Equities Note 6 [Member] | Principal [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Debt Conversion, Original Debt, Amount (in Dollars)																																											$ 107,200	$ 93,000
Eagle Equities Note 6 [Member] | Accrued Interest [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Debt Conversion, Original Debt, Amount (in Dollars)																																											$ 7,540	$ 6,324
Private Placement [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Debt Instrument, Convertible, Conversion Price (in Dollars per share)																																										$ 12.5
Debt Conversion, Converted Instrument, Shares Issued																																										133,440
Stock Issued During Period, Value, Conversion of Convertible Securities (in Dollars)																																										$ 1,668,000
Eagle Equities Note 7 [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Debt Instrument, Convertible, Conversion Price (in Dollars per share)																																									$ 12.492
Debt Conversion, Converted Instrument, Shares Issued																																									23,683
Debt Conversion, Original Debt, Amount (in Dollars)																																									$ 200,200
Eagle Equities Note 8 [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Debt Instrument, Convertible, Conversion Price (in Dollars per share)																																									$ 11.926
Debt Conversion, Converted Instrument, Shares Issued																																									12,792
Debt Conversion, Original Debt, Amount (in Dollars)																																									$ 114,400
Eagle Equities Note 9 [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Debt Instrument, Convertible, Conversion Price (in Dollars per share)																																									$ 12,492
Debt Conversion, Converted Instrument, Shares Issued																																									12,104
Debt Conversion, Original Debt, Amount (in Dollars)																																									$ 114,400
Eagle Equities Note 10 [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Debt Instrument, Convertible, Conversion Price (in Dollars per share)																																									$ 11,874
Debt Conversion, Converted Instrument, Shares Issued																																									21,903
Debt Conversion, Original Debt, Amount (in Dollars)																																									$ 200,200
The Good Clinic [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Conversion of Stock, Shares Issued																																							12,000
Service Provider [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Shares Issued, Price Per Share (in Dollars per share)																																						$ 15.5
Stock Issued During Period, Shares, Issued for Services																																						6,000
Underwriters of the 2021 Private Placement [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Stock Issued During Period, Shares, New Issues																																					9,227
Shares Issued, Price Per Share (in Dollars per share)																																					$ 13
Professional Fees [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Shares Issued, Price Per Share (in Dollars per share)																																			$ 0.01
Stock Issued During Period, Shares, Issued for Services																																			39
Series A Preferred Stock [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Conversion of Stock, Shares Issued																																							600,000
Preferred Stock, Shares Authorized																																																					500,000
Preferred Stock, Par or Stated Value Per Share (in Dollars per share)																																																					$ 0.01	$ 0.01
Preferred Stock, Liquidation Preference Per Share (in Dollars per share)																																																					$ 25
Preferred Stock, Dividend Rate, Percentage																																																					12%
Preferred Stock, Dividend Rate, Per-Dollar-Amount (in Dollars per share)																																																					$ 25
Preferred Stock, Shares Outstanding																																																					0	0
Dividends, Preferred Stock (in Dollars)																																																					$ 1,000
Preferred Stock, Shares Issued																																																					0	0
Preferred Stock, Value, Issued (in Dollars)																																																					$ 0	$ 0
Series A Preferred Stock [Member] | The Good Clinic [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Shares Issued, Shares, Share-Based Payment Arrangement, Forfeited																																							4,800
Conversion of Stock, Shares Converted																																							4,800
Series C Preferred Stock [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Stock Issued During Period, Shares, New Issues																																				3,000,000
Shares Issued, Price Per Share (in Dollars per share)																																																	$ 0.25		$ 12.5
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)																																				$ 0.5
Conversion of Stock, Shares Issued																																																	80,000		4,237,424		98,064
Conversion of Stock, Shares Converted																																																	1,000,000		1,059,356
Preferred Stock, Shares Authorized																																																					3,000,000
Preferred Stock, Par or Stated Value Per Share (in Dollars per share)																																																					$ 0.01	$ 0.01
Preferred Stock, Shares Outstanding																																																					1,038,708	940,644
Dividends, Preferred Stock (in Dollars)																																																					$ 66,447	$ 87,059
Preferred Stock, Voting Rights																																																					Voting Rights. Holders of the Series C Preferred Stock have the right to vote on any matter presented to holders of our Common Stock for their action or consideration at any meeting of the stockholders (or by written consent of stockholders in lieu of meeting), each holder of our Series C Preferred Stock shall be entitled to cast the number of votes equal to the number of whole shares of Common Stock into which the shares of Series C preferred Stock held by such holder, as described below, are convertible as of the record date for determining stockholders entitled to vote on (or consent to) such matter, voting with the Common Stock as a single class.
Preferred Stock, Convertible, Terms																																																					Conversion. Each holder of our Series C Preferred Stock is entitled to convert their shares of Series C Preferred Stock, in whole or in part, at the Conversion Rate, which is determined by dividing the Conversion Amount (the Stated Value of $1.05, plus any accrued but unpaid dividends) by the Conversion Price ($0.25 per share). In addition, upon certain triggering events, the holders of our Series C Preferred Stock have the right to convert their Series C Preferred Stock at the lesser of the Conversion Price or 75% of the average VWAP for the five trading days prior to the date of the notice of conversion. The Conversion Price is subject to adjustment upon certain stock splits and recapitalization as well as upon the sale of Common Stock or Common Stock Equivalents. Each share of the Series C Preferred Stock is convertible at the option of the holder thereof, or automatically or upon the closing of an underwritten offering of at least $10 million of the Company’s securities or upon listing of the Company’s Common Stock on a national securities exchange.
Preferred Stock, Convertible, Conversion Price (in Dollars per share)																																																			$ 0.25		$ 0.25
Preferred Stock, Dividend Payment Terms																																																					Dividends. Each share of Series C Preferred Stock accrues dividends on a quarterly basis in arrears, at the rate of 6% per annum of the Stated Value ($1.05 per share plus any accrued but unpaid dividends) and is to be paid within 15 days after the end of each of our fiscal quarters. Each holder of the Series C Preferred Stock is entitled to receive dividends or distributions on each share of the Series C Preferred Stock on an as converted into Common Stock basis when and if dividends are declared on the Common Stock by our Board of Directors.
Preferred Stock, Redemption Terms																																																					Redemption Rights. Upon receipt of a conversion notice, we have the right (but not the obligation) to redeem all or part of the Series C Preferred Stock (which the applicable holder of the Series C Preferred Stock is seeking to convert) at a price per share equal to the product of 125% of the (1) Stated Value plus (2) the Additional Amount (the “Redemption Price”). If we decide to exercise the redemption right, within one trading day, we shall deliver written notice to such holder(s) of Series C Preferred Stock that the Series C Preferred Stock will be redeemed (the “Redemption Notice”) on the date that is three trading days following the date of the Redemption Notice (such date, the “Redemption Date”). On the Redemption Date, we shall redeem the shares of Series C Preferred Stock specified in such request by paying in cash therefore a sum per share equal to the Redemption Price. In no event shall a Redemption Notice be given if we may not lawfully redeem our capital stock. On or before the Redemption Date, the Redemption Price for such shares shall be paid by wire transfer of immediately available funds to an account designated in writing by the applicable holder.
Preferred Stock, Preemptive Rights																																																					Preemptive or Similar Rights Additionally, except for a public offering or certain exempt issuances of our securities, holders of the Series C Preferred Stock shall have the right to participate in any offering of our Common Stock or Common Stock Equivalents (as defined in the COD) in a transaction exempt from registration under the Securities Act in an amount equal to an aggregate of 30% of the financing on the same terms, conditions and price provided to investors in such an offering, such right shall expire on the 15 month anniversary of the issuance date of the Series C Preferred Stock. Further, until the earlier of 18 months from the issuance date of the Series C Preferred Stock and the date that there are less than 20% of the shares of Series C Preferred Stock outstanding, the Investors have most favored nations protection in the event we issue or sell Common Stock or Common Stock Equivalents that the Investors believe are more favorable than the terms and conditions under the Private Placement.
Conversion of Stock, Amount Issued (in Dollars)																																																					$ 981
Class of Warrant or Right, Number of Securities Called by Warrants or Rights																																				6,300,000
Warrants and Rights Outstanding, Term																																				5 years
Proceeds from Issuance or Sale of Equity (in Dollars)																																				$ 3,000,000
Convertible Preferred Stock, Shares Issued upon Conversion																																																	4,000,001
Stock Issued During Period, Value, New Issues (in Dollars)																																																						$ 1,491,283
Preferred Stock, Shares Issued																																																					1,038,708	940,644
Preferred Stock, Value, Issued (in Dollars)																																																					$ 10,476	$ 9,406
Series C Preferred Stock [Member] | Warrants 2 [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Class of Warrant or Rights, Granted																																				6,300,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)																																				$ 0.75
Series C Preferred Stock [Member] | Cavalry Exchange Agreement [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Preferred Stock, Shares Issued																																																										1,000,000
Series C Preferred Stock [Member] | Mercer Exchange Agreement [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Preferred Stock, Shares Issued																																																									47,619
Series D Preferred Stock [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Stock Issued During Period, Shares, New Issues																														1,075,000	2,050,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)																														$ 25	$ 25
Preferred Stock, Shares Authorized																																																					10,000,000
Preferred Stock, Par or Stated Value Per Share (in Dollars per share)																																																					$ 0.01	$ 0.01
Preferred Stock, Dividend Rate, Percentage																																																					6%
Preferred Stock, Shares Outstanding																																																					3,100,000	3,100,000
Dividends, Preferred Stock (in Dollars)																																																					$ 195,299	$ 35,327
Preferred Stock, Voting Rights																																																					Voting Rights. Holders of the Series D Preferred Stock have the right to vote on any matter presented to holders of our Common Stock for their action or consideration at any meeting of the stockholders (or by written consent of stockholders in lieu of meeting), each holder of our Series C Preferred Stock shall be entitled to cast the number of votes equal to the number of whole shares of Common Stock into which the shares of Series D preferred Stock held by such holder, as described below, are convertible as of the record date for determining stockholders entitled to vote on (or consent to) such matter, voting with the Common Stock as a single class.
Preferred Stock, Convertible, Terms																																																					Conversion. Each holder of our Series D Preferred Stock is entitled to convert their shares of Series D Preferred Stock, in whole or in part, at the Conversion Rate, which is determined by dividing the Conversion Amount (the Stated Value of $1.05, plus any accrued but unpaid dividends) by the Conversion Price ($0.25 per share). In addition, upon certain triggering events, the holders of our Series C Preferred Stock have the right to convert their Series D Preferred Stock at the lesser of the Conversion Price or 75% of the average VWAP for the five trading days prior to the date of the notice of conversion. The Conversion Price is subject to adjustment upon certain stock splits and recapitalization as well as upon the sale of Common Stock or Common Stock Equivalents. Each share of the Series D Preferred Stock is convertible at the option of the holder thereof, or automatically or upon the closing of an underwritten offering of at least $10 million of the Company’s securities or upon listing of the Company’s Common Stock on a national securities exchange.
Preferred Stock, Convertible, Conversion Price (in Dollars per share)																																																					$ 0.25
Preferred Stock, Dividend Payment Terms																																																					Dividends. Each share of Series D Preferred Stock accrues dividends on a quarterly basis in arrears, at the rate of 6% per annum of the Stated Value ($1.05 per share plus any accrued but unpaid dividends) and is to be paid within 15 days after the end of each of our fiscal quarters. Each holder of the Series C Preferred Stock is entitled to receive dividends or distributions on each share of the Series D Preferred Stock on an as converted into Common Stock basis when and if dividends are declared on the Common Stock by our Board of Directors.
Preferred Stock, Redemption Terms																																																					Redemption Rights. Upon receipt of a conversion notice, we have the right (but not the obligation) to redeem all or part of the Series D Preferred Stock (which the applicable holder of the Series D Preferred Stock is seeking to convert) at a price per share equal to the product of 125% of the (1) Stated Value plus (2) the Additional Amount (the “Redemption Price”). If we decide to exercise the redemption right, within one trading day, we shall deliver written notice to such holder(s) of Series D Preferred Stock that the Series D Preferred Stock will be redeemed (the “Redemption Notice”) on the date that is three trading days following the date of the Redemption Notice (such date, the “Redemption Date”). On the Redemption Date, we shall redeem the shares of Series D Preferred Stock specified in such request by paying in cash therefore a sum per share equal to the Redemption Price. In no event shall a Redemption Notice be given if we may not lawfully redeem our capital stock. On or before the Redemption Date, the Redemption Price for such shares shall be paid by wire transfer of immediately available funds to an account designated in writing by the applicable holder.
Preferred Stock, Preemptive Rights																																																					Preemptive or Similar Rights Additionally, except for a public offering or certain exempt issuances of our securities, holders of the Series D Preferred Stock shall have the right to participate in any offering of our Common Stock or Common Stock Equivalents (as defined in the COD) in a transaction exempt from registration under the Securities Act in an amount equal to an aggregate of 30% of the financing on the same terms, conditions and price provided to investors in such an offering, such right shall expire on the 15 month anniversary of the issuance date of the Series D Preferred Stock. Further, until the earlier of 18 months from the issuance date of the Series D Preferred Stock and the date that there are less than 20% of the shares of Series D Preferred Stock outstanding, the Investors have most favored nations protection in the event we issue or sell Common Stock or Common Stock equivalents that the Investors believe are more favorable than the terms and conditions under the Private Placement.
Class of Warrant or Right, Number of Securities Called by Warrants or Rights																														45,150	85,050
Warrants and Rights Outstanding, Term																														5 years	5 years
Proceeds from Issuance or Sale of Equity (in Dollars)																														$ 999,250	$ 1,874,450
Debt Issuance Costs, Net (in Dollars)																														$ 75,750	$ 125,500
Stock Issued During Period, Value, New Issues (in Dollars)																																																						$ 1,753,282
Preferred Stock, Shares Issued																																																					3,100,000	3,100,000
Preferred Stock, Value, Issued (in Dollars)																																																					$ 31,000	$ 31,000
Series D Preferred Stock [Member] | Warrants 2 [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Class of Warrant or Rights, Granted																														45,150
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)																														$ 37.5
Preferred Stock, Preemptive Rights																															$37.50
Class of Warrant or Right, Number of Securities Called by Warrants or Rights																															85,050
Series D Preferred Stock [Member] | Cavalry Exchange Agreement [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Preferred Stock, Shares Issued																																																										750,000
Series D Preferred Stock [Member] | Mercer Exchange Agreement [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Preferred Stock, Shares Issued																																																									750,000
Series D Preferred Stock [Member] | Pinz Exchange Agreement [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Preferred Stock, Shares Issued																																																								100,000
Series D Preferred Stock [Member] | Anson East and Anson Investments Notes [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Preferred Stock, Shares Issued																																																							750,000
Series E Preferred Stock [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Stock Issued During Period, Shares, New Issues		10,000
Stock Issued During Period, Value, Conversion of Convertible Securities (in Dollars)		$ 1,100
Preferred Stock, Shares Authorized																																																					10,000
Preferred Stock, Par or Stated Value Per Share (in Dollars per share)		$ 0.01
Preferred Stock, Shares Outstanding																																																					0	0
Preferred Stock, Convertible, Conversion Price (in Dollars per share)		$ 0.05
Stock Issued During Period, Value, New Issues (in Dollars)		$ 1,000
Series X Preferred Stock [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Shares Issued, Shares, Share-Based Payment Arrangement, Forfeited																																	2,000
Preferred Stock, Shares Authorized																																																					27,324
Preferred Stock, Par or Stated Value Per Share (in Dollars per share)																																																					$ 0.01	$ 0.01
Preferred Stock, Liquidation Preference Per Share (in Dollars per share)																																																					$ 25
Preferred Stock, Shares Outstanding																																																					24,227	24,227
Dividends, Preferred Stock (in Dollars)																																																					$ 60,564	$ 61,818
Preferred Stock, Voting Rights																																																					Each one share of the Series X Preferred Stock is entitled to 400 votes on all matters submitted to a vote of our shareholders.
Preferred Stock, Dividend Payment Terms																																																					The Company reserves the right to pay the dividends in shares of the Company’s common stock at a price equal to the average closing price over the five days prior to the date of the dividend declaration.
Preferred Stock, Shares Issued																																																					24,227	24,227
Preferred Stock, Value, Issued (in Dollars)																																																					$ 242	$ 242
Valuation, Market Approach [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Shares Issued, Price Per Share (in Dollars per share)									$ 6.42
Valuation, Market Approach [Member] | Enright Note [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Shares Issued, Price Per Share (in Dollars per share)									$ 6.42
Uplisting Offering [Member] | Anson East and Anson Investments Notes [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Preferred Stock, Value, Issued (in Dollars)																																																							$ 375,000
Waiver Fee [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Stock Issued During Period, Shares, Other																									30,835
Shares Issued, Price Per Share (in Dollars per share)																									$ 12.5	$ 12.5
Other Noncash Expense (in Dollars)																																																				$ 385,431
(in Dollars)																																																				$ 198,273
Share-Based Payment Arrangement, Option [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount (in Dollars)																																																					$ 2,152,786
Gardner Agreement [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Debt Conversion, Converted Instrument, Amount (in Dollars)																													$ 500,000
Other Accrued Liabilities, Current (in Dollars)																													$ 294,912
Debt Instrument, Convertible, Conversion Price (in Dollars per share)																													$ 12.5
Gardner Agreement [Member] | Restricted Stock [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Debt Conversion, Converted Instrument, Shares Issued																													63,593
AJB Capital Investors [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Stock Issued During Period, Shares, New Issues	91,328
Stock Issued During Period, Shares, Other																										34,400
Contract, Price per share (in Dollars per share)																										$ 12.5
Adjustments to Additional Paid in Capital, Other (in Dollars)																										$ 226,106
AJB Capital Investors [Member] | Valuation, Market Approach [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Shares Issued, Price Per Share (in Dollars per share)																									$ 6.35	$ 6.35
AJB Capital Investors [Member] | Warrant and Commitment Fees [Member] | AJB Capital Note [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Debt Instrument, Unamortized Discount (in Dollars)																									$ 349,914	$ 349,914
Service Provider [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Common Stock, Par or Stated Value Per Share (in Dollars per share)			$ 16																		$ 6.88
Stock Issued During Period, Shares, New Issues			6,329																		15,000
Kishon Investments SPA [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Stock Issued During Period, Shares, New Issues																				12,741
Debt Instrument, Unamortized Discount (in Dollars)																				$ 27,777
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)																				$ 12.5
Debt Instrument, Fee Amount (in Dollars)																				$ 159,259
Debt Instrument, Face Amount (in Dollars)																				$ 277,777
Debt Instrument, Maturity Date																				Nov. 10, 2022
Class of Warrant or Right, Outstanding																				5,556
Warrants and Rights Outstanding (in Dollars)																				$ 159,259
Payments to Acquire Debt Securities, Available-for-Sale (in Dollars)																				$ 250,000
Officers and Board Members [Member]
Stockholders’ Equity (Deficit) (Details) [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value (in Dollars)																																																						$ 676,423

Stockholders_ Equity (Deficit_3

Stockholders’ Equity (Deficit) (Details) - Share-based Payment Arrangement, Option, Exercise Price Range - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share Based Payment Arrangement Option Exercise Price Range Abstract
Range of exercise prices	$ 1.5
Range of exercise prices	$ 16
Number of options outstanding (in Shares)	310,692	366,591	269,078
Weighted average remaining contractual life (years)	7 years 11 months 19 days
Weighted average exercise price of outstanding options	$ 10.01	$ 10.29	$ 1.5
Number of options exercisable (in Shares)	136,303
Weighted average exercise price of exercisable options	$ 7.89

Stockholders_ Equity (Deficit_4

Stockholders’ Equity (Deficit) (Details) - Share-based Payment Arrangement, Option, Activity - $ / shares			1 Months Ended	12 Months Ended
	May 12, 2021	Feb. 22, 2021	Jun. 29, 2021	Dec. 31, 2022	Dec. 31, 2021
Share Based Payment Arrangement Option Activity Abstract
Outstanding, Number of Shares				366,591	269,078
Outstanding, Weighted-Average Exercise Price				$ 10.29	$ 1.5
Options Vested and Exercisable, Number of Shares				136,303
Options Vested and Exercisable, Weighted-Average Exercise Price				$ 7.89
Granted, Number of Shares				4,000	285,900
Granted, Weighted-Average Exercise Price				$ 12.5	$ 13
Cancelled/Expired, Number of Shares				(59,899)	(7,000)
Cancelled/Expired, Weighted-Average Exercise Price				$ 12.18	$ 1.5
Exercised, Number of Shares	50,000	6,720	102,333		0
Exercised, Weighted-Average Exercise Price					$ 0
Outstanding, Number of Shares				310,692	366,591
Outstanding, Weighted-Average Exercise Price				$ 10.01	$ 10.29

Stockholders_ Equity (Deficit_5

Stockholders’ Equity (Deficit) (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions - Share-Based Payment Arrangement, Option [Member]	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Stockholders’ Equity (Deficit) (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Line Items]
Dividends	0%	0%
Term (years)	5 years
Minimum [Member]
Stockholders’ Equity (Deficit) (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Line Items]
Volatility	134.90%	153.50%
Risk-free interest rates	2.82%	0.82%
Term (years)		5 years
Maximum [Member]
Stockholders’ Equity (Deficit) (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Line Items]
Volatility	149.90%	183.50%
Risk-free interest rates	4.25%	1.69%
Term (years)		6 years 6 months

Stockholders_ Equity (Deficit_6

Stockholders’ Equity (Deficit) (Details) - Schedule of Stockholders' Equity Note, Warrants or Rights - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Schedule Of Stockholders Equity Note Warrants Or Rights Abstract
Outstanding, Number of Shares	596,400
Outstanding, Weighted Average Exercise Price	$ 31.25
Granted, Number of Shares	75,934	596,400
Granted, Weighted Average Exercise Price	$ 26.21	$ 31.25
Exercised, Number of Shares	0	0
Exercised, Weighted Average Exercise Price	$ 0	$ 0
Outstanding, Number of Shares	672,334	596,400
Outstanding, Weighted Average Exercise Price	$ 30.68	$ 31.25

Income Taxes (Details)

Income Taxes (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Deferred Tax Assets, Operating Loss Carryforwards	$ 9,679,000	$ 8,478,000

Income Taxes (Details) - Schedu

Income Taxes (Details) - Schedule of Components of Income Tax Expense - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Schedule Of Components Of Income Tax Expense Abstract
Current		$ 0	$ 0
Deferred		0	0
Total	$ 0	$ 0	$ 0

Income Taxes (Details) - Sche_2

Income Taxes (Details) - Schedule of Income Tax Rate Reconciliation - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Schedule Of Income Tax Rate Reconciliation Abstract
Expected tax at statutory rates	$ (4,879,000)	$ (2,351,000)
Expected tax at statutory rates	21%	21%
Permanent Differences	$ 1,610,000	$ 692,000
Permanent Differences	7%	6%
State Income Tax, Net of Federal benefit	$ 380,000	$ (612,000)
State Income Tax, Net of Federal benefit	2%	5%
Current Year Change in Valuation Allowance	$ 2,137,000	$ 2,291,000
Current Year Change in Valuation Allowance	9%	20%
Prior Year True-Ups	$ 752,000	$ (20,000)
Prior Year True-Ups	3%	0%
Income tax expense	$ 0	$ 0	$ 0
Income tax expense	0%	0%

Income Taxes (Details) - Sche_3

Income Taxes (Details) - Schedule of Deferred Income Taxes - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Schedule Of Deferred Income Taxes Abstract
Accrued payroll	$ 112,000	$ 22,000
ASC842-ROU Asset	(68,000)	(1,117,000)
ASC842-ROU (Liability)	830,000	1,189,000
Gain from derivatives	(130,000)	(4,000)
Waiver and commitment fee shares	(32,000)
Stock based compensation	(85,000)	398,000
Depreciation	33,000	(764,000)
Net operating loss	9,679,000	8,478,000
Net deferred tax assets (liabilities)	10,339,000	8,202,000
Valuation allowance	(10,339,000)	(8,202,000)
Net deferred tax assets (liabilities)	$ 0	$ 0

Fair Value of Financial Instr_3

Fair Value of Financial Instruments (Details) - Schedule of Derivative Financial Liabilities at Fair Value - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Fair Value of Financial Instruments (Details) - Schedule of Derivative Financial Liabilities at Fair Value [Line Items]
Derivative liabilities	$ 568,912	$ 0
Fair Value, Inputs, Level 1 [Member]
Fair Value of Financial Instruments (Details) - Schedule of Derivative Financial Liabilities at Fair Value [Line Items]
Derivative liabilities	0	0
Fair Value, Inputs, Level 2 [Member]
Fair Value of Financial Instruments (Details) - Schedule of Derivative Financial Liabilities at Fair Value [Line Items]
Derivative liabilities	0	0
Fair Value, Inputs, Level 3 [Member]
Fair Value of Financial Instruments (Details) - Schedule of Derivative Financial Liabilities at Fair Value [Line Items]
Derivative liabilities	$ 568,912	$ 0

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($)	Oct. 25, 2022	Dec. 31, 2022	Jul. 21, 2020	May 04, 2020
Commitments and Contingencies (Details) [Line Items]
Debt Instrument, Interest Rate, Effective Percentage			1%
Lease Termination Commitment Due		$ 25,000
Paid to Plaintiff [Member]
Commitments and Contingencies (Details) [Line Items]
Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Number of Shares (in Shares)	2,552
Paid to CEO [Member]
Commitments and Contingencies (Details) [Line Items]
Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Number of Shares (in Shares)	19,622
Payments for Legal Settlements	$ 3,000
PPP Loan [Member]
Commitments and Contingencies (Details) [Line Items]
Loan Proceeds Erroneously Given			$ 440,000
Debt Instrument, Interest Rate, Effective Percentage				1%

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)			12 Months Ended
	Jun. 01, 2023	Apr. 11, 2023	Dec. 31, 2022	Dec. 31, 2021	May 09, 2023	May 05, 2023	Apr. 04, 2023	Mar. 28, 2023	Mar. 23, 2023	Mar. 09, 2023	Mar. 01, 2023	Feb. 21, 2023	Feb. 15, 2023	Jan. 23, 2023	Jan. 12, 2023	Nov. 07, 2022	Jun. 29, 2021	Jun. 23, 2021	May 12, 2021	Feb. 22, 2021
Subsequent Events (Details) [Line Items]
Common Stock, Shares, Issued			4,630,372	4,266,669
Shares Issued, Price Per Share (in Dollars per share)																	$ 15	$ 10	$ 15	$ 15
Preferred Stock, Shares Authorized			100,000,000
Proceeds from Issuance of Debt (in Dollars)			$ 4,359,350	$ 0
Sheila Schweitzer [Member]
Subsequent Events (Details) [Line Items]
Salary and Wage, Officer, Excluding Cost of Good and Service Sold (in Dollars)	$ 200,000
Series E Preferred Stock [Member]
Subsequent Events (Details) [Line Items]
Preferred Stock, Shares Authorized			10,000
Preferred Stock, Par or Stated Value Per Share (in Dollars per share)																$ 0.01
Subsequent Event [Member]
Subsequent Events (Details) [Line Items]
Common Stock, Shares, Issued					19,622	2,552	94,738	18,472		15,265	13,555	150,000	9,846	8,063
Shares Issued, Price Per Share (in Dollars per share)					$ 0.94	$ 1.05	$ 1.32	$ 1.32		$ 1.32	$ 1.32	$ 2.63	$ 1.32	$ 4.33
Proceeds from Issuance of Debt (in Dollars)		$ 650,000
Proceeds from Debt, Net of Issuance Costs (in Dollars)		$ 511,000
Subsequent Event [Member] | Series F Preferred Stock [Member]
Subsequent Events (Details) [Line Items]
Preferred Stock, Shares Authorized									140,000
Preferred Stock, Value, Outstanding (in Dollars)									$ 1,000
Preferred Stock, Par or Stated Value Per Share (in Dollars per share)		$ 0.01
Subsequent Event [Member] | Series E Preferred Stock [Member]
Subsequent Events (Details) [Line Items]
Preferred Stock, Par or Stated Value Per Share (in Dollars per share)									$ 0.01
Service Provider [Member] | Subsequent Event [Member]
Subsequent Events (Details) [Line Items]
Common Stock, Shares, Issued						2,952								150,000
Shares Issued, Price Per Share (in Dollars per share)						$ 1.05								$ 3.45
Larry Diamond [Member] | Subsequent Event [Member]
Subsequent Events (Details) [Line Items]
Common Stock, Shares, Issued														666
Spartan Capital [Member] | Subsequent Event [Member]
Subsequent Events (Details) [Line Items]
Common Stock, Shares, Issued															150,000
Spartan Capital [Member] | Subsequent Event [Member] | After Completion of Gross Raise [Member]
Subsequent Events (Details) [Line Items]
Common Stock, Shares, Issued															50,000